|
HCC | Abstract Library |
![Abstract Library](/images/AbstractLibBanner.jpg) |
|
The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors. |
|
|
2. | Consensus statement on safety of combining transarterial radioembolization with 90yttrium microspheres with systemic anticancer agents for the treatment of liver malignancy |
|
J Vasc Interv Radiol. 2024 Jun 15:S10510443(24)003981.doi:10.1016/j.jvir.2024.06.006. Online ahead of print.
Andrew S Kennedy 1, Daniel B Brown 2, Marwan Fakih 3, Rohan Jeyarajah 4, Suzanne Jones 5, David Liu 6, David J Pinato 7, Bruno Sangro 8, Navesh K Sharma 9, Daniel Y Sze 10, Eric Van Cutsem 11, Harpreet S Wasan 12
|
|
|
3. | Characteristics and outcome of anti-hepatitis D virus positive patients with hepatocellular carcinoma |
|
Liver Int. 2024 Jul;44(7):1588-1599. doi: 10.1111/liv.15855. Epub 2024 Mar 1.
Edoardo G Giannini 1 2, Andrea Pasta 1 2, Giulia Pieri 1 2, Maria Corina Plaz Torres 1 2, Mariarosaria Marseglia 3 4, Filippo Pelizzaro 5, Angelo Sangiovanni 6, Giuseppe Cabibbo 7, Giorgia Ghittoni 8, Mariella Di Marco 9, Francesco Giuseppe Foschi 10, Maria Guarino 11, Elisabetta Biasini 12, Carlo Saitta 13, Claudia Campani 14, Gianluca Svegliati-Baroni 15, Antonio Gasbarrini 16, Maurizia Rossana Brunetto 17, Donatella Magalotti 18, Francesco Azzaroli 19, Andrea Mega 20, Rodolfo Sacco 21, Gerardo Nardone 22, David Sacerdoti 23, Alberto Masotto 24, Gianpaolo Vidili 25, Laura Bucci 4 26, Alessandro Vitale 27, Franco Trevisani 4 26; Italian Liver Cancer (ITA.LI.CA) group
Collaborators
Italian Liver Cancer (ITA.LI.CA) group:
Maurizio Biselli, Lorenzo Lani, Benedetta Stefanini, Valentina Santi, Alessandro Granito, Fabio Piscaglia, Francesco Tovoli, Luca Muratori, Francesca Benevento, Fabio Farinati, Gloria Allegrini, Calogero Cammà, Ciro Celsa, Paolo Giuffrida, Carmelo Marco Giacchetto, Gabriele Rancatore, Maria Vittoria Grassini, Roberta Ciccia, Alessandro Grova, Mauro Salvato, Valentina Adotti, Stefano Gitto, Fabio Marra, Martina Rosi, Vittoria Bevilacqua, Alberto Borghi, Fabio Conti, Anna Chiara Dall'Aglio, Giorgio Ercolani, Federica Mirici, Laura Schiadà, Chiara Scorzoni, Giulia Scandali, Francesca Romana Ponziani, Gabriele Missale, Andrea Olivani, Mario Capasso, Valentina Cossiga, Filomena Morisco, Ester Marina Cela, Antonio Facciorusso, Valentina Lauria, Giorgio Pelecca, Fabrizio Chegai, Fabio Coratella, Mariano Ortenzi, Serena Dell'Isola, Roberto Filomia, Concetta Pitrone, Giovanni Raimondo, Assunta Sauchella, Elton Dajti, Federico Ravaioli, Filippo Oliveri, Gabriele Ricco, Veronica Romagnoli, Alessandro Inno, Fabiana Marchetti, Pietro Coccoli, Antonio Malerba, Alberta Cappelli, Cristina Mosconi, Matteo Renzulli, Luca Marzi
|
|
|
4. | HES V2.0 outperforms GALAD for detection of HCC: A phase 3 biomarker study in the United States |
|
Hepatology. 2024 Jun 19. doi: 10.1097/HEP.0000000000000953. Online ahead of print.
Hashem B El-Serag 1 2, Qingchun Jin 3, Tayob Nabihah 3, Emad Salem 1, Michelle Luster 1, Abeer Alsarraj 2, Saira Khaderi 1, Amit G Singal 4, Jorge A Marrero 5, Sumeet K Asrani 6, Fasiha Kanwal 1 2
|
|
|
5. | Steatohepatitic Hepatocellular Carcinoma:A New Approach to Classifying Morphological Subtypes of Hepatocellular Carcinoma |
|
Hum Pathol. 2024 Jun 12:S0046-8177(24)00108-4. doi: 10.1016/j.humpath.2024.06.007.Online ahead of print.
Gwyneth S T Soon 1, Francesco Callea 2, Alastair D Burt 3, Sam Cook 3, Luigi Terracciano 4, Caner Ercan 5, Hans-Peter Dienes 6, Zachary D Goodman 7, Eve A Roberts 8, Andrew D Clouston 9, Annette S H Gouw 10, David E Kleiner 11, Young Nyun Park 12, Taek Chung 13, Peter Schirmacher 14, Dina Tiniakos 15, Konstantina Dimopoulou 16, Achim Weber 17, Katharina Endhardt 17, Michael Torbenson 18
|
|
|
|
|
|
|
|
|
|
|
10. | Combination and Optimal Sequencing of Systemic and Locoregional Therapies in Hepatocellular Carcinoma: Proceedings from the Society of Interventional Radiology Foundation Research Consensus Panel |
|
J Vasc Interv Radiol. 2024 Jun;35(6):818-824. doi: 10.1016/j.jvir.2024.02.017.
Lindsay M Thornton 1, Nadine Abi-Jaoudeh 2, Howard J Lim 3, Katerina Malagari 4, Benjamin Oren Spieler 5, Masatoshi Kudo 6, Richard S Finn 7, Riccardo Lencioni 8, Sarah B White 9, Nima Kokabi 10, D Rohan Jeyarajah 11, Prosanto Chaudhury 12, David Liu 13
|
|
|
|
|
|
|
|
|
14. | Statewide Survey of Primary Care and Subspecialty Providers on Hepatocellular Carcinoma Risk-Stratification and Surveillance Practices |
|
Dig Dis Sci. 2024 Apr 23. doi: 10.1007/s10620-024-08442-5. Online ahead of print.
Andrew M Moon 1 2 3, Rachel M Swier 4, Lindsay M Lane 5, A Sidney Barritt 4th 6 7, Hanna K Sanoff 8 9, Andrew F Olshan 10, Stephanie B Wheeler 8 11, George N Ioannou 12 13, Nicole J Kim 13, Scott Hagan 14, Philip Vutien 13, Thad Benefield 5, Louise M Henderson 8 5 10
|
|
|
|
|
|
|
|
|
|
|
|
|
20. | Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update |
|
J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745. Online ahead of print.
John D Gordan 1, Erin B Kennedy 2, Ghassan K Abou-Alfa 3 4, Eliza Beal 5, Richard S Finn 6, Terence P Gade 7, Laura Goff 8, Shilpi Gupta 9, Jennifer Guy 10, Hang T Hoang 11, Renuka Iyer 12, Ishmael Jaiyesimi 13, Minaxi Jhawer 14, Asha Karippot 15, Ahmed O Kaseb 16, R Kate Kelley 1, Jeremy Kortmansky 17, Andrea Leaf 18, William M Remak 19, Davendra P S Sohal 20, Tamar H Taddei 21, Andrea Wilson Woods 22, Mark Yarchoan 23, Michal G Rose 24
|
|
|
|
|
|
|
|
|
24. | a-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma |
|
Int J Cancer. 2024 Mar 15;154(6):1043-1056. doi: 10.1002/ijc.34799. Epub 2023 Nov 23.
Federico Rossari 1 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Changhoon Yoo 7, Jaekyung Cheon 8, Fabian Finkelmeier 9, Ho Yeong Lim 10, José Presa 11, Gianluca Masi 12 13, Francesca Bergamo 14, Elisabeth Amadeo 1, Francesco Vitiello 1, Takashi Kumada 15, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 8, Vera Himmelsbach 9, Massimo Iavarone 16, Giuseppe Cabibbo 17, Margarida Montes 11, Francesco Giuseppe Foschi 18, Caterina Vivaldi 12 13, Caterina Soldà 14, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 9, Masashi Hirooka 19, Kazuya Kariyama 20, Joji Tani 21, Masanori Atsukawa 22, Koichi Takaguchi 23, Ei Itobayashi 24, Shinya Fukunishi 25, Kunihiko Tsuji 26, Toru Ishikawa 27, Kazuto Tajiri 28, Hironori Ochi 29, Satoshi Yasuda 30, Hidenori Toyoda 30, Chikara Ogawa 31, Takashi Nishimura 32, Takeshi Hatanaka 33, Satoru Kakizaki 34, Noritomo Shimada 35, Kazuhito Kawata 36, Atsushi Hiraoka 37, Fujimasa Tada 37, Hideko Ohama 37, Kazuhiro Nouso 20, Asahiro Morishita 21, Akemi Tsutsui 23, Takuya Nagano 23, Norio Itokawa 22, Tomomi Okubo 22, Michitaka Imai 27, Hisashi Kosaka 38, Atsushi Naganuma 39, Yohei Koizumi
|
|
|
25. | Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy |
|
J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. Online ahead of print.
N M Batt 1, B Rodrigues 1, S Bloom 1 2, R Sawhney 1 2, E S George 3, A Hodge 1 2, N Vootukuru 1, C McCrae 1, Surbhi Sood 3, S K Roberts 4 5, A Dev 6, S Bell 5 6, A Thompson 7 8, M C Ryan 7 8, W Kemp 4, P J Gow 9, Siddharth Sood 10, A J Nicoll 1 2
|
|
|
|
|
|
|
|
|
29. | Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy |
|
J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. Online ahead of print.
N M Batt 1, B Rodrigues 1, S Bloom 1 2, R Sawhney 1 2, E S George 3, A Hodge 1 2, N Vootukuru 1, C McCrae 1, Surbhi Sood 3, S K Roberts 4 5, A Dev 6, S Bell 5 6, A Thompson 7 8, M C Ryan 7 8, W Kemp 4, P J Gow 9, Siddharth Sood 10, A J Nicoll 1 2
|
|
|
30. | Global prevalence of MAFLD-related hepatocellular carcinoma: A systematic review and meta-analysis |
|
Clin Mol Hepatol. 2024 Apr 16. doi: 10.3350/cmh.2024.0109. Online ahead of print.
Harry Crane 1, Guy D Eslick 2, Cameron Gofton 1 3, Anjiya Shaikh 4, George Cholankeril 5, Mark Cheah 6, Jian-Hong Zhong 7, Gianluca Svegliati-Baroni 8, Alessandro Vitale 9, Beom Kyung Kim 10, Sang Hoon Ahn 10, Mi Na Kim 10, Simone Strasser 11, Jacob George 1
|
|
|
|
|
32. | Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib |
|
Intern Emerg Med. 2024 Mar 29. doi: 10.1007/s11739-024-03578-8. Online ahead of print.
Bernardo Stefanini # 1, Francesco Tovoli # 2 3, Franco Trevisani 2 4, Mariarosaria Marseglia 3, Giovan Giuseppe Di Costanzo 5, Giuseppe Cabibbo 6, Rodolfo Sacco 7 8, Filippo Pellizzaro 9, Tiziana Pressiani 10, Rusi Chen 2, Francesca Romana Ponziani 11, Francesco Giuseppe Foschi 12, Giulia Magini 13, Alessandro Granito 2 3, Fabio Piscaglia 2 3; Italian Liver Cancer (ITA.LI.CA) group
|
|
|
33. | Lean body mass index is a marker of advanced tumor features in patients with hepatocellular carcinoma |
|
World J Hepatol. 2024 Mar 27;16(3):393-404. doi: 10.4254/wjh.v16.i3.393.
Andrew Scott deLemos 1, Jing Zhao 2, Milin Patel 3, Banks Kooken 3, Karan Mathur 4, Hieu Minh Nguyen 5, Areej Mazhar 6, Maggie McCarter 2, Heather Burney 7, Carla Kettler 7, Naga Chalasani 8, Samer Gawrieh 8
|
|
|
34. | Medicaid expansion and palliative care for advanced-stage liver cancer |
|
J Gastrointest Surg. 2024 Apr;28(4):434-441. doi: 10.1016/j.gassur.2024.01.042.Epub 2024 Feb 12.
Henrique A Lima 1, Parit Mavani 2, Muhammad Musaab Munir 2, Yutaka Endo 2, Selamawit Woldesenbet 2, Muhammad Muntazir Mehdi Khan 2, Karol Rawicz-Pruszynski 3, Usama Waqar 4, Erryk Katayama 2, Vivian Resende 1, Mujtaba Khalil 2, Timothy M Pawlik 5
|
|
|
|
|
|
|
37. | No correlation between MASLD and poor outcome of Atezolizumab-Bevacizumab therapy in patients with advanced HCC |
|
Liver Int. 2024 Apr;44(4):931-943. doi: 10.1111/liv.15833. Epub 2024 Jan 30.
Francisca-Dora Copil 1, Claudia Campani 2, Marie Lequoy 3, Philippe Sultanik 1, Lorraine Blaise 4, Mathilde Wagner 5, Nathalie Ganne-Carrié 2 4, Violaine Ozenne 3, Dominique Thabut 1 6, Jean-Charles Nault 2 4, Vlad Ratziu 1 6, Manon Allaire 1 2 7
|
|
|
38. | Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update |
|
J Clin Oncol. 2024 Mar 19:JCO2302745. doi: 10.1200/JCO.23.02745. Online ahead of print.
John D Gordan 1, Erin B Kennedy 2, Ghassan K Abou-Alfa 3 4, Eliza Beal 5, Richard S Finn 6, Terence P Gade 7, Laura Goff 8, Shilpi Gupta 9, Jennifer Guy 10, Hang T Hoang 11, Renuka Iyer 12, Ishmael Jaiyesimi 13, Minaxi Jhawer 14, Asha Karippot 15, Ahmed O Kaseb 16, R Kate Kelley 1, Jeremy Kortmansky 17, Andrea Leaf 18, William M Remak 19, Davendra P S Sohal 20, Tamar H Taddei 21, Andrea Wilson Woods 22, Mark Yarchoan 23, Michal G Rose 24
|
|
|
|
|
|
|
|
|
42. | a-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma |
|
Int J Cancer. 2024 Mar 15;154(6):1043-1056. doi: 10.1002/ijc.34799. Epub 2023 Nov 23.
Federico Rossari 1 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Changhoon Yoo 7, Jaekyung Cheon 8, Fabian Finkelmeier 9, Ho Yeong Lim 10, José Presa 11, Gianluca Masi 12 13, Francesca Bergamo 14, Elisabeth Amadeo 1, Francesco Vitiello 1, Takashi Kumada 15, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 8, Vera Himmelsbach 9, Massimo Iavarone 16, Giuseppe Cabibbo 17, Margarida Montes 11, Francesco Giuseppe Foschi 18, Caterina Vivaldi 12 13, Caterina Soldà 14, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 9, Masashi Hirooka 19, Kazuya Kariyama 20, Joji Tani 21, Masanori Atsukawa 22, Koichi Takaguchi 23, Ei Itobayashi 24, Shinya Fukunishi 25, Kunihiko Tsuji 26, Toru Ishikawa 27, Kazuto Tajiri 28, Hironori Ochi 29, Satoshi Yasuda 30, Hidenori Toyoda 30, Chikara Ogawa 31, Takashi Nishimura 32, Takeshi Hatanaka 33, Satoru Kakizaki 34, Noritomo Shimada 35, Kazuhito Kawata 36, Atsushi Hiraoka 37, Fujimasa Tada 37, Hideko Ohama 37, Kazuhiro Nouso 20, Asahiro Morishita 21, Akemi Tsutsui 23, Takuya Nagano 23, Norio Itokawa 22, Tomomi Okubo 22, Michitaka Imai 27, Hisashi Kosaka 38, Atsushi Naganuma 39, Yohei Koizumi
|
|
|
43. | Metabolic-associated fatty liver disease and hepatocellular carcinoma: a prospective study of characteristics and response to therapy |
|
J Gastroenterol Hepatol. 2024 Feb 18. doi: 10.1111/jgh.16501. Online ahead of print.
N M Batt 1, B Rodrigues 1, S Bloom 1 2, R Sawhney 1 2, E S George 3, A Hodge 1 2, N Vootukuru 1, C McCrae 1, Surbhi Sood 3, S K Roberts 4 5, A Dev 6, S Bell 5 6, A Thompson 7 8, M C Ryan 7 8, W Kemp 4, P J Gow 9, Siddharth Sood 10, A J Nicoll 1 2
|
|
|
|
|
45. | ASK1/p38 axis inhibition blocks the release of mitochondrial "danger signals" from hepatocytes and suppresses progression to cirrhosis and liver cancer |
|
Hepatology. 2024 Feb 20. doi: 10.1097/HEP.0000000000000801. Online ahead of print.
Zhenwei Peng 1 2, Guangyan Wei 1 2, Pinzhu Huang 2, Heansika Matta 2, Gao Wen 2, Ping An 2, Shuangshuang Zhao 2, Yi Lin 2, Li Tan 2 3, Kahini Vaid 2, Disha Skelton-Badlani 2, Imad Nasser 4, Grant Budas 5, David Lopez 5, Li Li 5, David Breckenridge 5, Rob Myers 5, John McHutchison 5, Ming Kuang 3 6, Yury V Popov 2
|
|
|
|
|
47. | Geographic Disparities in Access to Liver Transplant for Advanced Cirrhosis: Time to Ring the Alarm! |
|
Am J Transplant. 2024 Feb 20:S1600-6135(24)00160-6. doi: 10.1016/j.ajt.2024.02.018.Online ahead of print.
Jasmohan S Bajaj 1, Ashok Choudhury 2, Vinay Kumaran 3, Florence Wong 4, Wai Kay Seto 5, Mario Reis Alvares-Da-Silva 6, Hailemichael Desalgn 7, Peter C Hayes 8, Ramazan Idilman 9, Mark Topazian 7, Aldo Torre 10, Qing Xie 11, Jacob George 12, Patrick S Kamath 13
|
|
|
|
|
|
|
50. | FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma |
|
Clin Cancer Res. 2024 Jan 17;30(2):269-273.doi: 10.1158/1078-0432.CCR-23-2124.
Timil H Patel 1, Jamie R Brewer 1, Jiaxin Fan 2, Joyce Cheng 2, Yuan-Li Shen 2, Yue Xiang 3, Hong Zhao 3, Steven J Lemery 1 4, Richard Pazdur 1 4, Paul G Kluetz 1 4, Lola A Fashoyin-Aje 1 4
|
|
|
|
|
52. | Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part II - Non-surgical treatments |
|
Dig Liver Dis. 2024 Mar;56(3):394-405. doi: 10.1016/j.dld.2023.10.028.Epub 2023 Dec 4.
Giuseppe Cabibbo 1, Bruno Daniele 2, Mauro Borzio 3, Andrea Casadei-Gardini 4, Umberto Cillo 5, Agostino Colli 6, Massimiliano Conforti 7, Vincenzo Dadduzio 8, Francesco Dionisi 9, Fabio Farinati 10, Ivan Gardini 7, Edoardo Giovanni Giannini 11, Rita Golfieri 12, Maria Guido 13, Andrea Mega 14, Michela Cinquini 15, Fabio Piscaglia 16, Lorenza Rimassa 17, Laura Romanini 18, Anna Pecorelli 19, Rodolfo Sacco 20, Marta Scorsetti 21, Luca Viganò 22, Alessandro Vitale 5, Franco Trevisani 23
|
|
|
53. | Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC |
|
Hepatology. 2024 Feb 1;79(2):355-367. doi: 10.1097/HEP.0000000000000538.Epub 2023 Jul 17.
Marco Senzolo 1, Sarah Shalaby 1, Marco Grasso 1, Alessandro Vitale 2, Enrico Pizzirani 3, Giulio Barbiero 3, Alberto Zanetto 1, Paolo Feltracco 4, Paolo Simioni 5, Patrizia Burra 1, Umberto Cillo 2
|
|
|
|
|
|
|
|
|
57. | Hepatocellular Carcinoma Diagnosis and Management in 2021: A National Veterans Affairs Quality Improvement Project |
|
Clin Gastroenterol Hepatol. 2024 Feb;22(2):324-338. doi: 10.1016/j.cgh.2023.07.002.Epub 2023 Jul 15.
Shari S Rogal 1, Tamar H Taddei 2, Alexander Monto 3, Vera Yakovchenko 4, Heather Patton 5, Monica Merante 4, Patrick Spoutz 6, Linda Chia 6, Jennifer Yudkevich 7, Ayse Aytaman 8, Atoosa Rabiee 9, Binu V John 10, Boris Blechacz 11, Cindy X Cai 12, HoChong Gilles 13, Anand S Shah 14, Heather McCurdy 15, Puneet Puri 16, Janice Jou 17, Khurram Mazhar 18, Jason A Dominitz 19, Jennifer Anwar 20, Timothy R Morgan 21, George N Ioannou 19
|
|
|
58. | Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) - Part I - Surgical treatments |
|
Dig Liver Dis. 2024 Feb;56(2):223-234. doi: 10.1016/j.dld.2023.10.029.Epub 2023 Nov 28.
Giuseppe Cabibbo 1, Bruno Daniele 2, Mauro Borzio 3, Andrea Casadei-Gardini 4, Umberto Cillo 5, Agostino Colli 6, Massimiliano Conforti 7, Vincenzo Dadduzio 8, Francesco Dionisi 9, Fabio Farinati 10, Ivan Gardini 7, Edoardo Giovanni Giannini 11, Rita Golfieri 12, Maria Guido 13, Andrea Mega 14, Silvia Minozzi 15, Fabio Piscaglia 16, Lorenza Rimassa 17, Laura Romanini 18, Anna Pecorelli 19, Rodolfo Sacco 20, Marta Scorsetti 21, Luca Viganò 22, Alessandro Vitale 5, Franco Trevisani 23
|
|
|
|
|
|
|
|
|
|
|
|
|
64. | Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines |
|
Int J Radiat Oncol Biol Phys. 2024 Feb 1;118(2):337351.doi:10.1016/j.ijrobp.2023.08.015. Epub 2023 Aug 18.
Sun Hyun Bae 1, Seok-Joo Chun 2, Joo-Hyun Chung 2, Eunji Kim 3, Jin-Kyu Kang 4, Won Il Jang 5, Ji Eun Moon 6, Isaure Roquette 7, Xavier Mirabel 7, Tomoki Kimura 8, Masayuki Ueno 9, Ting-Shi Su 10, Alison C Tree 11, Matthias Guckenberger 12, Simon S Lo 13, Marta Scorsetti 14, Ben J Slotman 15, Rupesh Kotecha 16, Arjun Sahgal 17, Alexander V Louie 17, Mi-Sook Kim 18
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
81. | Combined hepatocellular-cholangiocarcinoma compared to hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Different survival, similar recurrence: Report of a large study on repurposed databases with propensity score matching |
|
Surgery. 2023 Nov 17:S0039-6060(23)00710-9. doi: 10.1016/j.surg.2023.09.040.Online ahead of print.
Boris Amory 1, Claire Goumard 2, Alexis Laurent 3, Serena Langella 4, Daniel Cherqui 5, Ephrem Salame 6, Louise Barbier 6, Olivier Soubrane 7, Olivier Farges 8, Christian Hobeika 8, Takayuki Kawai 9, Jean-Marc Regimbeau 10, François Faitot 11, Patrick Pessaux 12, Stéphanie Truant 13, Emmanuel Boleslawski 13, Astrid Herrero 14, Jean-Yves Mabrut 15, Laurence Chiche 16, Marcello Di Martino 17, Rami Rhaiem 18, Lilian Schwarz 19, Vivian Resende 20, Julien Calderaro 21, Jérémy Augustin 21, Stefano Caruso 21, Daniele Sommacale 22, Stefan Hofmeyr 23, Alessandro Ferrero 4, David Fuks 24, Eric Vibert 5, Guido Torzilli 25, Olivier Scatton 2, Raffaele Brustia 26; AFC-ICC-2009, AFC-LLR-2018, and PRS-2019 Study Group
|
|
|
82. | Association Between the Presence of Metabolic Comorbidities and Liver-Related Events in Patients With Chronic Hepatitis B |
|
Clin Gastroenterol Hepatol. 2023 Nov;21(12):30893096.e1. doi:10.1016/j.cgh.2023.03.024.Epub 2023 Mar 31.
Lesley A Patmore 1, Warshan K Katwaroe 2, Daniel van der Spek 2, Hannah S J Choi 3, Keyur Patel 3, Sylvia Brakenhoff 2, Adriaan J van der Meer 2, Willem P Brouwer 2, Laurens A van Kleef 2, Rob J de Knegt 2, Bettina E Hansen 4, Rob A de Man 2, Jordan J Feld 4, Harry L A Janssen 5, Milan J Sonneveld 2
|
|
|
|
|
|
|
85. | GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study |
|
Hepatol Commun. 2023 Sep 15;7(10):e0262. doi: 10.1097/HC9.0000000000000262.eCollection 2023 Oct 1.
Erica Villa 1, Rossella Donghia 2, Valentina Baldaccini 1, Calogero C Tedesco 2, Endrit Shahini 2, Raffaele Cozzolongo 2, Sara Ascari 1, Pasqua Letizia Pesole 2, Sergio Coletta 2, Rosina Maria Critelli 1, Simone Lasagni 1 3, Filippo Schepis 1, Filippo Semellini 1, Gianluigi Giannelli 2
|
|
|
86. | Survival benefit of second line therapies for recurrent hepatocellular carcinoma: repeated hepatectomy, thermoablation and second-line transplant referral in a real life national scenario |
|
HPB (Oxford). 2023 Oct;25(10):1223-1234. doi: 10.1016/j.hpb.2023.06.004. Epub 2023 Jun 12.
Simone Famularo 1, Umberto Cillo 2, Andrea Lauterio 3, Matteo Donadon 4, Alessandro Vitale 2, Matteo Serenari 5, Federica Cipriani 6, Federico Fazio 7, Mario Giuffrida 8, Francesco Ardito 9, Tommaso Dominioni 10, Mattia Garancini 11, Quirino Lai 12, Daniele Nicolini 13, Sarah Molfino 14, Pasquale Perri 15, Enrico Pinotti 16, Simone Conci 17, Cecilia Ferrari 18, Matteo Zanello 19, Stefan Patauner 20, Giuseppe Zimmitti 21, Paola Germani 22, Marco Chiarelli 23, Maurizio Romano 24, Michela De Angelis 25, Giuliano La Barba 26, Albert Troci 27, Valentina Ferraro 28, Francesco Izzo 29, Adelmo Antonucci 30, Andrea Belli 29, Riccardo Memeo 28, Michele Crespi 27, Giorgio Ercolani 26, Luigi Boccia 25, Giacomo Zanus 24, Paola Tarchi 22, Moh'd Abu Hilal 21, Antonio Frena 20, Elio Jovine 19, Guido Griseri 18, Andrea Ruzzenente 17, Mauro Zago 31, Gianluca Grazi 15, Gian L Baiocchi 14, Marco Vivarelli 13, Massimo Rossi 12, Fabrizio Romano 11, Marcello Maestri 10, Felice Giuliante 9, Raffaele D Valle 8, Alessandro Ferrero 7, Luca Aldrighetti 6, Luciano De Carlis 3, Matteo Cescon 5, Guido Torzilli 32; HE.RC.O.LE.S. Group Contributors
|
|
|
87. | The effectiveness of ablative and non-surgical therapies for early hepatocellular carcinoma: Systematic review and network meta-analysis of randomised controlled trials |
|
Cancer Med. 2023 Nov;12(22):20759-20772. doi: 10.1002/cam4.6643.Epub 2023 Oct 30.
Emily South 1, Ros Wade 1, Sumayya Anwer 1, Sahar Sharif-Hurst 1, Melissa Harden 1, Helen Fulbright 1, Sofia Dias 1, Mark Simmonds 1, Ian Rowe 2, Patricia Thornton 3, Tze Min Wah 2, Alison Eastwood 1
|
|
|
|
|
|
|
|
|
|
|
|
|
93. | Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial |
|
Lancet. 2023 Nov 18;402(10415):1835-1847.doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.
Shukui Qin 1, Minshan Chen 2, Ann-Lii Cheng 3, Ahmed O Kaseb 4, Masatoshi Kudo 5, Han Chu Lee 6, Adam C Yopp 7, Jian Zhou 8, Lu Wang 9, Xiaoyu Wen 10, Jeong Heo 11, Won Young Tak 12, Shinichiro Nakamura 13, Kazushi Numata 14, Thomas Uguen 15, David Hsiehchen 16, Edward Cha 17, Stephen P Hack 17, Qinshu Lian 17, Ning Ma 17, Jessica H Spahn 17, Yulei Wang 18, Chun Wu 19, Pierce K H Chow 20; IMbrave050 investigators
IMbrave050 investigators:
Alexander Thompson, Mark Danta, Pirooz Poursoltan, Andrew Kiberu, Renuka Chittajallu, Siddarth Sood, Rudolf Stauber, Matthias Pinter, Markus Peck-Radosavljevic, Jochen Decaestecker, Pieter-Jan Cuyle, Gontran Verset, Hans Van Vlierberghe, Sergio De Azevedo, Livia Andrade, Ademar Cunha Júnior, Luiza Faria, Cheng Tzu Yen, Leandro Colli, Jamil Asselah, Petr Kavan, Vladimir Marquez, Mayur Brahmania, Qiang Li, Baocai Xing, Yabing Guo, Zhendong Chen, Haitao Zhao, Tao Peng, Liming Wang, Lu Wang, Hongming Liu, Feixiang Wu, Lunxiu Qin, Qichang Zheng, Jieer Ying, Haitao Li, Tianfu Wen, Shukui Qin, Xiaoyu Wen, Yunpeng Liu, Minshan Chen, Boqing Wang, Yuxian Bai, Yifu He, Hong Zhao, Dong Zhou, Chaoliu Dai, Gaojun Teng, Shuzhong Cui, Yi Gao, Xizhi Zhang, Zheng Lu, Tao Yin, Youming Ding, Weidong Jia, Yongxiang Xia, Beicheng Sun, Qiang Xia, Yufeng Yuan, Huichuan Sun, Xuetao Shi, Adrián Guzmán, Luis Corrales, Zdenek Kral, Peter Priester, Eugen Kubala, Jean Frederic Blanc, Marc Bourliere, Jean Marie Peron, Christophe Borg, Jean-Pierre Bronowicki, Nathalie Ganne, Thomas Decaens, Thomas Uguen, Alexandra Heurgue, Joerg Trojan, Maria Angeles Gonzalez-Carmona, Christoph Roderburg, Thomas Ettrich, Clemens Schotten, Arne Kandulski, Thomas Yau, Lam Chan, Mario Scartozzi, Gianluca Masi, Silvia Fanello, Pier Maria Battezzati, Francesco Leonardi, Michele Ghidini, Kazushi Numata, Manabu Morimoto, Hisashi Hidaka, Kaoru Tsuchiya, Tatsuya Yamashita, Naoya Kato, Masatoshi Kudo, Atsushi Hagihara, Hironori Koga, Tomohiro Arakawa, Ikuo Nakamura, Yusuke Kawamura, Tomokazu Kawaoka, Mitsuo Shimada, Kiyoshi Hasegawa, Hiroyuki Marusawa, Shinchiro Nakamura, Atsushi Hiraoka, Hiromitsu Hayashi, Shin Takeda, Han Chu Lee, Seung Woon Paik, Do Young Kim, Jung Il Lee, Sook-Hyang Jeong, Won Kim, Won Young Tak, Jeong Heo, Hyeyeong Kim, Hong Jae Chon, Jaeyoun Cheong, Seung Kew Yoon, Jung-Hwan Yoon, Ricardo Villalobos, Jorge Luis Martinez Rodriguez, Victor Oyervides Juarez, Carlos Alberto Hernández, Heinz-Josef Klumpen, Judith de Vos-Geelen, Edward Gane, < |
|
|
94. | Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial |
|
Radiology. 2023 Oct;309(1):e230727. doi: 10.1148/radiol.230727.
Esika Savsani 1, Colette M Shaw 1, Flemming Forsberg 1, Corinne E Wessner 1, Andrej Lyshchik 1, Patrick O'Kane 1, Ji-Bin Liu 1, Rashmi Balasubramanya 1, Christopher G Roth 1, Haresh Naringrekar 1, Scott W Keith 1, Allison Tan 1, Kevin Anton 1, Kristen Bradigan 1, Jesse Civan 1, Susan Schultz 1, Susan Shamimi-Noori 1, Stephen Hunt 1, Michael C Soulen 1, Robert F Mattrey 1, Yuko Kono 1, John R Eisenbrey 1
|
|
|
95. | Intermittent Fasting Primes the Tumor Microenvironment and Improves Nanomedicine Delivery in Hepatocellular Carcinoma |
|
Small. 2023 Oct;19(43):e2208042. doi: 10.1002/smll.202208042. Epub 2023 Jun 27.
Svea Becker 1 2, Jeffrey Momoh 2, Ilaria Biancacci 2, Diana Möckel 2, Qingbi Wang 1, Jan-Niklas May 2, Huan Su 1, Lena Susanna Candels 1, Marie-Luise Berres 1, Fabian Kiessling 2, Maximilian Hatting 1, Twan Lammers 2, Christian Trautwein 1
|
|
|
96. | Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study |
|
Gastroenterology. 2023 Oct;165(4):1053-1063.e6.doi: 10.1053/j.gastro.2023.06.027. Epub 2023 Jul 8.
K Rajender Reddy 1, Dale McLerran 2, Tracey Marsh 2, Neehar Parikh 3, Lewis R Roberts 4, Myron Schwartz 5, Mindie H Nguyen 6, Alex Befeler 7, Stephanie Page-Lester 2, Runlong Tang 2, Sudhir Srivastava 8, Jo Ann Rinaudo 8, Ziding Feng 2, Jorge A Marrero 9
|
|
|
97. | The number of hepatocellular carcinoma foci as predictor of poor response to tumor-directed therapies in patients awaiting liver transplantation: a prospective cohort study |
|
Eur J Gastroenterol Hepatol. 2023 Oct 1;35(10):1224-1229.doi: 10.1097/MEG.0000000000002631. Epub 2023 Aug 14.
Yucel Aydin 1, Ali R Koksal 1, Paul Thevenot 2, Kelley Nunez 2, Mohamed Elgamal 3, Ulkuhan I Koksal 4, Tyler Sandow 2, Martin Moehlen 1, Frederic Regenstein 1, Veysel Tahan 5, Ari Cohen 2 6
|
|
|
98. | Intermittent Fasting Primes the Tumor Microenvironment and Improves Nanomedicine Delivery in Hepatocellular Carcinoma |
|
Small. 2023 Oct;19(43):e2208042. doi: 10.1002/smll.202208042. Epub 2023 Jun 27.
Svea Becker 1 2, Jeffrey Momoh 2, Ilaria Biancacci 2, Diana Möckel 2, Qingbi Wang 1, Jan-Niklas May 2, Huan Su 1, Lena Susanna Candels 1, Marie-Luise Berres 1, Fabian Kiessling 2, Maximilian Hatting 1, Twan Lammers 2, Christian Trautwein 1
|
|
|
99. | Generation of an Alagille syndrome (ALGS) patient-derived induced pluripotent stem cell line (TRNDi032-A) carrying a heterozygous mutation (p.Cys682Leufs*7) in the JAG1 gene |
|
Stem Cell Res. 2023 Oct 18:73:103231. doi: 10.1016/j.scr.2023.103231. Online ahead of print.
Omer Hatim 1, Ivan Pavlinov 1, Miao Xu 1, Kaari Linask 2, Jeanette Beers 2, Chengyu Liu 3, Karsten Baumgärtel 4, Melissa Gilbert 5, Nancy Spinner 5, Catherine Chen 1, Jizhong Zou 2, Wei Zheng 6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
107. | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study |
|
Lancet. 2023 Sep 30;402(10408):1133-1146.doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.
Shukui Qin 1, Stephen L Chan 2, Shanzhi Gu 3, Yuxian Bai 4, Zhenggang Ren 5, Xiaoyan Lin 6, Zhendong Chen 7, Weidong Jia 8, Yongdong Jin 9, Yabing Guo 10, Xiaohua Hu 11, Zhiqiang Meng 12, Jun Liang 13, Ying Cheng 14, Jianping Xiong 15, Hong Ren 16, Fang Yang 17, Wei Li 18, Yajin Chen 19, Yong Zeng 20, Alexander Sultanbaev 21, Monika Pazgan-Simon 22, Margaryta Pisetska 23, Davide Melisi 24, Dmitriy Ponomarenko 25, Yurii Osypchuk 26, Ivan Sinielnikov 27, Tsai-Sheng Yang 28, Xiao Liang 29, Chunxia Chen 29, Linna Wang 29, Ann-Lii Cheng 30, Ahmed Kaseb 31, Arndt Vogel 32; CARES-310 Study Group
Collaborators
Shukui Qin, Stephen L Chan, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Yurii Osypchuk, Ivan Sinielnikov, Tsai-Sheng Yang, Xiao Liang, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Ping Hao, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bozena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, Marina Nechaeva, Chia-Jui Yen, Wei-Wen Su, Yen-Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gomez-Martin, Min-Hee Ryu, Han-Sang Kim, Jee-Hyun Kim, Oleg Zarubenkov, Rashida Orlova, Elena Poddubskaya, Natalia Fadeeva, Yulia Makarova, Yee Chao, Chao-Hung Hung, Maryna Neffa, Oleksandr Vynnychenko, Adam Burgoyne, Chunyi Hao, Raphael U Mohr, Roberto Diaz-Beveridge, Jaime Feliu-Batlle, Antonio Cubillo-Gracian, Ann-Shing Lee, Bruno Daniele, Lorenzo Antonuzzo, Angelo Sangiovanni, Antonio Gasbarrini, Mario Scartozzi, Mi Sun Ahn, Sung-Yong Oh, Sergey Orlov, Hakan Harputluoglu, Berna Oksuzoglu, Chiun Hsu, Kun-Ming Rau, Oleksandr Krechkovskyi, Vladimir Yareshko, Henry Xiong, Fa-Chyi Lee, Yixing Jiang, Afshin Gabayan, Mary Crow, Christophe Van Steenkiste, Gontran Verset
|
|
|
|
|
|
|
|
|
|
|
112. | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study |
|
Lancet. 2023 Sep 30;402(10408):1133-1146.doi: 10.1016/S0140-6736(23)00961-3. Epub 2023 Jul 24.
Shukui Qin 1, Stephen L Chan 2, Shanzhi Gu 3, Yuxian Bai 4, Zhenggang Ren 5, Xiaoyan Lin 6, Zhendong Chen 7, Weidong Jia 8, Yongdong Jin 9, Yabing Guo 10, Xiaohua Hu 11, Zhiqiang Meng 12, Jun Liang 13, Ying Cheng 14, Jianping Xiong 15, Hong Ren 16, Fang Yang 17, Wei Li 18, Yajin Chen 19, Yong Zeng 20, Alexander Sultanbaev 21, Monika Pazgan-Simon 22, Margaryta Pisetska 23, Davide Melisi 24, Dmitriy Ponomarenko 25, Yurii Osypchuk 26, Ivan Sinielnikov 27, Tsai-Sheng Yang 28, Xiao Liang 29, Chunxia Chen 29, Linna Wang 29, Ann-Lii Cheng 30, Ahmed Kaseb 31, Arndt Vogel 32; CARES-310 Study Group
Collaborators
Shukui Qin, Stephen L Chan, Ann-Lii Cheng, Ahmed Kaseb, Arndt Vogel, Shanzhi Gu, Yuxian Bai, Zhenggang Ren, Xiaoyan Lin, Zhendong Chen, Weidong Jia, Yongdong Jin, Yabing Guo, Xiaohua Hu, Zhiqiang Meng, Jun Liang, Ying Cheng, Jianping Xiong, Hong Ren, Fang Yang, Wei Li, Yajin Chen, Yong Zeng, Alexander Sultanbaev, Monika Pazgan-Simon, Margaryta Pisetska, Davide Melisi, Dmitriy Ponomarenko, Yurii Osypchuk, Ivan Sinielnikov, Tsai-Sheng Yang, Xiao Liang, Chunxia Chen, Linna Wang, Mingxiang Zhang, Li Xu, Xianglin Yuan, Da Li, Jierer Ying, Jingdong Zhang, Tao Zhang, Kangsheng Gu, Yifu He, Ping Hao, Da Jiang, Shu Zhang, Baocai Xing, Baihong Zhang, Dong Wang, Xiaofeng Zhai, Houjie Liang, Bozena Cybulska-Stopa, Mikhail Dvorkin, Daniil Stroyakovskiy, Marina Nechaeva, Chia-Jui Yen, Wei-Wen Su, Yen-Hao Chen, Igor Bondarenko, Lin Yang, Weijia Fang, Carlos Gomez-Martin, Min-Hee Ryu, Han-Sang Kim, Jee-Hyun Kim, Oleg Zarubenkov, Rashida Orlova, Elena Poddubskaya, Natalia Fadeeva, Yulia Makarova, Yee Chao, Chao-Hung Hung, Maryna Neffa, Oleksandr Vynnychenko, Adam Burgoyne, Chunyi Hao, Raphael U Mohr, Roberto Diaz-Beveridge, Jaime Feliu-Batlle, Antonio Cubillo-Gracian, Ann-Shing Lee, Bruno Daniele, Lorenzo Antonuzzo, Angelo Sangiovanni, Antonio Gasbarrini, Mario Scartozzi, Mi Sun Ahn, Sung-Yong Oh, Sergey Orlov, Hakan Harputluoglu, Berna Oksuzoglu, Chiun Hsu, Kun-Ming Rau, Oleksandr Krechkovskyi, Vladimir Yareshko, Henry Xiong, Fa-Chyi Lee, Yixing Jiang, Afshin Gabayan, Mary Crow, Christophe Van Steenkiste, Gontran Verset
|
|
|
|
|
114. | Associations of Race and Ethnicity with Hepatocellular Carcinoma, Decompensation, and Mortality in US Veterans with Cirrhosis |
|
Cancer Epidemiol Biomarkers Prev. 2023 Aug 1;32(8):1069-1078.doi: 10.1158/1055-9965.EPI-22-1291.
Trang VoPham # 1 2, Anne Cravero # 3, Lauren D Feld 4, Pamela Green 5, Ziding Feng 6, Kristin Berry 5, Nicole J Kim 4, Philip Vutien 4, Jason A Mendoza 7 8 9, George N Ioannou 1 4
|
|
|
115. | Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients |
|
Eur J Cancer. 2023 Aug:189:112933. doi: 10.1016/j.ejca.2023.05.021. Epub 2023 Jun 1.
Mara Persano 1, Margherita Rimini 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, José Presa 10, Gianluca Masi 11, Changhoon Yoo 12, Sara Lonardi 13, Francesco Tovoli 14, Takashi Kumada 15, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Takashi Niizeki 5, Margarida Montes 10, Caterina Vivaldi 11, Caterina Soldà 13, Bernardo Stefanini 14, Atsushi Hiraoka 16, Takuya Sho 4, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 17, Giovanni Di Costanzo 18, Fabio Marra 19, Emiliano Tamburini 20, Giuseppe Cabibbo 21, Francesco Giuseppe Foschi 22, Marianna Silletta 23, Masashi Hirooka 24, Kazuya Kariyama 25, Joji Tani 26, Masanori Atsukawa 27, Koichi Takaguchi 28, Ei Itobayashi 29, Shinya Fukunishi 30, Kunihiko Tsuji 31, Toru Ishikawa 32, Kazuto Tajiri 33, Hironori Ochi 34, Satoshi Yasuda 35, Hidenori Toyoda 35, Chikara Ogawa 36, Takashi Nishimura 37, Takeshi Hatanaka 38, Satoru Kakizaki 39, Noritomo Shimada 40, Kazuhito Kawata 41, Fujimasa Tada 16, Hideko Ohama 16, Kazuhiro Nouso 25, Asahiro Morishita 26, Akemi Tsutsui 28, Takuya Nagano 28, Norio Itokawa 27, Tomomi Okubo 27, Taeang Arai 27, Michitaka Imai 32, Hisashi Kosaka 42, Atsushi Naganuma 43, Yohei Koizumi 24, Shinichiro Nakamura 3, Masaki Kaibori 42, Hiroko Iijima 37, Yoichi Hiasa 24, Claudia Campani 19, Elisabeth Amadeo 44, Federico Rossari 44, Valentina Burgio 44, Stefano Cascinu 2, Mario Scartozzi 45,&nbs |
|
|
116. | Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy |
|
Hepatol Commun. 2023 Sep 15;7(10):e0261. doi: 10.1097/HC9.0000000000000261.eCollection 2023 Oct 1.
Bernhard Scheiner 1 2 3, Katharina Lampichler 4, Katharina Pomej 1 2, Lucian Beer 4, Lorenz Balcar 1 2, Riccardo Sartoris 5, Mohamed Bouattour 6, Sabrina Sidali 6, Michael Trauner 1, Mattias Mandorfer 1, Thomas Reiberger 1, Martina Scharitzer 4, Dietmar Tamandl 4, David J Pinato 3 7, Maxime Ronot 5 8, Matthias Pinter 1 2
|
|
|
|
|
118. | Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study |
|
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602.doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
Mara Persano # 1, Margherita Rimini # 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, Lorenza Rimassa 10 11, José Presa 12, Gianluca Masi 13 14, Changhoon Yoo 15, Sara Lonardi 16, Francesco Tovoli 17, Takashi Kumada 18, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Tiziana Pressiani 11, Takumi Kawaguchi 5, Margarida Montes 12, Caterina Vivaldi 13 14, Caterina Soldà 16, Fabio Piscaglia 17, Atsushi Hiraoka 19, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 20, Giovanni Di Costanzo 21, Fabio Marra 22, Mario Scartozzi 1, Emiliano Tamburini 23, Giuseppe Cabibbo 24, Francesco Giuseppe Foschi 25, Marianna Silletta 26, Masashi Hirooka 27, Kazuya Kariyama 28, Joji Tani 29, Masanori Atsukawa 30, Koichi Takaguchi 31, Ei Itobayashi 32, Shinya Fukunishi 33, Kunihiko Tsuji 34, Toru Ishikawa 35, Kazuto Tajiri 36, Hironori Ochi 37, Satoshi Yasuda 38, Hidenori Toyoda 38, Chikara Ogawa 39, Takashi Nishimura 40, Takeshi Hatanaka 41, Satoru Kakizaki 42, Noritomo Shimada 43, Kazuhito Kawata 44, Fujimasa Tada 19, Hideko Ohama
|
|
|
119. | Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma in the United States: An Update |
|
Dig Dis Sci. 2023 Oct;68(10):4050-4059. doi: 10.1007/s10620-023-08084-z.Epub 2023 Aug 16.
Yassine Kilani 1, Syeda Ashna Fatima Kamal 2, Fnu Vikash 3, Sindhu Vikash 3, Mohammad Aldiabat 4, Saqr Alsakarneh 5, Yazan Aljabiri 6, Haris Sohail 6, Vikash Kumar 7, Laith Numan 8, Kawtar Al Khalloufi 9
|
|
|
120. | The Impact of a Liver Transplant Program on the Outcomes of Hepatocellular Carcinoma |
|
Ann Surg. 2023 Aug 1;278(2):230-238. doi: 10.1097/SLA.0000000000005849.Epub 2023 Mar 30.
Yutaka Endo 1, Kazunari Sasaki 2, Zorays Moazzam 1, Selamawit Woldesenbet 1, Jason Yang 1, Henrique Araujo Lima 1, Laura Alaimo 1, Muhammad Musaab Munir 1, Chanza F Shaikh 1, Austin Schenk 1, Minoru Kitago 3, Timothy M Pawlik 1
|
|
|
121. | Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients |
|
J Cancer Res Clin Oncol. 2023 Aug;149(10):7565-7577. doi: 10.1007/s00432-023-04678-2.Epub 2023 Mar 28.
Margherita Rimini 1 2, Mara Persano 3, Toshifumi Tada 4, Goki Suda 5, Shigeo Shimose 6, Masatoshi Kudo 7, Jaekyung Cheon 8, Fabian Finkelmeier 9, Ho Yeong Lim 10, José Presa 11, Francesca Salani 12 13, Sara Lonardi 14, Fabio Piscaglia 15, Takashi Kumada 16, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Marta Schirripa 17 18, Margarida Montes 10, Caterina Vivaldi 11 12, Caterina Soldà 14, Atsushi Hiraoka 19, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Masashi Hirooka 20, Kazuya Kariyama 21, Joji Tani 22, Masanori Atsukawa 23, Koichi Takaguchi 24, Ei Itobayashi 25, Shinya Fukunishi 26, Kunihiko Tsuji 27, Toru Ishikawa 28, Kazuto Tajiri 29, Hironori Ochi 30, Satoshi Yasuda 31, Hidenori Toyoda 31, Chikara Ogawa 32, Takashi Nishimura 33, Takeshi Hatanaka 34, Satoru Kakizaki 35, Noritomo Shimada 36, Kazuhito Kawata 37, Fujimasa Tada 19, Hideko Ohama 19, Kazuhiro Nouso 21, Asahiro Morishita 22, Akemi Tsutsui 24, Takuya Nagano 24, Norio Itokawa 23, Tomomi Okubo 23, Taeang Arai 23, Michitaka Imai 28, Hisashi Kosaka 38, Atsushi Naganuma 39, Yohei Koizumi 21, Shinichiro Nakamura
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
132. | Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis |
|
Lancet Gastroenterol Hepatol. 2023 Sep;8(9):829-836.doi: 10.1016/S2468-1253(23)00157-7. Epub 2023 Jul 4.
Daniel Q Huang 1, Nabil Noureddin 2, Veeral Ajmera 2, Maral Amangurbanova 2, Ricki Bettencourt 2, Emily Truong 3, Tolga Gidener 4, Harris Siddiqi 2, Abdul M Majzoub 5, Tarek Nayfeh 6, Nobuharu Tamaki 7, Namiki Izumi 8, Masato Yoneda 9, Atsushi Nakajima 9, Ramazan Idilman 10, Mesut Gumussoy 10, Digdem Kuru Oz 11, Ayse Erden 11, Alina M Allen 4, Mazen Noureddin 12, Rohit Loomba 13
|
|
|
|
|
134. | Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC |
|
Clin Res Hepatol Gastroenterol. 2023 Sep 2;47(8):102199. doi: 10.1016/j.clinre.2023.102199.Online ahead of print.
Sayma Chaibi 1, Edouard Larrey 1, Jean Pierre Couty 2, Philippe Sultanik 1, Claudia Campani 3, Lorraine Blaise 4, Mathilde Wagner 5, Chantal Desdouets 2, Jean Charles Nault 3, Dominique Thabut 6, Manon Allaire 7
|
|
|
|
|
|
|
|
|
138. | Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion |
|
Eur Radiol. 2023 Jul 13. doi: 10.1007/s00330-023-09919-z. Online ahead of print.
Bachir Taouli 1, Ahmed Ba-Ssalamah 2, Julius Chapiro 3, Jagpreet Chhatwal 4, Kathryn Fowler 5, Tae Wook Kang 6, Gesine Knobloch 7, Dow-Mu Koh 8, Masatoshi Kudo 9, Jeong Min Lee 10, Takamichi Murakami 11, David J Pinato 12, Kristina I Ringe 13, Bin Song 14, Parissa Tabrizian 15, Jin Wang 16, Jeong Hee Yoon 10, Mengsu Zeng 17, Jian Zhou 18, Valérie Vilgrain 19
|
|
|
|
|
140. | Diagnostic approach to focal liver lesions at cross-sectional imaging: a primer for beginners |
|
Eur Rev Med Pharmacol Sci. 2023 Aug;27(15):7201-7225.doi: 10.26355/eurrev_202308_33293.
A Borgheresi 1, A Agostini, L Pierpaoli, A Zannotti, S Capodagli-Colarizi, M Gabelloni, F De Muzio, M C Brunese, F Bruno, P Palumbo, F Grassi, R Fusco, V Granata, N Gandolfo, V Miele, A Barile, A Giovagnoni
|
|
|
|
|
|
|
|
|
|
|
145. | Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients |
|
Cancer Immunol Immunother. 2023 Jul;72(7):1957-1969.doi: 10.1007/s00262-023-03390-x. Epub 2023 Feb 22.
Cheng-Long Han # 1, Bao-Wen Tian # 1, Lun-Jie Yan 1, Zi-Niu Ding 1, Hui Liu 1, Xin-Cheng Mao 1, Jin-Cheng Tian 1, Jun-Shuai Xue 1, Si-Yu Tan 1, Zhao-Ru Dong 1, Yu-Chuan Yan 1, Jian-Guo Hong 1, Zhi-Qiang Chen 1, Dong-Xu Wang 1, Tao Li 2
|
|
|
|
|
|
|
|
|
|
|
|
|
151. | International Liver Cancer Association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance |
|
J Hepatol. 2023 Jul;79(1):226-239.doi: 10.1016/j.jhep.2023.02.022. Epub 2023 Feb 26.
Amit G Singal 1, Marco Sanduzzi-Zamparelli 2, Pierre Nahon 3, Maxime Ronot 4, Yujin Hoshida 5, Nicole Rich 5, Maria Reig 2, Valerie Vilgrain 4, Jorge Marrero 6, Josep M Llovet 7, Neehar D Parikh 8, Augusto Villanueva 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
164. | Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma |
|
Biology (Basel). 2023 Jul 11;12(7):984. doi: 10.3390/biology12070984.
Riccardo Nevola 1 2, Giovanni Tortorella 1, Valerio Rosato 2, Luca Rinaldi 1, Simona Imbriani 1, Pasquale Perillo 2, Davide Mastrocinque 2, Marco La Montagna 1, Antonio Russo 3, Giovanni Di Lorenzo 1, Maria Alfano 1, Maria Rocco 1, Carmen Ricozzi 1, Klodian Gjeloshi 1, Ferdinando Carlo Sasso 1, Raffaele Marfella 1, Aldo Marrone 1, Loreta Anesti Kondili 4, Nicolino Esposito 2, Ernesto Claar 2, Domenico Cozzolino 1
|
|
|
|
|
|
|
|
|
168. | Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept |
|
Lancet Oncol. 2023 Jul;24(7):e312-e322. doi: 10.1016/S1470-2045(23)00186-9.
Alessandro Vitale 1, Giuseppe Cabibbo 2, Massimo Iavarone 3, Luca Viganò 4, David J Pinato 5, Francesca Romana Ponziani 6, Quirino Lai 7, Andrea Casadei-Gardini 8, Ciro Celsa 9, Giovanni Galati 10, Martina Gambato 11, Laura Crocetti 12, Matteo Renzulli 13, Edoardo G Giannini 14, Fabio Farinati 11, Franco Trevisani 15, Umberto Cillo 11; HCC Special Interest Group of the Italian Association for the Study of the Liver
Collaborators
- HCC Special Interest Group of the Italian Association for the Study of the Liver:
Umberto Baccarani, Giuseppina Brancaccio, Raffaele Cozzolongo, Alessandro Cucchetti, Nicoletta De Matthaeis, Stefano Di Sandro, Simone Famularo, Michele Finotti, Francesco G Foschi, Davide Ghinolfi, Marco Guarracino, Salvatore Gruttadauria, Maria Guarino, Alba Kostandini, Ilaria Lenci, Giovanni B Levi Sandri, Tommaso M Manzia, Giovanni Marasco, Mario Masarone, Chiara Mazzarelli, Fabio Melandro, Luca Miele, Filomena Morisco, Daniele Nicolini, Duilio Pagano, Filippo Pelizzaro, Giulia Pieri, Fabio Piscaglia, Maria Corina Plaz Torres, Riccardo Pravisani, Maria Rendina, Fabrizio Romano, Francesco P Russo, Rodolfo Sacco, Angelo Sangiovanni, Carlo Sposito, Raffaella Tortora, Francesco Tovoli, Mauro Viganò, Paola Violi
|
|
|
|
|
|
|
|
|
|
|
173. | LKB1 signaling and patient survival outcomes in hepatocellular carcinoma |
|
Pharmacol Res. 2023 Jun;192:106757. doi: 10.1016/j.phrs.2023.106757.Epub 2023 Apr 5.
Khoa Nguyen 1, Katherine Hebert 2, Emily McConnell 2, Nicole Cullen 2, Thomas Cheng 2, Susanna Awoyode 2, Elizabeth Martin 2, Weina Chen 3, Tong Wu 3, Suresh K Alahari 4, Reza Izadpanah 5, Bridgette M Collins-Burow 2, Sean B Lee 3, David H Drewry 6, Matthew E Burow 7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
184. | Disruption of proteome by an oncogenic fusion kinase alters metabolism in fibrolamellar hepatocellular carcinoma |
|
Sci Adv. 2023 Jun 23;9(25):eadg7038. doi: 10.1126/sciadv.adg7038. Epub 2023 Jun 21.
Solomon N Levin 1, Michael D Tomasini 1, James Knox 1, Mahsa Shirani 1, Bassem Shebl 1, David Requena 1, Jackson Clark 1, Søren Heissel 2, Hanan Alwaseem 2, Rodrigo Surjan 3, Ron Lahasky 4 5, Henrik Molina 2, Michael S Torbenson 6, Barbara Lyons 5 7, Rachael D Migler 5, Philip Coffino 1, Sanford M Simon 1 5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
191. | Imaging of hepatocellular carcinoma recurrence after liver transplantation |
|
Insights Imaging. 2023 May 15;14(1):84. doi: 10.1186/s13244-023-01425-6.
Giuseppe Mamone 1, Settimo Caruso 2, Mariapina Milazzo 2, Giorgia Porrello 2, Ambra Di Piazza 2, Giovanni Gentile 2, Vincenzo Carollo 2, Francesca Crinò 2, Gianluca Marrone 2, Gianvincenzo Sparacia 2, Luigi Maruzzelli 2, Roberto Miraglia 2, Salvatore Gruttadauria 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
198. | Treatment-related adverse events of first-line immunotherapy versus sorafenib for advanced hepatocellular carcinoma: a meta-analysis |
|
Expert Opin Drug Saf. 2023 Apr;22(4):323-329.doi: 10.1080/14740338.2023.2152793. Epub 2022 Nov 29.
Alessandro Rizzo 1, Riccardo Carloni 2, Angela Dalia Ricci 3, Antonio Cusmai 1, Mariarita Laforgia 4, Concetta Calabrò 4, Valentina Ungaro 4, Donato Oreste 5, Mario Sollitto 5, Gennaro Palmiotti 1, Giovanni Brandi 2
|
|
|
199. | Liver transplantation and hepatocellular carcinoma: is TIPS deleterious? A multicentric retrospective study of the ARCHET research group with propensity score matching |
|
Langenbecks Arch Surg. 2023 Apr 13;408(1):149. doi: 10.1007/s00423-023-02875-8.
Christophe Laurent 1, Michel Rayar 2, Charlotte Maulat 3, Fabrice Muscari 3, Arthur Marichez 4, Emilie Gregoire 5, Sophie Chopinet 5, Jean Yves Mabrut 6, Karim Boudjema 2, Mickael Lesurtel 6, Jean-Philippe Adam 4, Kayvan Mohkam 6, Laurence Chiche 4
|
|
|
200. | The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022 |
|
ESMO Open. 2023 May 30;8(3):101567. doi: 10.1016/j.esmoop.2023.101567.Online ahead of print.
M Ducreux 1, G K Abou-Alfa 2, T Bekaii-Saab 3, J Berlin 4, A Cervantes 5, T de Baere 6, C Eng 4, P Galle 7, S Gill 8, T Gruenberger 9, K Haustermans 10, A Lamarca 11, P Laurent-Puig 12, J M Llovet 13, F Lordick 14, T Macarulla 15, D Mukherji 16, K Muro 17, R Obermannova 18, J-M O'Connor 19, E M O'Reilly 20, P Osterlund 21, P Philip 22, G Prager 23, E Ruiz-Garcia 24, B Sangro 25, T Seufferlein 26, J Tabernero 27, C Verslype 10, H Wasan 28, E Van Cutsem 10
|
|
|
|
|
202. | Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era? |
|
Cancers (Basel). 2023 May 27;15(11):2950. doi: 10.3390/cancers15112950.
Riccardo Nevola 1 2, Augusto Delle Femine 2, Valerio Rosato 1, Loreta Anesti Kondili 3, Maria Alfano 2, Davide Mastrocinque 1, Simona Imbriani 2, Pasquale Perillo 1, Domenico Beccia 2, Angela Villani 2, Rachele Ruocco 2, Livio Criscuolo 2, Marco La Montagna 2, Antonio Russo 4, Aldo Marrone 2, Ferdinando Carlo Sasso 2, Raffaele Marfella 2, Luca Rinaldi 2, Nicolino Esposito 1, Giuseppe Barberis 5, Ernesto Claar 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
213. | Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis |
|
Cancers (Basel). 2023 Apr 2;15(7):2122. doi: 10.3390/cancers15072122.
Victor Lopez-Lopez 1 2 3, Kohei Miura 4, Christoph Kuemmerli 5, Antonio Capel 6, Dilmurodjon Eshmuminov 7, David Ferreras 1 2, Alberto Baroja-Mazo 2, Pedro Cascales-Campos 1 2, María Isabel Jiménez-Mascuñán 1 2, José Antonio Pons 8, Maria Isabel Castellon 9, Francisco Sánchez-Bueno 1 2, Ricardo Robles-Campos 1 2, Pablo Ramírez 1 2
|
|
|
214. | Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment |
|
JGH Open. 2023 Apr 3;7(4):249-260. doi: 10.1002/jgh3.12879.eCollection 2023 Apr.
Daniel R A Cox 1 2, William Chung 3 4, Josephine Grace 3 4, Darren Wong 3 4, Numan Kutaiba 5, Dinesh Ranatunga 5, Richard Khor 6 7 8, Marcos V Perini 1 2, Michael Fink 1 2, Robert Jones 1 2 4, Mark Goodwin 5, Alex Dobrovic 1, Adam Testro 3 4, Vijayaragavan Muralidharan 1 2
|
|
|
|
|
|
|
217. | Prevention of Hepatocellular Carcinoma (HCC). White Paper of the Texas Collaborative Center for Hepatocellular Cancer (TeCH) Multi-stakeholder Conference |
|
Clin Gastroenterol Hepatol. 2023 Apr 20;S1542-3565(23)00237-9.doi: 10.1016/j.cgh.2023.03.029. Online ahead of print.
Hashem B El-Serag 1, John W Ward 2, Sumeet K Asrani 3, Amit G Singal 4, Nicole Rich 4, Aaron P Thrift 5, Salil Deshpande 6, Barbara J Turner 7, Ahmed O Kaseb 8, Ariel C Harrison 9, Brett E Fortune 10, Fasiha Kanwal 9
|
|
|
|
|
219. | Risk factors for HCC in contemporary cohorts of patients with cirrhosis |
|
Hepatology. 2023 Mar 1;77(3):997-1005. doi: 10.1002/hep.32434. Epub 2023 Feb 17.
Fasiha Kanwal 1 2 3, Saira Khaderi 1, Amit G Singal 4, Jorge A Marrero 4, Nicole Loo 5, Sumeet K Asrani 6, Christopher I Amos 7, Aaron P Thrift 7, Xiangjun Gu 7, Michelle Luster 1, Abeer Al-Sarraj 1 2 3, Jing Ning 8, Hashem B El-Serag 1 2 3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
231. | Radioembolization for Hepatocellular Carcinoma-Current Evidence and Patterns of Utilization |
|
J Vasc Interv Radiol. 2023 Mar 29;S1051-0443(23)00254-3.doi: 10.1016/j.jvir.2023.03.020. Online ahead of print.
Hayley Briody 1, David Duong 2, Sern Wei Yeoh 3, Russell Hodgson 4, Tuck Leong Yong 4, Anthony Hannah 5, Michael J Lee 6, Sum Leong 7, Julian Maingard 8, Hamed Asadi 9, Hong Kuan Kok 10
|
|
|
|
|
|
|
|
|
|
|
|
|
237. | Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score |
|
PLoS One. 2023 Feb 28;18(2):e0282309. doi: 10.1371/journal.pone.0282309. eCollection 2023.
Aaron P Thrift 1 2, Fasiha Kanwal 3 4, Yanhong Liu 1 2, Saira Khaderi 3, Amit G Singal 5, Jorge A Marrero 5, Nicole Loo 6, Sumeet K Asrani 7, Michelle Luster 3, Abeer Al-Sarraj 3 4, Jing Ning 8, Spiridon Tsavachidis 1, Xiangjun Gu 1, Christopher I Amos 1 2, Hashem B El-Serag 3 4
|
|
|
|
|
239. | Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification |
|
Ann Surg Oncol. 2023 Feb;30(2):750-759. doi: 10.1245/s10434-022-12832-2.Epub 2022 Nov 20.
Zorays Moazzam 1, Laura Alaimo 1 2, Yutaka Endo 1, Henrique A Lima 1, Chanza F Shaikh 1, Francesca Ratti 3, Hugo P Marques 4, François Cauchy 5, Vincent Lam 6, George A Poultsides 7, Irinel Popescu 8, Sorin Alexandrescu 8, Guillaume Martel 9, Alfredo Guglielmi 2, Tom Hugh 10, Luca Aldrighetti 3, Itaru Endo 11, Timothy M Pawlik 12
|
|
|
|
|
|
|
242. | Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study |
|
Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):921-928.doi: 10.1007/s00259-022-06002-5. Epub 2022 Oct 25.
Jules Gregory 1 2 3 4, Lambros Tselikas 5, Caroline Allimant 6, Thierry de Baere 5, Irene Bargellini 7, Jon Bell 8, José Ignacio Bilbao 9, Antoine Bouvier 10, Julius Chapiro 11, Carlo Chiesa 12, Thomas Decaens 13, Alban Denys 14, Rafael Duran 14, Julien Edeline 15, Etienne Garin 16, Julien Ghelfi 13, Thomas Helmberger 17, Farah Irani 18, Marnix Lam 19, Robert Lewandowski 20, David Liu 21, Romaric Loffroy 22, David C Madoff 11, Charles Mastier 23, Riad Salem 20, Bruno Sangro 24, Daniel Sze 25, Valérie Vilgrain 26 27, Michael Vouche 28, Boris Guiu 6, Maxime Ronot 26 27
|
|
|
|
|
244. | LI-RADS: Looking Back, Looking Forward |
|
Radiology. 2023 Apr;307(1):e222801. doi: 10.1148/radiol.222801. Epub 2023 Feb 28.
Victoria Chernyak 1, Kathryn J Fowler 1, Richard K G Do 1, Aya Kamaya 1, Yuko Kono 1, An Tang 1, Donald G Mitchell 1, Jeffrey Weinreb 1, Cynthia S Santillan 1, Claude B Sirlin 1
|
|
|
245. | Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial |
|
Clin Oncol. 2023 Mar 20;41(9):1747-1757.doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13.
Thomas Yau 1, Vittorina Zagonel 2, Armando Santoro 3 4, Mirelis Acosta-Rivera 5, Su Pin Choo 6, Ana Matilla 7 8, Aiwu Ruth He 9, Antonio Cubillo Gracian 10 11, Anthony B El-Khoueiry 12, Bruno Sangro 13, Tarek E Eldawy 14, Jordi Bruix 15, Giovanni Luca Frassineti 16, Gina M Vaccaro 17, Marina Tschaika 18, Christian Scheffold 19, Petra Koopmans 18, Jaclyn Neely 18, Fabio Piscaglia 20
|
|
|
246. | Updates on LI-RADS Treatment Response Criteria for Hepatocellular Carcinoma: Focusing on MRI |
|
J Magn Reson Imaging. 2023 Mar 5. doi: 10.1002/jmri.28659. Online ahead of print.
Richa Patel 1, Anum Aslam 2, Neehar D Parikh 3, Benjamin Mervak 2, Eman Mubarak 2, Lily Higgins 2, Kayli Lala 2, Jack F Conner 4, Valerie Khaykin 5, Mustafa Bashir 6, Richard Kinh Gian Do 7, Lauren M B Burke 8, Elainea N Smith 9, Charles Y Kim 6, Kimberly L Shampain 2, Dawn Owen 10, Mishal Mendiratta-Lala 2
|
|
|
|
|
248. | Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin |
|
Aliment Pharmacol Ther. 2023 Mar;57(6):600-609. doi: 10.1111/apt.17371.Epub 2023 Jan 10.
Rebecca W Zeng 1, Jie Ning Yong 1, Darren J H Tan 1, Clarissa E Fu 1, Wen Hui Lim 1, Jieling Xiao 1, Kai En Chan 1, Caitlyn Tan 1, Xin Lei Goh 1, Douglas Chee 2, Nicholas Syn 1, Eunice X Tan 1 2 3, Mark D Muthiah 1 2 3, Cheng Han Ng 1, Nobuharu Tamaki 4, Sung Won Lee 5 6, Beom Kyung Kim 7 8, Mindie H Nguyen 9, Rohit Loomba 10, Daniel Q Huang 1 2 3 10
|
|
|
249. | Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada |
|
Cancer Treat Rev. 2023 Apr;115:102526. doi: 10.1016/j.ctrv.2023.102526.Epub 2023 Mar 2.
Jason K Wong 1, Howard J Lim 2, Vincent C Tam 3, Kelly W Burak 4, Laura A Dawson 5, Prosanto Chaudhury 6, Robert J Abraham 7, Brandon M Meyers 8, Gonzalo Sapisochin 9, David Valenti 10, Setareh Samimi 11, Ravi Ramjeesingh 12, Amol Mujoomdar 13, Ilidio Martins 14, Elijah Dixon 15, Maja Segedi 16, David M Liu 17
|
|
|
|
|
|
|
252. | Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma |
|
Clin Cancer Res. 2023 Feb 16;29(4):754-763.doi: 10.1158/1078-0432.CCR-22-1983.
Xuyang Song 1, Robin Kate Kelley 2, Anis A Khan 1, Nathan Standifer 3, Diansong Zhou 4, KyoungSoo Lim 1, Rajesh Krishna 5, Lu Liu 6, Kun Wang 6, Patricia McCoon 7, Alejandra Negro 8, Philip He 9, Megan Gibbs 1, John F Kurland 10, Ghassan K Abou-Alfa 11 12
|
|
|
253. | Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial |
|
Dig Liver Dis. 2023 Apr;55(4):464-470.doi: 10.1016/j.dld.2023.01.161. Epub 2023 Feb 16.
Philippe Merle 1, Jean-Frédéric Blanc 2, Julien Edeline 3, Karine Le Malicot 4, Manon Allaire 5, Eric Assenat 6, Meriem Guarssifi 4, Mohamed Bouattour 7, Jean-Marie Péron 8, Pierre Laurent-Puig 9, Massimo Levrero 10, Charlotte Costentin 11, Boris Guiu 12, Harry Sokol 13, David Tougeron 14, Thomas Aparicio 15, Jean-Charles Nault 16, Jean-Marc Phelip 17
|
|
|
|
|
255. | Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population |
|
Eur J Cancer. 2023 Feb;180:9-20.doi: 10.1016/j.ejca.2022.11.017. Epub 2022 Nov 25. Andrea Casadei-Gardini 1, Margherita Rimini 2, Toshifumi Tada 3, Goki Suda 4, Shigeo Shimose 5, Masatoshi Kudo 6, Jaekyung Cheon 7, Fabian Finkelmeier 8, Ho Yeong Lim 9, Lorenza Rimassa 10, José Presa 11, Gianluca Masi 12, Changhoon Yoo 13, Sara Lonardi 14, Francesco Tovoli 15, Takashi Kumada 16, Naoya Sakamoto 4, Hideki Iwamoto 5, Tomoko Aoki 6, Hong Jae Chon 7, Vera Himmelsbach 8, Tiziana Pressiani 17, Margarida Montes 11, Caterina Vivaldi 12, Caterina Soldà 14, Fabio Piscaglia 15, Atsushi Hiraoka 18, Takuya Sho 4, Takashi Niizeki 5, Naoshi Nishida 6, Christoph Steup 8, Massimo Iavarone 19, Giovanni Di Costanzo 20, Fabio Marra 21, Mario Scartozzi 22, Emiliano Tamburini 23, Giuseppe Cabibbo 24, Francesco Giuseppe Foschi 25, Marianna Silletta 26, Masashi Hirooka 27, Kazuya Kariyama 28, Joji Tani 29, Masanori Atsukawa 30, Koichi Takaguchi 31, Ei Itobayashi 32, Shinya Fukunishi 33, Kunihiko Tsuji 34, Toru Ishikawa 35, Kazuto Tajiri 36, Hironori Ochi 37, Satoshi Yasuda 38, Hidenori Toyoda 38, Chikara Ogawa 39, Takashi Nishimura 40, Takeshi Hatanaka 41, Satoru Kakizaki 42, Noritomo Shimada 43, Kazuhito Kawata 44, Fujimasa Tada 18, Hideko Ohama 18, Kazuhiro Nouso 28, Asahiro Morishita 29, Akemi Tsutsui 31, Takuya Nagano 31, Norio Itokawa 30, Tomomi Okubo 30, Taeang Arai 30, Michitaka Imai 35, Hisashi Kosaka 45, Atsushi Naganuma 46, Yohei Koizumi 28, Shinichiro Nakamura 3, Masaki Kaibori 45, Hiroko Iijima 40, Yoichi Hiasa 27, Valentina Burgio 2, Mara Persano 22, Angelo Della Corte 47, Francesca Ratti 48, Francesco De Cobelli 47< |
|
|
|
|
257. | Predictors of early and late hepatocellular carcinoma recurrence |
|
World J Gastroenterol. 2023 Feb 28;29(8):1243-1260. doi: 10.3748/wjg.v29.i8.1243.
Riccardo Nevola 1 2, Rachele Ruocco 1, Livio Criscuolo 1, Angela Villani 1, Maria Alfano 1, Domenico Beccia 1, Simona Imbriani 1, Ernesto Claar 3, Domenico Cozzolino 1, Ferdinando Carlo Sasso 1, Aldo Marrone 1, Luigi Elio Adinolfi 1, Luca Rinaldi 1
|
|
|
|
|
259. | Machine Learning Predictive Model to Guide Treatment Allocation for Recurrent Hepatocellular Carcinoma After Surgery |
|
AMA Surg. 2023 Feb 1;158(2):192-202. doi: 10.1001/jamasurg.2022.6697.
Simone Famularo 1 2, Matteo Donadon 1 2, Federica Cipriani 3, Federico Fazio 4, Francesco Ardito 5, Maurizio Iaria 6, Pasquale Perri 7, Simone Conci 8, Tommaso Dominioni 9, Quirino Lai 10, Giuliano La Barba 11, Stefan Patauner 12, Sarah Molfino 13, Paola Germani 14, Giuseppe Zimmitti 15, Enrico Pinotti 16, Matteo Zanello 17, Luca Fumagalli 18, Cecilia Ferrari 19, Maurizio Romano 20 21, Antonella Delvecchio 22, Maria Grazia Valsecchi 23, Adelmo Antonucci 24, Fabio Piscaglia 25, Fabio Farinati 26, Yoshikuni Kawaguchi 27, Kiyoshi Hasegawa 27, Riccardo Memeo 22, Giacomo Zanus 20 21, Guido Griseri 19, Marco Chiarelli 18, Elio Jovine 17, Mauro Zago 16 18, Moh'd Abu Hilal 15, Paola Tarchi 14, Gian Luca Baiocchi 13, Antonio Frena 12, Giorgio Ercolani 11, Massimo Rossi 10, Marcello Maestri 9, Andrea Ruzzenente 8, Gian Luca Grazi 7, Raffaele Dalla Valle 6, Fabrizio Romano 28, Felice Giuliante 5, Alessandro Ferrero 4, Luca Aldrighetti 3, Davide P Bernasconi 23, Guido Torzilli 1 2; HE.RC.O.LE.S. Group
|
|
|
|
|
|
|
262. | Non-alcoholic Fatty Liver Disease (NAFLD), Type 2 Diabetes, and Non-viral Hepatocarcinoma: Pathophysiological Mechanisms and New Therapeutic Strategies |
|
Biomedicines. 2023 Feb 6;11(2):468. doi: 10.3390/biomedicines11020468.
Erica Vetrano 1, Luca Rinaldi 1, Andrea Mormone 1, Chiara Giorgione 1, Raffaele Galiero 1, Alfredo Caturano 1, Riccardo Nevola 1, Raffaele Marfella 1, Ferdinando Carlo Sasso 1
|
|
|
|
|
|
|
|
|
266. | HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma |
|
Hepatology. 2023 Mar 1;77(3):774-788. doi: 10.1002/hep.32692. Epub 2023 Feb 17.
Na Sun 1 2, Ceng Zhang 1 3, Yi-Te Lee 1, Benjamin V Tran 4, Jing Wang 1, Hyoyong Kim 1, Junseok Lee 1, Ryan Y Zhang 1, Jasmine J Wang 1 5, Junhui Hu 6, Zhicheng Zhang 6, Manaf S Alsudaney 7, Kuan-Chu Hou 1, Hubert Tang 1, Tiffany X Zhang 1, Icy Y Liang 1, Ziang Zhou 1, Mengxiang Chen 1, Angela Hsiao-Jiun Yeh 8, Wenyuan Li 9, Xianghong Jasmine Zhou 9, Helena R Chang 4, Steven-Huy B Han 8, Saeed Sadeghi 8, Richard S Finn 8, Sammy Saab 8, Ronald W Busuttil 4, Mazen Noureddin 7 10, Walid S Ayoub 7 10, Alexander Kuo 7 10, Vinay Sundaram 7 10, Buraq Al-Ghaieb 7 10, Juvelyn Palomique 7, Kambiz Kosari 7, Irene K Kim 7, Tsuyoshi Todo 7, Nicholas N Nissen 7, Maria Lauda Tomasi 10, Sungyong You 11, Edwin M Posadas 5, James X Wu 4, Madhuri Wadehra 9, Myung-Shin Sim 12, Yunfeng Li 9, Hanlin L Wang 9, Samuel W French 9, Shelly C Lu 10 13, Lily Wu 6, Renjun Pei 2, Li Liang 14 15, Ju Dong Yang 7 10 13, Vatche G Agopian 4 16, Hsian-Rong Tseng 1 16, Yazhen Zhu 1 9 16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
274. | Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database |
|
Gut. 2023 Jan;72(1):141-152. doi: 10.1136/gutjnl-2021-324915. Epub 2021 Dec 21.
Alessandro Vitale # 1, Gianluca Svegliati-Baroni # 2 3, Alessio Ortolani 4, Monica Cucco 5 6, Giulio V Dalla Riva 7, Edoardo G Giannini 8, Fabio Piscaglia 9, Gianludovico Rapaccini 10, Mariella Di Marco 11, Eugenio Caturelli 12, Marco Zoli 13, Rodolfo Sacco 14, Giuseppe Cabibbo 15, Fabio Marra 16, Andrea Mega 17, Filomena Morisco 18, Antonio Gasbarrini 19, Francesco Giuseppe Foschi 20, Gabriele Missale 21, Alberto Masotto 22, Gerardo Nardone 23, Giovanni Raimondo 24, Francesco Azzaroli 25, Gianpaolo Vidili 26, Filippo Oliveri 27, Filippo Pelizzaro 1, Rafael Ramirez Morales 1, Umberto Cillo 1, Franco Trevisani 28, Luca Miele 29 30, Giulio Marchesini 31, Fabio Farinati 1; Italian Liver Cancer (ITA.LI.CA) group
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
282. | FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far? |
|
Int J Mol Sci. 2023 Jan 31;24(3):2685. doi: 10.3390/ijms24032685.
Iason Psilopatis 1, Christos Damaskos 2 3, Anna Garmpi 4, Panagiotis Sarantis 5, Evangelos Koustas 5, Efstathios A Antoniou 3 6, Dimitrios Dimitroulis 6, Gregory Kouraklis 6, Michail V Karamouzis 5, Kleio Vrettou 7, Georgios Marinos 8, Konstantinos Kontzoglou 3 6, Nikolaos Garmpis 3 6
|
|
|
|
|
284. | An Open-Access, Interactive Decision-Support Tool to Facilitate Guideline-Driven Care for Hepatocellular Carcinoma |
|
Gastroenterology Res. 2022 Dec;15(6):297-307. doi: 10.14740/gr1573.Epub 2022 Dec 1.
Robert J Wong 1, Channa Jayasekera 2, Patricia Jones 3, Fasiha Kanwal 4, Amit G Singal 5, Aijaz Ahmed 6, Robert Taglienti 7, Zobair Younossi 8, Laura Kulik 9, Neil Mehta 10
|
|
|
|
|
|
|
287. | Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2 |
|
Oncologist. 2022 Dec 9;27(12):e938-e948. doi: 10.1093/oncolo/oyac183.
Richard S Finn 1, Thomas Yau 2, Chih-Hung Hsu 3, Enrico N De Toni 4, Lipika Goyal 5, Peter R Galle 6, ShuKui Qin 7, Sujata Rao 8, Fangfang Sun 8, Chunxiao Wang 8, Ryan C Widau 8, Andrew X Zhu 9 10
|
|
|
|
|
|
|
290. | A history of variceal bleeding is associated with further bleeding under atezolizumab-bevacizumab in patients with HCC |
|
Liver Int. 2022 Dec;42(12):2843-2854. doi: 10.1111/liv.15458. Epub 2022 Oct 26.
Edouard Larrey 1, Bertille Campion 1, Manon Evain 1, Philippe Sultanik 1, Lorraine Blaise 2, Héloïse Giudicelli 1, Mathilde Wagner 3, Philippe Cluzel 4, Marika Rudler 1 5, Nathalie Ganne-Carrié 2 6, Dominique Thabut 1 5, Manon Allaire 1 6
|
|
|
|
|
292. | Surgical approach to microwave and radiofrequency liver ablation for hepatocellular carcinoma and colorectal liver metastases less than 5 cm: a systematic review and meta-analysis |
|
Surg Endosc. 2022 Dec 21. doi: 10.1007/s00464-022-09815-5.Online ahead of print.
Moustafa Abdalla 1, Amelia T Collings 2, Rebecca Dirks 2, Edwin Onkendi 3, Daniel Nelson 4, Ahmad Ozair 5, Emily Miraflor 6, Faique Rahman 7, Jake Whiteside 2, Mihir M Shah 8, Subhashini Ayloo 9, Ahmed Abou-Setta 10, Iswanto Sucandy 11, Ali Kchaou 12, Samuel Douglas 13, Patricio Polanco 14, Timothy Vreeland 15, Joseph Buell 16, Mohammed T Ansari 17, Aurora D Pryor 18, Bethany J Slater 19, Ziad Awad 20, William Richardson 21, Adnan Alseidi 22, D Rohan Jeyarajah 23, Eugene Ceppa 24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
299. | Pathogenesis to management of hepatocellular carcinoma |
|
Genes Cancer. 2022 Dec 13;13:72-87. doi: 10.18632/genesandcancer.226.eCollection 2022.
Ben L Da 1, Kelly I Suchman 2, Lawrence Lau 3, Atoosa Rabiee 4, Aiwu Ruth He 5, Kirti Shetty 6, Herbert Yu 7, Linda L Wong 8, Richard L Amdur 9, James M Crawford 10, Sharon S Fox 10, Gregory M Grimaldi 11, Priya K Shah 11, Jonathan Weinstein 12, David Bernstein 1, Sanjaya K Satapathy 1, Nyasha Chambwe 13, Xiyan Xiang 14, Lopa Mishra 14
|
|
|
|
|
301. | Safety and Efficacy of 166Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study |
|
J Nucl Med. 2022 Dec;63(12):1891-1898. doi: 10.2967/jnumed.122.263823.Epub 2022 May 19.
Margot T M Reinders 1, Karel J van Erpecum 2, Maarten L J Smits 3, Arthur J A T Braat 3, Joep de Bruijne 2, Rutger Bruijnen 3, Dave Sprengers 4, Robert A de Man 4, Erik Vegt 5, Jan N M IJzermans 6, Adriaan Moelker 5, Marnix G E H Lam 1
|
|
|
302. | Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance |
|
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2818-2825.e1.doi: 10.1016/j.cgh.2021.12.014. Epub 2021 Dec 10.
Amit G Singal 1, Sarah Reddy 2, Himani Radadiya Aka Patel 3, Deyaun Villarreal 3, Aisha Khan 4, Yan Liu 4, Vanessa Cerda 3, Nicole E Rich 2, Caitlin C Murphy 3, Jasmin A Tiro 3, Jennifer R Kramer 5, Ruben Hernaez 5
|
|
|
303. | SIRT in 2025 |
|
Cardiovasc Intervent Radiol. 2022 Nov;45(11):1622-1633.doi: 10.1007/s00270-022-03228-6. Epub 2022 Aug 8.
Francesca Romana Ponziani # 1, Francesco Santopaolo # 1, Alessandro Posa 2, Maurizio Pompili 1 3, Alessandro Tanzilli 2, Marta Maestri 1, Maria Pallozzi 1, Francesca Ibba 1, Riccardo Manfredi 2 3, Antonio Gasbarrini # 1 3, Roberto Iezzi # 4 5
|
|
|
|
|
|
|
|
|
|
|
|
|
309. | Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review |
|
Int J Mol Sci. 2022 Nov 15;23(22):14117. doi: 10.3390/ijms232214117.
Christos Damaskos 1 2, Nikolaos Garmpis 2 3, Dimitrios Dimitroulis 3, Anna Garmpi 4, Iason Psilopatis 5, Panagiotis Sarantis 6, Evangelos Koustas 6, Prodromos Kanavidis 7, Dionysios Prevezanos 1, Gregory Kouraklis 7, Michail V Karamouzis 6, Georgios Marinos 8, Konstantinos Kontzoglou 2 3, Efstathios A Antoniou 2 3
|
|
|
|
|
|
|
|
|
|
|
314. | Stereotactic Radiotherapy after Incomplete Transarterial (Chemo-) Embolization (TAE\TACE) versus Exclusive TAE or TACE for Treatment of Inoperable HCC: A Phase III Trial (NCT02323360) |
|
Curr Oncol. 2022 Nov 16;29(11):8802-8813. doi: 10.3390/curroncol29110692.
Tiziana Comito 1, Mauro Loi 2, Ciro Franzese 1 3, Elena Clerici 1, Davide Franceschini 1, Marco Badalamenti 1, Maria Ausilia Teriaca 1, Lorenza Rimassa 3 4, Vittorio Pedicini 5, Dario Poretti 5, Luigi Alessandro Solbiati 3 5, Guido Torzilli 3 6, Roberto Ceriani 7, Ana Lleo 3 7, Alessio Aghemo 3 7, Armando Santoro 3 4, Marta Scorsetti 1 3
|
|
|
315. | Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis |
|
ESMO Open. 2022 Oct 5;7(6):100591. doi: 10.1016/j.esmoop.2022.100591. Online ahead of print.
M Rimini 1, L Rimassa 2, K Ueshima 3, V Burgio 1, S Shigeo 4, T Tada 5, G Suda 6, C Yoo 7, J Cheon 8, D J Pinato 9, S Lonardi 10, M Scartozzi 11, M Iavarone 12, G G Di Costanzo 13, F Marra 14, C Soldà 15, E Tamburini 16, F Piscaglia 17, G Masi 18, G Cabibbo 19, F G Foschi 20, M Silletta 21, T Pressiani 22, N Nishida 3, H Iwamoto 4, N Sakamoto 6, B-Y Ryoo 7, H J Chon 8, F Claudia 9, T Niizeki 4, T Sho 6, B Kang 8, A D'Alessio 9, T Kumada 23, A Hiraoka 24, M Hirooka 25, K Kariyama 26, J Tani 27, M Atsukawa 28, K Takaguchi 29, E Itobayashi 30, S Fukunishi 31, K Tsuji 32, T Ishikawa 33, K Tajiri 34, H Ochi 35, S Yasuda 36, H Toyoda 36, C Ogawa 37, T Nishimur 38, T Hatanaka 39, S Kakizaki 40, N Shimada 41, K Kawata 42, T Tanaka 24, H Ohama 31, K Nouso 26, A Morishita 27, A Tsutsui 29, T Nagano 29, N Itokawa 28, T Okubo 28, T Arai 28, M Imai 33, A Naganuma 43, Y Koizumi 25, S Nakamura 5, K Joko 35, H Iijima 38, Y Hiasa 25, F Pedica 44, F De Cobelli 45, F Ratti 46, L Alrighetti 46, M Kudo 3, S Cascinu 47, A Casadei-Gardini 48
|
|
|
|
|
|
|
|
|
319. | Artificial Intelligence in the Diagnosis of Hepatocellular Carcinoma: A Systematic Review |
|
J Clin Med. 2022 Oct 28;11(21):6368. doi: 10.3390/jcm11216368.
Alessandro Martinino 1, Mohammad Aloulou 2, Surobhi Chatterjee 3, Juan Pablo Scarano Pereira 4, Saurabh Singhal 5, Tapan Patel 6, Thomas Paul-Emile Kirchgesner 7, Salvatore Agnes 8, Salvatore Annunziata 9, Giorgio Treglia 10 11 12, Francesco Giovinazzo 8
|
|
|
|
|
|
|
322. | Hepatocellular Carcinoma, Alpha Fetoprotein, and Liver Allocation for Transplantation: Past, Present and Future |
|
Curr Oncol. 2022 Oct 8;29(10):7537-7551. doi: 10.3390/curroncol29100593.
Brianna Ruch 1, Josiah Wagler 1, Kayla Kumm 1, Chi Zhang 2 3, Nitin N Katariya 1, Mauricio Garcia-Saenz-de-Sicilia 4, Emmanouil Giorgakis 5, Amit K Mathur 1
|
|
|
323. | Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma in cirrhosis: a randomized trial |
|
J Gastroenterol Hepatol. 2015 Mar;30(3):559-65.doi: 10.1111/jgh.12791.
Giovan Giuseppe Di Costanzo 1, Raffaella Tortora, Giuseppe D'Adamo, Massimo De Luca, Filippo Lampasi, Luigi Addario, Alfonso Galeota Lanza, Francesco Paolo Picciotto, Maria Teresa Tartaglione, Gabriella Cordone, Michele Imparato, Silvana Mattera, Claudio Maurizio Pacella
|
|
|
|
|
|
|
|
|
|
|
328. | Downstaging Therapies for Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation: A Systematic Review and Meta-Analysis on Intention-to-Treat Outcomes |
|
Cancers (Basel). 2022 Oct 18;14(20):5102. doi: 10.3390/cancers14205102.
Marcello Di Martino 1, Alessandro Vitale 2, Daniele Ferraro 1, Marilisa Maniscalco 1, Donatella Pisaniello 1, Giuseppe Arenga 1, Federica Falaschi 1, Alfonso Terrone 1, Alessandro Iacomino 1 2, Alfonso Galeota Lanza 3, Ciro Esposito 4, Umberto Cillo 2, Giovanni Vennarecci 1
|
|
|
329. | Securing Wider EU Commitment to the Elimination of HCV |
|
Liver Int. 2022 Oct 5. doi: 10.1111/liv.15446. Online ahead of print.
Heiner Wedemeyer 1, Tammo L Tergast 1, Jeffrey V Lazarus 2, Homie Razavi 3, Kostas Bakoyannis 4, Ricardo Baptista-Leite 5 6, Marco Bartoli 7, Philip Bruggmann 8, Cristian-Silviu Busoi 9, Maria Buti 10, Manuel Carballo 11, Laurent Castera 12, Massimo Colombo 13, Rodrigo Sousa Coutinho 14, Yuval Dadon 15, Gamal Esmat 16, Rafael Esteban 10, Joan Colom Farran 17, Mark Gillyon-Powell 18, David Goldberg 19, Sharon Hutchinson 20, Harry L A Janssen 21, George Kalamitsis 22, Loreta A Kondili 23, John S Lambert 24, Rui Tato Marinho 25, Mojca Maticic 26 27, Aldo Patricello 9, Markus Peck-Radosavljevic 28, Stanislas Pol 29, Mario Poljak 30, Cora Pop 31, Tomislov Sokol 9, Vana Sypsa 32, Nurdan Tözün 33, Zobair Younossi 34, Alessio Aghemo 35, George V Papatheodoridis 36, Angelos Hatzakis 32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
338. | Early derangement of INR predicts liver failure after liver resection for hepatocellular carcinoma |
|
Surgeon. 2022 Oct;20(5):e288-e295. doi: 10.1016/j.surge.2022.01.002.Epub 2022 Feb 7.
A N S Silva 1, M Greensmith 2, R K Praseedom 2, A Jah 2, E L Huguet 2, S J F Harper 2, S S Liau 2, B Basu 3, G J Alexander 4, R Brais 5, T C See 6, M Hoare 7, P Gibbs 2, A Balakrishnan 8
|
|
|
|
|
|
|
341. | Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature |
|
Hepatol Commun. 2022 Sep;6(9):2581-2593. doi: 10.1002/hep4.1991. Epub 2022 Jun 16.
Myung-Ho Kim 1, Mi-Young Kim 1 2 3, Shadi Salloum 1, Tongqi Qian 4, Lai Ping Wong 5 6, Min Xu 1, Yoojin Lee 1, Stuti G Shroff 7, Ruslan I Sadreyev 5 7, Kathleen E Corey 1, Thomas F Baumert 8 9, Yujin Hoshida 4, Raymond T Chung 1
|
|
|
|
|
|
|
|
|
|
|
|
|
347. | Histologic type predicts disparate outcomes in pediatric hepatocellular neoplasms: A Pediatric Surgical Oncology Research Collaborative study |
|
Cancer. 2022 Jul 15;128(14):2786-2795. doi: 10.1002/cncr.34256. Epub 2022 May 13.
Scott S Short 1, Zachary J Kastenberg 1, Guo Wei 1, Alex Bondoc 2, Roshni Dasgupta 2, Greg M Tiao 2, Erin Watters 2, Todd E Heaton 3, Dimitra Lotakis 3, Michael P La Quaglia 3, Andrew J Murphy 4, Andrew M Davidoff 4, Sara A Mansfield 4, Max R Langham 4, Timothy B Lautz 5, Riccardo A Superina 5, Katherine C Ott 5, Marcus M Malek 6, Katrina M Morgan 6, Eugene S Kim 7, Abigail Zamora 7, Danny Lascano 7, Jonathan Roach 8, Joseph T Murphy 9, David H Rothstein 10, Sanjeev A Vasudevan 11, Richard Whitlock 11, Dave R Lal 12, Brian Hallis 12, Andreana Bütter 13, Reto M Baertschiger 14, Eveline Lapidus-Krol 14, Juan Putra 15, Elisabeth R Tracy 16, Jennifer H Aldrink 17, Jordan Apfeld 17, Hau D Le 18, Keon Y Park 18, Barrie S Rich 19, Richard D Glick 19, Elizabeth A Fialkowski 20, Alan F Utria 20, Rebecka L Meyers 1, Kimberly J Riehle 10
|
|
|
|
|
349. | Objective Response Predicts Survival in Advanced Hepatocellular Carcinoma Treated with Systemic Therapies |
|
Clin Cancer Res. 2022 Aug 15;28(16):3443-3451.doi: 10.1158/1078-0432.CCR-21-3135.
Masatoshi Kudo # 1, Robert Montal # 2 3, Richard S Finn 4, Florian Castet 3, Kazuomi Ueshima 1, Naoshi Nishida 1, Philipp K Haber 5, Youyou Hu 6, Yasutaka Chiba 7, Myron Schwartz 5, Tim Meyer 8 9, Riccardo Lencioni 10 11, Josep M Llovet 3 5 12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
359. | Gadoxetic acid uptake as a molecular imaging biomarker for sorafenib resistance in patients with hepatocellular carcinoma: a post hoc analysis of the SORAMIC trial |
|
J Cancer Res Clin Oncol. 2022 Sep;148(9):2487-2496.doi: 10.1007/s00432-021-03803-3. Epub 2021 Sep 20.
Osman Öcal # 1, Daniel Rössler # 2, Antonio Gasbarrini 3, Thomas Berg 4, Heinz-Josef Klümpen 5, Irene Bargellini 6, Bora Peynircioglu 7, Otto van Delden 8, Christian Schulz 2, Kerstin Schütte 9 10, Roberto Iezzi 11, Maciej Pech 12, Peter Malfertheiner 2, Bruno Sangro 13, Jens Ricke 1, Max Seidensticker 14
|
|
|
360. | Hepatocellular Carcinoma Incidence in Alcohol-Associated Cirrhosis: Systematic Review and Meta-analysis |
|
Clin Gastroenterol Hepatol. 2022 Aug 5;S1542-3565(22)00727-3.doi: 10.1016/j.cgh.2022.06.032. Online ahead of print.
Daniel Q Huang 1, Darren J H Tan 2, Cheng Han Ng 2, Maral Amangurbanova 3, Nancy Sutter 3, Phoebe Wen Lin Tay 2, Wen Hui Lim 2, Jie Ning Yong 2, Ansel Tang 2, Nicholas Syn 2, Mark D Muthiah 4, Eunice X X Tan 4, Shravan Dave 3, Benjamin Tay 5, Abdul M Majzoub 6, Danielle Gerberi 7, Beom Kyung Kim 8, Rohit Loomba 9
|
|
|
|
|
|
|
|
|
364. | Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival |
|
Dig Liver Dis. 2022 Jul;54(7):927-936. doi: 10.1016/j.dld.2021.08.025. Epub 2021 Sep 25.
Filippo Pelizzaro 1, Giulia Peserico 2, Marco D'Elia 1, Nora Cazzagon 1, Francesco Paolo Russo 3, Alessandro Vitale 4, Edoardo G Giannini 5, Manuela Piccinnu 6, Gian Ludovico Rapaccini 7, Maria Di Marco 8, Eugenio Caturelli 9, Marco Zoli 10, Rodolfo Sacco 11, Giuseppe Cabibbo 12, Fabio Marra 13, Andrea Mega 14, Filomena Morisco 15, Antonio Gasbarrini 16, Gianluca Svegliati-Baroni 17, Francesco Giuseppe Foschi 18, Andrea Olivani 19, Alberto Masotto 20, Gerardo Nardone 21, Giovanni Raimondo 22, Francesco Azzaroli 23, Gianpaolo Vidili 24, Filippo Oliveri 25, Franco Trevisani 26, Fabio Farinati 27, Italian Liver Cancer (ITA.LI.CA) Study Group
|
|
|
365. | Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation |
|
JCI Insight. 2022 Jul 8;7(13):e159254. doi: 10.1172/jci.insight.159254.
Emilie Crouchet 1, Shen Li 2, Mozhdeh Sojoodi 2, Simonetta Bandiera 1, Naoto Fujiwara 3, Hussein El Saghire 1, Shijia Zhu 3, Tongqi Qian 3, Fahmida Akter Rasha 3, Fabio Del Zompo 1, Stephen C Barrett 2, Eugénie Schaeffer 1, Marine A Oudot 1, Clara Ponsolles 1, Sarah C Durand 1, Sarani Ghoshal 2, Gunisha Arora 2, Fabio Giannone 1 4 5, Raymond T Chung 6, Nevena Slovic 1, Nicolaas Van Renne 1, Emanuele Felli 1 4 5, Patrick Pessaux 1 4 5, Joachim Lupberger 1, Nathalie Pochet 7 8 9, Catherine Schuster 1, Kenneth K Tanabe 2, Yujin Hoshida 3, Bryan C Fuchs 2, Thomas F Baumert 1 4
|
|
|
366. | Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis |
|
Transpl Int. 2022 Jul 5;35:10175. doi: 10.3389/ti.2022.10175. eCollection 2022.
Ryan Lamm 1, Peter J Altshuler 1, Keyur Patel 1, Osama Shaheen 1, Angel Paulo Amante 1, Jesse Civan 2, Warren Maley 1, Adam Frank 1, Carlo Ramirez 1, Jaime Glorioso 1, Ashesh Shah 1, Hien Dang 1, Adam S Bodzin 1
|
|
|
|
|
368. | Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment |
|
Nat Commun. 2022 Jul 8;13(1):3964. doi: 10.1038/s41467-022-31312-5.
Kai Markus Schneider # 1 2, Antje Mohs # 1, Wenfang Gui 1, Eric J C Galvez 3, Lena Susanna Candels 1, Lisa Hoenicke 3, Uthayakumar Muthukumarasamy 3, Christian H Holland 4 5, Carsten Elfers 1, Konrad Kilic 1, Carolin Victoria Schneider 1 6, Robert Schierwagen 7 8, Pavel Strnad 1, Theresa H Wirtz 1, Hanns-Ulrich Marschall 9, Eicke Latz 10 11 12, Benjamin Lelouvier 13, Julio Saez-Rodriguez 4 5, Willem de Vos 14 15, Till Strowig 3, Jonel Trebicka 7 8, Christian Trautwein 16
|
|
|
|
|
|
|
|
|
|
|
373. | Patient-reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases |
|
Hepatology. 2022 Jul;76(1):251-274. doi: 10.1002/hep.32313. Epub 2022 Jan 22.
Marina Serper 1 2 3, Neehar D Parikh 4, Grace Thiele 1, Nadia Ovchinsky 5, Shivang Mehta 6, Alexander Kuo 7, Chanda Ho 8, Fasiha Kanwal 9 10 11, Michael Volk 12, Sumeet K Asrani 13, Marwan S Ghabril 14, John R Lake 15, Raphael B Merriman 16, Timothy R Morgan 17, Elliot B Tapper 4 18
|
|
|
|
|
375. | Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial |
|
Lancet Oncol. 2022 Aug;23(8):995-1008.doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
Robin Kate Kelley 1, Lorenza Rimassa 2, Ann-Lii Cheng 3, Ahmed Kaseb 4, Shukui Qin 5, Andrew X Zhu 6, Stephen L Chan 7, Tamar Melkadze 8, Wattana Sukeepaisarnjaroen 9, Valery Breder 10, Gontran Verset 11, Edward Gane 12, Ivan Borbath 13, Jose David Gomez Rangel 14, Baek-Yeol Ryoo 15, Tamta Makharadze 16, Philippe Merle 17, Fawzi Benzaghou 18, Kamalika Banerjee 19, Saswati Hazra 19, Jonathan Fawcett 19, Thomas Yau 20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
388. | HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis |
|
J Hepatol. 2022 Jul;77(1):128-139. doi: 10.1016/j.jhep.2022.01.023.Epub 2022 Feb 6.
Amit G Singal 1, Emily Zhang 2, Manasa Narasimman 2, Nicole E Rich 2, Akbar K Waljee 3, Yujin Hoshida 2, Ju Dong Yang 4, Maria Reig 5, Giuseppe Cabibbo 6, Pierre Nahon 7, Neehar D Parikh 3, Jorge A Marrero 8
|
|
|
|
|
390. | Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial |
|
Clin Cancer Res. 2022 Jun 13;28(12):2547-2554.doi: 10.1158/1078-0432.CCR-21-3807
Gontran Verset 1, Ivan Borbath 2, Mark Karwal 3, Chris Verslype 4, Hans Van Vlierberghe 5, Adel Kardosh 6, Vittorina Zagonel 7, Per Stal 8, Debashis Sarker 9, Daniel H Palmer 10, Arndt Vogel 11, Julien Edeline 12, Stephane Cattan 13, Masatoshi Kudo 14, Ann-Lii Cheng 15, Sadahisa Ogasawara 16, Bruno Daniele 17, Stephen L Chan 18, Jennifer J Knox 19, Shukui Qin 20, Abby B Siegel 21, Michael Chisamore 21, Ken Hatogai 21, Anran Wang 21, Richard S Finn # 22, Andrew X Zhu # 23 24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
402. | Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials |
|
Clin Cancer Res. 2022 Jun 1;28(11):2297-2305.doi: 10.1158/1078-0432.CCR-21-4000.
Josep M Llovet 1 2 3, Amit G Singal 4, Augusto Villanueva 1, Richard S Finn 5, Masatoshi Kudo 6, Peter R Galle 7, Masafumi Ikeda 8, Sophie Callies 9, Louise M McGrath 9, Chunxiao Wang 9, Paolo Abada 9, Ryan C Widau 9, Elena Gonzalez-Gugel 9, Andrew X Zhu 10 11
|
|
|
|
|
404. | The rs429358 Locus in Apolipoprotein E Is Associated With Hepatocellular Carcinoma in Patients With Cirrhosis |
|
Hepatol Commun. 2022 May;6(5):1213-1226. doi: 10.1002/hep4.1886.Epub 2021 Dec 27.
Hamish Innes 1 2 3, Hans Dieter Nischalke 4, Indra Neil Guha 5, Karl Heinz Weiss 6, Will Irving 5, Daniel Gotthardt 7, Eleanor Barnes 8, Janett Fischer 9, M Azim Ansari 8, Jonas Rosendahl 10, Shang-Kuan Lin 8, Astrid Marot 11 12, Vincent Pedergnana 13, Markus Casper 14, Jennifer Benselin 5, Frank Lammert 14, John McLauchlan 15, Philip L Lutz 4, Victoria Hamill 1 3, Sebastian Mueller 16 17, Joanne R Morling 2 5, Georg Semmler 18 19, Florian Eyer 20, Johann von Felden 21, Alexander Link 22, Arndt Vogel 23, Jens U Marquardt 24, Stefan Sulk 25, Jonel Trebicka 26 27, Luca Valenti 28 29, Christian Datz 19, Thomas Reiberger 18, Clemens Schafmayer 30, Thomas Berg 9, Pierre Deltenre # 11 31 32, Jochen Hampe # 25 33, Felix Stickel # 34, Stephan Buch # 25
|
|
|
405. | Clinical Utility of Albumin Bilirubin Grade as a Prognostic Marker in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization: a Systematic Review and Meta-analysis |
|
J Gastrointest Cancer. 2022 May 30
Gauri Mishra 1 2, Ammar Majeed 3 4, Anouk Dev 5 3, Guy D Eslick 6, David J Pinato 7, Hirofumi Izumoto, Atsushi Hiraoka 8, Teh-Ia Huo 9 10, Po-Hong Liu 11, Philip J Johnson 12, Stuart K Roberts 3 4
|
|
|
406. | Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis: HCC and Steatosis or Steatohepatitis |
|
Neoplasia. 2022 Aug;30:100809. doi: 10.1016/j.neo.2022.100809.Epub 2022 May 27.
Fausto Petrelli 1, Michele Manara 2, Silvia Colombo 3, Gabriella De Santi 2, Michele Ghidini 4, Marco Mariani 2, Alessandro Iaculli 5, Emanuele Rausa 6, Valentina Rampulla 2, Marcella Arru 2, Matteo Viti 2, Veronica Lonati 7, Antonio Ghidini 8, Andrea Luciani 7, Antonio Facciorusso 9
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
413. | Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
|
Eur J Cancer. 2022 May;167:1-12. doi: 10.1016/j.ejca.2022.02.009.Epub 2022 Mar 29.
Masatoshi Kudo 1, Richard S Finn 2, Julien Edeline 3, Stéphane Cattan 4, Sadahisa Ogasawara 5, Daniel H Palmer 6, Chris Verslype 7, Vittorina Zagonel 8, Laetitia Fartoux 9, Arndt Vogel 10, Debashis Sarker 11, Gontran Verset 12, Stephen L Chan 13, Jennifer Knox 14, Bruno Daniele 15, Thomas Yau 16, Ellen B Gurary 17, Abby B Siegel 18, Anran Wang 19, Ann-Lii Cheng 20, Andrew X Zhu 21, KEYNOTE-224 Investigators
|
|
|
|
|
|
|
416. | BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update |
|
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018.Epub 2021 Nov 19.
Maria Reig 1, Alejandro Forner 2, Jordi Rimola 3, Joana Ferrer-Fàbrega 4, Marta Burrel 5, Ángeles Garcia-Criado 3, Robin K Kelley 6, Peter R Galle 7, Vincenzo Mazzaferro 8, Riad Salem 9, Bruno Sangro 10, Amit G Singal 11, Arndt Vogel 12, Josep Fuster 13, Carmen Ayuso 14, Jordi Bruix 15
|
|
|
417. | Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial |
|
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218.doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.
Ahmed Omar Kaseb 1, Elshad Hasanov 2, Hop Sanderson Tran Cao 3, Lianchun Xiao 4, Jean-Nicolas Vauthey 3, Sunyoung S Lee 5, Betul Gok Yavuz 5, Yehia I Mohamed 5, Aliya Qayyum 6, Sonali Jindal 7, Fei Duan 7, Sreyashi Basu 7, Shalini S Yadav 7, Courtney Nicholas 7, Jing Jing Sun 7, Kanwal Pratap Singh Raghav 5, Asif Rashid 8, Kristen Carter 5, Yun Shin Chun 3, Ching-Wei David Tzeng 3, Divya Sakamuri 5, Li Xu 5, Ryan Sun 4, Vittorio Cristini 9, Laura Beretta 10, James C Yao 5, Robert A Wolff 5, James Patrick Allison 11, Padmanee Sharma 12
|
|
|
|
|
|
|
|
|
|
|
|
|
423. | Nivolumab versus sorafenib in advanced hepatocellular carcinoma |
|
Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5.Epub 2021 Dec 13.
(CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
Thomas Yau 1, Joong-Won Park 2, Richard S Finn 3, Ann-Lii Cheng 4, Philippe Mathurin 5, Julien Edeline 6, Masatoshi Kudo 7, James J Harding 8, Philippe Merle 9, Olivier Rosmorduc 10, Lucjan Wyrwicz 11, Eckart Schott 12, Su Pin Choo 13, Robin Kate Kelley 14, Wolfgang Sieghart 15, Eric Assenat 16, Renata Zaucha 17, Junji Furuse 18, Ghassan K Abou-Alfa 8, Anthony B El-Khoueiry 19, Ignacio Melero 20, Damir Begic 21, Gong Chen 21, Jaclyn Neely 21, Tami Wisniewski 21, Marina Tschaika 21, Bruno Sangro 22
|
|
|
424. | Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis |
|
Gut. 2022 Mar;71(3):593-604. doi: 10.1136/gutjnl-2020-323663.Epub 2021 Mar 19.
Victor Sapena # 1, Marco Enea # 2, Ferran Torres # 3 4, Ciro Celsa # 2 5, Jose Rios 3 4, Giacomo Emanuele Maria Rizzo 2, Pierre Nahon 6, Zoe Mariño 7, Ryosuke Tateishi 8, Tatsuya Minami 8, Angelo Sangiovanni 9 10, Xavier Forns 7, Hidenori Toyoda 11, Stefano Brillanti 12, Fabio Conti 12, Elisabetta Degasperi 9 10, Ming-Lung Yu 13 14, Pei-Chien Tsai 13, Kevin Jean 15 16, Mohamed El Kassas 17, Hend Ibrahim Shousha 18, Ashraf Omar 18, Claudio Zavaglia 19, Hiroko Nagata 20, Mina Nakagawa 21 22, Yasuhiro Asahina 23, Amit G Singal 24, Caitlin Murphy 24, Mohamed Kohla 25, Chiara Masetti 26, Jean-François Dufour 27 28, Nicolas Merchante 29, Luisa Cavalletto 30, Liliana Lc Chemello 30, Stanislas Pol 31, Javier Crespo 32 33, Jose Luis Calleja 34 35, Rosanna Villani 36, Gaetano Serviddio 36, Alberto Zanetto 37, Sarah Shalaby 37, Francesco Paolo Russo 37, Rob Bielen 38 39, Franco Trevisani 40, Calogero Cammà 2, Jordi Bruix 1, Giuseppe Cabibbo 41, Maria Reig 42
|
|
|
425. | Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial |
|
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):219-229.doi: 10.1016/S2468-1253(21)00385-X. Epub 2022 Jan 20.
Thomas U Marron 1, Maria Isabel Fiel 2, Pauline Hamon 3, Nathalie Fiaschi 4, Edward Kim 5, Stephen C Ward 2, Zhen Zhao 6, Joel Kim 3, Paul Kennedy 7, Ganesh Gunasekaran 8, Parissa Tabrizian 8, Deborah Doroshow 9, Meredith Legg 9, Ashley Hammad 9, Assaf Magen 3, Alice O Kamphorst 10, Muhammed Shareef 11, Namita T Gupta 4, Raquel Deering 4, Wei Wang 4, Fang Wang 4, Pradeep Thanigaimani 4, Jayakumar Mani 4, Leanna Troncoso 3, Alexandra Tabachnikova 3, Christie Chang 3, Guray Akturk 12, Mark Buckup 3, Steven Hamel 12, Giorgio Ioannou 12, Clotilde Hennequin 3, Hajra Jamal 3, Haley Brown 3, Antoinette Bonaccorso 13, Daniel Labow 8, Umut Sarpel 8, Talia Rosenbloom 14, Max W Sung 15, Baijun Kou 4, Siyu Li 4, Vladimir Jankovic 4, Nicola James 4, Sara C Hamon 4, Hung Kam Cheung 4, Jennifer S Sims 4, Elizabeth Miller 4, Nina Bhardwaj 16, Gavin Thurston 4, Israel Lowy 4, Sacha Gnjatic 17, Bachir Taouli 18, Myron E Schwartz 19, Miriam Merad 20
|
|
|
426. | . Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma |
|
J Hepatol. 2022 Apr;76(4):862-873.doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11
Ann-Lii Cheng 1, Shukui Qin 2, Masafumi Ikeda 3, Peter R Galle 4, Michel Ducreux 5, Tae-You Kim 6, Ho Yeong Lim 7, Masatoshi Kudo 8, Valeriy Breder 9, Philippe Merle 10, Ahmed O Kaseb 11, Daneng Li 12, Wendy Verret 13, Ning Ma 14, Alan Nicholas 15, Yifan Wang 16, Lindong Li 17, Andrew X Zhu 18, Richard S Finn 19
|
|
|
|
|
|
|
|
|
|
|
|
|
432. | Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma |
|
Cancers (Basel). 2022 Mar 23;14(7):1634. doi: 10.3390/cancers14071634.
Gael S Roth 1 2 3, Olivier Hernandez 2, Najeh Daabek 4 5, Bleuenn Brusset 2, Yann Teyssier 1 6, Julien Ghelfi 1 3 6, Marie Noelle Hilleret 2, Christian Sengel 6, Ivan Bricault 1 6, Thomas Decaens 1 2 3, Charlotte Costentin 1 2 3
|
|
|
|
|
|
|
435. | Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience |
|
Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298.eCollection 2022.
Tiago de Castro 1, Leonie S Jochheim 2, Melanie Bathon 1, Sabrina Welland 1, Bernhard Scheiner 3, Kateryna Shmanko 4, Daniel Roessler 5, Najib Ben Khaled 5, Matthias Jeschke 2, Johannes M Ludwig 6, Jens U Marquardt 7, Arndt Weinmann 4, Matthias Pinter 3, Christian M Lange 2, Arndt Vogel 8, Anna Saborowski 1
|
|
|
436. | Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma |
|
J Hepatol. 2021 Dec;75(6):1387-1396. doi: 10.1016/j.jhep.2021.07.037.Epub 2021 Aug 27.
Jens Ricke 1, Regina Schinner 2, Max Seidensticker 2, Antonio Gasbarrini 3, Otto M van Delden 4, Holger Amthauer 5, Bora Peynircioglu 6, Irene Bargellini 7, Roberto Iezzi 8, Enrico N De Toni 9, Peter Malfertheiner 10, Maciej Pech 11, Bruno Sangro 12
|
|
|
|
|
438. | Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression |
|
Clin Gastroenterol Hepatol. 2022 Feb;20(2):283-292.e10.doi: 10.1016/j.cgh.2021.05.002. Epub 2021 May 28.
Lorenzo A Orci 1, Marco Sanduzzi-Zamparelli 2, Berta Caballol 3, Victor Sapena 3, Nicola Colucci 4, Ferran Torres 5, Jordi Bruix 3, María Reig 6, Christian Toso 7
|
|
|
439. | Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade |
|
Br J Cancer. 2022 Mar;126(4):569-575. doi: 10.1038/s41416-021-01532-5.Epub 2021 Oct 7.
Robin Kate Kelley # 1, Rebecca Miksad # 2 3 4, Irfan Cicin 5, YenHsun Chen 6, Heinz-Josef Klümpen 7, Stefano Kim 8, Zhong-Zhe Lin 9, Jillian Youkstetter 10, Saswati Hazra 10, Suvajit Sen 10, Ann-Lii Cheng 9, Anthony B El-Khoueiry 11, Tim Meyer 12, Ghassan K Abou-Alfa 13 14
|
|
|
|
|
441. | Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial |
|
J Cancer Res Clin Oncol. 2022 Feb;148(2):475-485.doi: 10.1007/s00432-021-03627-1. Epub 2021 Apr 14.
Osman Öcal 1, Kerstin Schütte 2, Juozas Kupcinskas 3, Egidijus Morkunas 3, Gabija Jurkeviciute 3, Enrico N de Toni 4, Najib Ben Khaled 4, Thomas Berg 5, Peter Malfertheiner 4, Heinz Josef Klümpen 6, Christian Sengel 7, Bristi Basu 8, Juan W Valle 9, Julia Benckert 10, Antonio Gasbarrini 11, Daniel Palmer 12, Ricarda Seidensticker 1, Moritz Wildgruber 1, Bruno Sangro 13, Maciej Pech 14, Jens Ricke 1, Max Seidensticker 15
|
|
|
|
|
|
|
444. | Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study |
|
Hepatology. 2022 Mar 21. doi: 10.1002/hep.32468. Online ahead of print.
Antonio D'Alessio 1 2, Claudia Angela Maria Fulgenzi 1 3, Naoshi Nishida 4, Martin Schönlein 5, Johann von Felden 6, Kornelius Schulze 6, Henning Wege 6, Vincent E Gaillard 7, Anwaar Saeed 8, Brooke Wietharn 8, Hannah Hildebrand 8, Linda Wu 9, Celina Ang 9, Thomas U Marron 9, Arndt Weinmann 10, Peter R Galle 10, Dominik Bettinger 11, Bertram Bengsch 11 12 13, Arndt Vogel 14, Lorenz Balcar 15, Bernhard Scheiner 15, Pei-Chang Lee 16, Yi-Hsiang Huang 16 17, Suneetha Amara 18, Mahvish Muzaffar 18, Abdul Rafeh Naqash 18 19, Antonella Cammarota 2 20, Nicola Personeni 2 20, Tiziana Pressiani 20, Rohini Sharma 1, Matthias Pinter 15, Alessio Cortellini 1, Masatoshi Kudo 4, Lorenza Rimassa 2 20, David J Pinato 1 21
|
|
|
445. | T cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma |
|
J Hepatol. 2022 Mar 31;S0168-8278(22)00180-5. doi: 10.1016/j.jhep.2022.02.032.Online ahead of print.
Maryam Barsch 1, Henrike Salié 1, Alexandra Emilia Schlaak 1, Zhen Zhang 1, Moritz Hess 2, Lena Sophie Mayer 1, Catrin Tauber 1, Patricia Otto-Mora 1, Takuya Ohtani 3, Tobias Nilsson 1, Lara Wischer 1, Frances Winkler 1, Sasikant Manne 3, Andrew Rech 3, Annette Schmitt-Graeff 4, Peter Bronsert 4, Maike Hofmann 1, Christoph Neumann-Haefelin 1, Tobias Boettler 1, Stefan Fichtner-Feigl 5, Florian van Boemmel 6, Thomas Berg 6, Lorenza Rimassa 7, Luca Di Tommaso 8, Anwaar Saeed 9, Antonio D'Alessio 10, David J Pinato 11, Dominik Bettinger 1, Harald Binder 2, E John Wherry 3, Michael Schultheiss 1, Robert Thimme 1, Bertram Bengsch 12
|
|
|
446. | The largest western experience on salvage hepatectomy for recurrent hepatocellular carcinoma: propensity score-matched analysis on behalf of He.RC.O.Le.Study Group |
|
HPB (Oxford). 2022 Jan 11;S1365-182X(22)00001-6. doi: 10.1016/j.hpb.2022.01.001.Online ahead of print.
Maurizio Iaria 1, Giorgio Bianchi 2, Federico Fazio 3, Francesco Ardito 4, Pasquale Perri 5, Nicholas Pontarolo 6, Simone Conci 7, Matteo Donadon 8, Matteo Zanello 9, Quirino Lai 10, Simone Famularo 11, Sarah Molfino 12, Ivano Sciannamea 13, Luca Fumagalli 14, Paola Germani 15, Antonio Floridi 16, Cecilia Ferrari 17, Giuseppe Zimmitti 18, Albert Troci 19, Mauro Zago 20, Valentina Ferraro 21, Federica Cipriani 22, Stefan Patauner 23, Giuliano La Barba 24, Maurizio Romano 25, Giacomo Zanus 25, Giorgio Ercolani 26, Antonio Frena 23, Luca Aldrighetti 22, Riccardo Memeo 21, Enrico Pinotti 27, Michele Crespi 19, Moh'd Abu Hilal 18, Guido Griseri 17, Paola Tarchi 15, Marco Chiarelli 14, Adelmo Antonucci 13, Gian L Baiocchi 12, Fabrizio Romano 28, Massimo Rossi 10, Elio Jovine 9, Guido Torzilli 8, Andrea Ruzzenente 7, Marcello Maestri 6, Gian L Grazi 5, Felice Giuliante 4, Alessandro Ferrero 3, Raffaele Dalla Valle 2, HE.RC.O.LE.S. GROUP
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
455. | Are Current National Review Board Downstaging Protocols for Hepatocellular Carcinoma Too Restrictive? |
|
J Am Coll Surg. 2022 Apr 1;234(4):579-588. doi: 10.1097/XCS.0000000000000140.
Ola Ahmed 1, Neeta Vachharajani 1, Kris P Croome 2, Parissa Tabrizian 3, Vatche Agopian 4, Karim Halazun 5, Johnny C Hong 6, Leigh Anne Dageforde 7, William C Chapman 1, Mb Majella Doyle 1, Primary Liver Tumor Study Group
Primary Liver Tumor Study Group: Erin Maynard 8, Yikyung Park 9, Su-Hsin Chang 9, Adeel S Khan 10
|
|
|
456. | UNOS Down-staging Criteria for Liver Transplantation of Hepatocellular Carcinoma: Systematic Review and Meta-Analysis of 25 Studies |
|
Clin Gastroenterol Hepatol. 2022 Feb 15;S1542-3565(22)00144-6.doi: 10.1016/j.cgh.2022.02.018. Online ahead of print.
Darren Jun Hao Tan 1, Wen Hui Lim 2, Jie Ning Yong 2, Cheng Han Ng 2, Mark D Muthiah 3, Eunice X Tan 3, Jieling Xiao 2, Snow Yunni Lim 2, Ansel Shao Pin Tang 2, Xin Hui Pan 2, Tousif Kabir 4, Glenn K Bonney 5, Raghav Sundar 6, Nicholas Syn 7, Beom Kyung Kim 8, Yock Young Dan 9, Mazen Noureddin 10, Rohit Loomba 11, Daniel Q Huang 12
|
|
|
|
|
|
|
459. | Risk Factors for Hepatocellular Cancer in Contemporary Cohorts of Patients with Cirrhosis |
|
Hepatology. 2022 Mar 1. doi: 10.1002/hep.32434. Online ahead of print.
Fasiha Kanwal 1 2 3, Saira Khaderi 1, Amit G Singal 4, Jorge A Marrero 4, Nicole Loo 5, Sumeet K Asrani 6, Christopher I Amos 7, Aaron P Thrift 7, Xiangjun Gu 7, Michelle Luster 1, Abeer Al-Sarraj 1 2 3, Jing Ning 8, Hashem B El-Serag 1 2 3
|
|
|
|
|
|
|
462. | Incidence and Mortality of Cancers of the Biliary Tract, Gallbladder, and Liver by Sex, Age, Race/Ethnicity, and Stage at Diagnosis: United States, 2013 to 2017 |
|
Cancer Epidemiol Biomarkers Prev. 2021 Sep;30(9):1607-1614.doi: 10.1158/1055-9965.EPI-21-0265. Epub 2021 Jul
Taylor D Ellington 1 2, Behnoosh Momin 2, Reda J Wilson 2, S Jane Henley 2, Manxia Wu 2, A Blythe Ryerson 3
|
|
|
|
|
|
|
|
|
466. | Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment |
|
Cardiovasc Intervent Radiol. 2022 Feb 4. doi: 10.1007/s00270-021-03031-9.Online ahead of print.
Josep M Llovet 1 2 3, Arndt Vogel 4, David C Madoff 5, Richard S Finn 6, Sadahisa Ogasawara 7, Zhenggang Ren 8, Kalgi Mody 9, Jerry J Li 10, Abby B Siegel 10, Leonid Dubrovsky 10, Masatoshi Kudo 11
|
|
|
|
|
468. | Survival Analysis Using ALBI Grade for Patients Treated with DEE-TACE for Hepatocellular Carcinoma |
|
J Vasc Interv Radiol. 2022 Feb 9;S1051-0443(22)00061-6. doi: 10.1016/j.jvir.2022.02.005.Online ahead of print.
Lindsay B Young 1, Parissa Tabrizian 1, Jeffrey Sung 2, Derek Biederman 3, Vivian L Bishay 1, Mona Ranade 4, Rahul S Patel 1, Francis S Nowakowski 1, Aaron M Fischman 1, Robert A Lookstein 1, Edward Kim 1
|
|
|
469. | A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma |
|
Clin Gastroenterol Hepatol. 2021 Dec;19(12):2597-2605.e4.doi: 10.1016/j.cgh.2020.08.065. Epub 2020 Sep 2.
Naga P Chalasani 1, Tiruvidaimarudur S Ramasubramanian 2, Abhik Bhattacharya 2, Marilyn C Olson 2, David K Edwards V 3, Lewis R Roberts 4, John B Kisiel 4, K Rajender Reddy 5, Graham P Lidgard 3, Scott C Johnson 3, Janelle J Bruinsma 2
|
|
|
470. | Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival |
|
J Gastrointest Surg. 2021 Jul;25(7):1727-1735. doi: 10.1007/s11605-020-04765-6.Epub 2020 Aug 10.
Theodoros Michelakos # 1, Filippos Kontos # 1, Yurie Sekigami 1, Motaz Qadan 1, Lei Cai 1, Onofrio Catalano 2, Vikram Deshpande 3, Madhukar S Patel 1, Teppei Yamada 1, Nahel Elias 1, Leigh Anne Dageforde 1, Shoko Kimura 1, Tatsuo Kawai 1, Kenneth K Tanabe 1, James F Markmann 1, Heidi Yeh 1, Cristina R Ferrone 4
|
|
|
|
|
472. | Laparoscopic major hepatectomy for hepatocellular carcinoma in elderly patients: a multicentric propensity score based analysis |
|
Surg Endosc. 2021 Jul;35(7):3642-3652. doi: 10.1007/s00464-020-07843-7. Epub 2020 Aug 3.
Antonella Delvecchio 1, Maria Conticchio 1, Francesca Ratti 2, Maximiliano Gelli 3 4, Ferdinando Massimiliano Anelli 5, Alexis Laurent 6, Giulio Cesare Vitali 7, Paolo Magistri 8, Giacomo Assirati 8, Emanuele Felli 9, Taiga Wakabayashi 9, Patrick Pessaux 9, Tullio Piardi 10 11, Fabrizio Di Benedetto 8, Nicola de'Angelis 6, Javier Briceño-Delgado 5, Rene Adam 4, Daniel Cherqui 4, Luca Aldrighetti 2, Riccardo Memeo 12
|
|
|
|
|
|
|
|
|
|
|
|
|
478. | Association of dietary fat intake and hepatocellular carcinoma among US adults |
|
Cancer Med. 2021 Oct;10(20):7308-7319. doi: 10.1002/cam4.4256. Epub 2021 Sep 18.
Iman Moussa 1, Rena S Day 2, Ruosha Li 3, Ahmed Kaseb 4, Prasun K Jalal 5, Carrie Daniel-MacDougall 6, Rikita I Hatia 6, Ahmed Abdelhakeem 7, Asif Rashid 8, Yun Shin Chun 9, Donghui Li 4, Manal M Hassan 6
|
|
|
479. | Early Versus Late Hepatocellular Carcinoma Recurrence After Transplantation: Predictive Factors, Patterns, and Long-term Outcome |
|
Transplantation. 2021 Aug 1;105(8):1778-1790.doi: 10.1097/TP.0000000000003434.
Nada El-Domiaty 1 2, Faouzi Saliba 1, Eric Vibert 1, Vincent Karam 1, Rodolphe Sobesky 1, Wafaa Ibrahim 3, Gabriella Pittau 1, Oriana Ciacio 1, Chady Salloum 1, Khaled Amer 4, Maysaa A Saeed 2, Jihan A Shawky 2, Antonio Sa Cunha 1, Olivier Rosmorduc 1, Daniel Cherqui 1, René Adam 1, Didier Samuel 1
|
|
|
480. | Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study |
|
Clin Gastroenterol Hepatol. 2021 Jul;19(7):1469-1479.e19.doi: 10.1016/j.cgh.2020.09.027. Epub 2020 Sep 17.
Donghee Kim 1, Nia Adeniji 1, Nyann Latt 2, Sonal Kumar 3, Patricia P Bloom 4, Elizabeth S Aby 5, Ponni Perumalswami 6, Marina Roytman 7, Michael Li 8, Alexander S Vogel 8, Andreea M Catana 9, Kara Wegermann 10, Rotonya M Carr 11, Costica Aloman 12, Vincent L Chen 13, Atoosa Rabiee 14, Brett Sadowski 15, Veronica Nguyen 16, Winston Dunn 17, Kenneth D Chavin 18, Kali Zhou 19, Blanca Lizaola-Mayo 20, Akshata Moghe 21, José Debes 5, Tzu-Hao Lee 10, Andrea D Branch 6, Kathleen Viveiros 8, Walter Chan 8, David M Chascsa 20, Paul Kwo 1, Renumathy Dhanasekaran 22
|
|
|
|
|
|
|
483. | SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study) |
|
J Gastrointest Cancer. 2021 Sep;52(3):907-914. doi: 10.1007/s12029-020-00502-z.
Ryan D Hirsch 1 2, Chris Mills 3, Rohit Sawhney 4 5, Siddharth Sood 6, Virginia Bird 6, Gauri Mishra 7, Anouk Dev 7, William Kemp 8 9, John Lubel 8 9, Stuart K Roberts 8 9, Paul Gow 3, Amanda J Nicoll 4 5 6
|
|
|
484. | HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk |
|
Hepatology. 2021 Jun;73(6):2278-2292. doi: 10.1002/hep.31555. Epub 2021 Jun 15.
Jeffrey S Morris 1, Manal M Hassan 2, Ye Emma Zohner 3, Zeya Wang 3 4, Lianchun Xiao 5, Asif Rashid 6, Abedul Haque 7, Reham Abdel-Wahab 8, Yehia I Mohamed 8, Karri L Ballard 9, Robert A Wolff 8, Bhawana George 7, Liang Li 5, Genevera Allen 3 10, Michael Weylandt 3, Donghui Li 8, Wenyi Wang 4, Kanwal Raghav 8, James Yao 8, Hesham M Amin 7, Ahmed Omar Kaseb 8
|
|
|
|
|
|
|
|
|
488. | Charlson comorbidity index and G8 in older old adult(=80 years) hepatocellular carcinoma patients treated with stereotactic body radiotherapy |
|
J Geriatr Oncol. 2021 Sep;12(7):1100-1103. doi: 10.1016/j.jgo.2021.01.001. Epub 2021 Jan 16.
Mauro Loi 1, Tiziana Comito 2, Ciro Franzese 3, Isacco Desideri 4, Luca Dominici 5, Lorenzo Lo Faro 2, Elena Clerici 2, Davide Franceschini 2, Davide Baldaccini 2, Marco Badalamenti 2, Giacomo Reggiori 2, Francesca Lobefalo 2, Marta Scorsetti 3
|
|
|
489. | Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis |
|
2021 Jun;23(6):868-876. doi: 10.1016/j.hpb.2020.11.1150. Epub 2020 Dec 29.
Joshua P Kronenfeld 1, Emily L Ryon 1, David Goldberg 2, Rachel M Lee 3, Adam Yopp 4, Annie Wang 5, Ann Y Lee 5, Sommer Luu 6, Cary Hsu 6, Eric Silberfein 6, Maria C Russell 3, Nipun B Merchant 1, Neha Goel 7
|
|
|
490. | Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis |
|
Am J Surg. 2021 Sep;222(3):570-576. doi: 10.1016/j.amjsurg.2021.01.015. Epub 2021 Jan 13.
Diamantis I Tsilimigras 1, J Madison Hyer 1, Adrian Diaz 1, Dimitrios Moris 1, Alizeh Abbas 1, Mary Dillhoff 1, Jordan M Cloyd 1, Aslam Ejaz 1, Joal D Beane 1, Allan Tsung 1, Timothy M Pawlik 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
507. | Circadian Clock and Liver Cancer |
|
Cancers (Basel). 2021 Jul 20;13(14):3631. doi: 10.3390/cancers13143631.
María Crespo 1, Magdalena Leiva 1, Guadalupe Sabio 1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
514. | Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study |
|
J Clin Oncol. 2021 Jul 22;JCO2003555. doi: 10.1200/JCO.20.03555. Online ahead of print.
Robin Kate Kelley 1, Bruno Sangro 2, William Harris 3, Masafumi Ikeda 4, Takuji Okusaka 5, Yoon-Koo Kang 6, Shukui Qin 7, David W-M Tai 8, Ho Yeong Lim 9, Thomas Yau 10, Wei-Peng Yong 11, Ann-Lii Cheng 12, Antonio Gasbarrini 13, Silvia Damian 14, Jordi Bruix 15, Mitesh Borad 16, Johanna Bendell 17, Tae-You Kim 18, Nathan Standifer 19, Philip He 20, Mallory Makowsky 20, Alejandra Negro 20, Masatoshi Kudo 21, Ghassan K Abou-Alfa 22 23
|
|
|
|
|
516. | Adiposity, Adulthood Weight Change and Risk of Incident Hepatocellular Carcinoma |
|
Cancer Prev Res (Phila). 2021 Jul 15;canprevres.0549.2020.doi: 10.1158/1940-6207.CAPR-20-0549. Online ahead of print.
Tracey G Simon 1, Mi Na Kim 2, Xiao Luo 3, Xing Liu 3, Wanshui Yang 4, Yanan Ma 4, Dawn Qingqing Chong 5, Charles S Fuchs 6, Meir J Stampfer 7, Edward L Giovannucci 8, Andrew T Chan 9, Xuehong Zhang 10
|
|
|
|
|
|
|
|
|
520. | Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis |
|
Liver Cancer. 2021 Jun;10(3):240-248. doi: 10.1159/000515302. Epub 2021 May 6.
Arndt Vogel 1, Lorenza Rimassa 2, Hui-Chan Sun 3, Ghassan K Abou-Alfa 4, Anthony El-Khoueiry 5, David J Pinato 6, Javier Sanchez Alvarez 7, Monica Daigl 7, Panos Orfanos 7, Michael Leibfried 8, Marie-Hélène Blanchet Zumofen 7, Vincent E Gaillard 7, Philippe Merle 9
|
|
|
521. | High rate of complete histopathological response in hepatocellular carcinoma patients after combined transarterial chemoembolization and stereotactic body radiation therapy |
|
World J Gastroenterol. 2021 Jun 28;27(24):3630-3642.doi: 10.3748/wjg.v27.i24.3630.
Ulrike Bauer 1, Sabine Gerum 2, Falk Roeder 2, Stefan Münch 3, Stephanie E Combs 3, Alexander B Philipp 4, Enrico N De Toni 4, Martha M Kirstein 5, Arndt Vogel 5, Carolin Mogler 6, Bernhard Haller 7, Jens Neumann 8, Rickmer F Braren 9, Marcus R Makowski 9, Philipp Paprottka 10, Markus Guba 11, Fabian Geisler 1, Roland M Schmid 1, Andreas Umgelter 1, Ursula Ehmer
|
|
|
|
|
|
|
|
|
525. | Laparoscopic surgery versus radiofrequency ablation for the treatment of single hepatocellular carcinoma =3 cm in the elderly: a propensity score matching analysis |
|
HPB (Oxford). 2021 Jun 8;S1365-182X(21)00159-3. doi: 10.1016/j.hpb.2021.05.008.Online ahead of print.
Maria Conticchio 1, Antonella Delvecchio 1, Francesca Ratti 2, Maximiliano Gelli 3, Ferdinando M Anelli 4, Alexis Laurent 5, Giulio C Vitali 6, Paolo Magistri 7, Giacomo Assirati 7, Emanuele Felli 8, Taiga Wakabayashi 8, Patrick Pessaux 8, Tullio Piardi 9, Fabrizio Di Benedetto 7, Nicola de'Angelis 5, Delgado F Javier Briceno 4, Antonio G Rampoldi 10, René Adam 11, Daniel Cherqui 11, Luca Aldrighetti 2, Riccardo Memeo 12
|
|
|
526. | Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease etiology |
|
Liver Int. 2021 Jun 26. doi: 10.1111/liv.14994. Online ahead of print.
Peter R Galle 1, Masatoshi Kudo 2, Josep M Llovet 3 4 5, Richard S Finn 6, Mark Karwal 7, Denis Pezet 8, Tae-You Kim 9, Tsai-Sheng Yang 10, Sara Lonardi 11, Jiri Tomasek 12, Jean-Marc Phelip 13, Yann Touchefeu 14, Su-Jin Koh 15, Guido Stirnimann 16, Kun Liang 17, Kenyon D Ogburn 17, Chunxiao Wang 17, Paolo Abada 17, Ryan C Widau 17, Andrew X Zhu 18 19
|
|
|
|
|
|
|
529. | Limited tumor progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival |
|
J Hepatol. 2021 Jun 22;S0168-8278(21)00435-9. doi: 10.1016/j.jhep.2021.06.015.Online ahead of print.
Joana Ferrer-Fàbrega 1, Jaime Sampson-Dávila 2, Alejandro Forner 3, Victor Sapena 4, Alba Díaz 5, Ramón Vilana 6, Miquel Navasa 7, Constantino Fondevila 8, Rosa Miquel 9, Carmen Ayuso 6, Juan Carlos García-Valdecasas 8, Jordi Bruix 3, María Reig 3, Josep Fuster 10
|
|
|
|
|
|
|
532. | External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV |
|
JHEP Rep. 2021 Apr 24;3(4):100298. doi: 10.1016/j.jhepr.2021.100298. eCollection 2021 Aug.
Thierry Poynard 1 2, Jean Marc Lacombe 3, Olivier Deckmyn 4, Valentina Peta 2 4, Sepideh Akhavan 1, Victor de Ledinghen 5, Fabien Zoulim 6, Didier Samuel 7 8, Philippe Mathurin 9, Vlad Ratziu 1 2, Dominique Thabut 1 2, Chantal Housset 2, Hélène Fontaine 10, Stanislas Pol 10, Fabrice Carrat 3
|
|
|
533. | Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma |
|
ESMO Open. 2021 Jun 15;6(4):100190. doi: 10.1016/j.esmoop.2021.100190. Online ahead of print.
I G Rapposelli 1, S Shimose 2, T Kumada 3, S Okamura 2, A Hiraoka 4, G G Di Costanzo 5, F Marra 6, E Tamburini 7, A Forgione 8, F G Foschi 9, M Silletta 10, S Lonardi 11, G Masi 12, M Scartozzi 13, M Nakano 2, H Shibata 14, K Kawata 15, A Pellino 16, C Vivaldi 12, E Lai 13, A Takata 2, K Tajiri 17, H Toyoda 18, R Tortora 5, C Campani 6, M G Viola 19, F Piscaglia 8, F Conti 9, C A M Fulgenzi 10, G L Frassineti 1, M D Rizzato 20, F Salani 21, G Astara 13, T Torimura 2, M Atsukawa 22, T Tada 23, V Burgio 24, M Rimini 25, S Cascinu 26, A Casadei-Gardini 27
|
|
|
|
|
|
|
|
|
537. | Understanding the patient experience in hepatocellular carcinoma: a qualitative patient interview study |
|
Qual Life Res. 2021 Jun 11. doi: 10.1007/s11136-021-02903-4. Online ahead of print.
Nikunj Patel 1, Joshua Maher 2, Xandra Lie 3, Chad Gwaltney 4, Afsaneh Barzi 5, Mark Karwal 6, Teresa Macarulla 7, Hui-Chuan Sun 8, Jörg Trojan 9, Oren Meyers 10, Christina Workman 11, Shethah Morgan 12, Alejandra Negro 11, Gordon Cohen 11
|
|
|
538. | Evidence-based management of HCC: Systematic review and meta-analysis of randomized controlled trials (2002-2020) |
|
Gastroenterology. 2021 Jun 11;S0016-5085(21)03119-X. doi: 10.1053/j.gastro.2021.06.008.Online ahead of print.
Philipp K Haber 1, Marc Puigvehí 2, Florian Castet 3, Vennis Lourdusamy 1, Robert Montal 4, Parissa Tabrizian 1, Michael Buckstein 1, Edward Kim 1, Augusto Villanueva 1, Myron Schwartz 1, Josep M Llovet 5
|
|
|
539. | Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase 3 REFLECT Study |
|
Clin Cancer Res. 2021 Jun 9;clincanres.4219.2020. doi: 10.1158/1078-0432.CCR-20-4219.Online ahead of print.
Richard S Finn 1, Masatoshi Kudo 2, Ann-Lii Cheng 3, Lucjan Wyrwicz 4, Roger Kai-Cheong Ngan 5, Jean-Frederic Blanc 6, Ari D Baron 7, Arndt Vogel 8, Masafumi Ikeda 9, Fabio Piscaglia 10, Kwang-Hyub Han 11, Shu-Kui Qin 12, Yukinori Minoshima 13, Michio Kanekiyo 14, Min Ren 15, Ryo Dairiki 16, Toshiyuki Tamai 17, Corina E Dutcus 18, Hiroki Ikezawa 19, Yasuhiro Funahashi 13, Thomas R Jeffry Evans 20
|
|
|
|
|
541. | Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences |
|
Ultrasound Med Biol. 2021 Jun 12;S0301-5629(21)00218-0.doi: 10.1016/j.ultrasmedbio.2021.05.006. Online ahead of print.
Lauren J Delaney 1, Mohamed Tantawi 1, Corinne E Wessner 1, Priscilla Machado 1, Flemming Forsberg 1, Andrej Lyshchik 1, Patrick O'Kane 1, Ji-Bin Liu 1, Jesse Civan 2, Allison Tan 1, Kevin Anton 1, Colette M Shaw 1, John R Eisenbrey 3
|
|
|
542. | Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients with Cirrhosis |
|
Clin Gastroenterol Hepatol. 2021 Jun 10;S1542-3565(21)00615-7. doi: 10.1016/j.cgh.2021.06.012.Online ahead of print.
Haley Schoenberger 1, Nicolas Chong 1, David T Fetzer 2, Nicole E Rich 1, Takeshi Yokoo 2, Gaurav Khatri 2, Jocelyn Olivares 3, Neehar D Parikh 4, Adam C Yopp 5, Jorge A Marrero 3, Amit G Singal 6
|
|
|
|
|
544. | Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial |
|
Lancet Gastroenterol Hepatol. 2021 Jun 1;S2468-1253(21)00110-2.
doi: 10.1016/S2468-1253(21)00110-2. Online ahead of print.
Arndt Vogel 1, Shukui Qin 2, Masatoshi Kudo 3, Yun Su 4, Stacie Hudgens 5, Tatsuya Yamashita 6, Jung-Hwan Yoon 7, Laetitia Fartoux 8, Krzysztof Simon 9, Carlos López 10, Max Sung 11, Kalgi Mody 4, Tatsuroh Ohtsuka 4, Toshiyuki Tamai 4, Lee Bennett 12, Genevieve Meier 4, Valery Breder 13
|
|
|
545. | Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine |
|
Clin Gastroenterol Hepatol. 2021 Jun 2;S1542-3565(21)00601-7. doi: 10.1016/j.cgh.2021.05.062.Online ahead of print.
Jiyoon Park 1, An K Le 2, Tai-Chung Tseng 3, Ming-Lun Yeh 4, Dae Won Jun 5, Huy Trinh 6, Grace Lh Wong 7, Chien-Hung Chen 8, Cheng-Yuan Peng 9, Sung Eun Kim 10, Hyunwoo Oh 11, Min-Sun Kwak 11, Ka Shing Cheung 12, Hidenori Toyoda 13, Yao-Chun Hsu 14, Jae Yoon Jeong 15, Eileen L Yoon 16, Teerapat Ungtrakul 17, Jian Zhang 18, Qing Xie 19, Sang Bong Ahn 20, Masaru Enomoto 21, Jae-Jun Shim 22, Chris Cunningham 23, Soung Won Jeong 24, Yong Kyun Cho 25, Eiichi Ogawa 26, Rui Huang 27, Dong-Hyun Lee 28, Hirokazu Takahashi 29, Pei-Chien Tsai 4, Chung-Feng Huang 5, Chia-Yen Dai 5, Cheng-Hao Tseng 14, Satoshi Yasuda 13, Ritsuzo Kozuka 21, Jiayi Li 30, Christopher Wong 31, Clifford C Wong 31, Changqing Zhao 32, Joseph Hoang 33, Yuichiro Eguchi 29, Chao Wu 27, Yasuhito Tanaka 34, Ed Gane 35, Tawesak Tanwandee 36, Ramsey Cheung 33, Man-Fung Yuen 12, Hyo-Suk Lee 11, Ming-Lung Yu 4, Jia-Horng Kao 3, Hwai-I Yang 37, Mindie H Nguyen 38
|
|
|
|
|
547. | Skeletal Muscle Volume Is an Independent Predictor of Survival after Sorafenib Treatment Failure for Hepatocellular Carcinoma |
|
Cancers (Basel). 2021 May 7;13(9):2247. doi: 10.3390/cancers13092247.
Issei Saeki 1, Takahiro Yamasaki 2, Yurika Yamauchi 1, Taro Takami 1, Tomokazu Kawaoka 3, Shinsuke Uchikawa 3, Akira Hiramatsu 3, Hiroshi Aikata 3, Reo Kawano 4, Kazufumi Kobayashi 5 6, Takayuki Kondo 5, Sadahisa Ogasawara 5 6, Tetsuhiro Chiba 5, Kazuaki Chayama 3, Naoya Kato 5, Isao Sakaida 1
|
|
|
548. | Sustained Complete Response after Biological Downstaging in Patients with Hepatocellular Carcinoma: XXL-Like Prioritization for Liver Transplantation or "Wait and See" Strategy? |
|
Cancers (Basel). 2021 May 17;13(10):2406. doi: 10.3390/cancers13102406.
Alessandro Vitale 1, Federica Scolari 1, Alessandra Bertacco 1, Enrico Gringeri 1, Francesco D'Amico 1, Domenico Bassi 1, Francesco Enrico D'Amico 1, Paolo Angeli 2, Patrizia Burra 3, Quirino Lai 4, Umberto Cillo 1
|
|
|
|
|
550. | Liver Transplantation for Hepatocellular Carcinoma: A Real-Life Comparison of Milan Criteria and AFP Model |
|
Cancers (Basel). 2021 May 19;13(10):2480. doi: 10.3390/cancers13102480.
Bleuenn Brusset 1 2, Jerome Dumortier 3, Daniel Cherqui 4, Georges-Philippe Pageaux 5, Emmanuel Boleslawski 6, Ludivine Chapron 2, Jean-Louis Quesada 2, Sylvie Radenne 7, Didier Samuel 4, Francis Navarro 5, Sebastien Dharancy 6, Thomas Decaens 1 2 8
|
|
|
551. | The Hepatic Innovation Team Collaborative: A Successful Population-Based Approach to Hepatocellular Carcinoma Surveillance |
|
Cancers (Basel). 2021 May 7;13(9):2251. doi: 10.3390/cancers13092251.
Shari S Rogal 1 2, Vera Yakovchenko 3, Rachel Gonzalez 4, Angela Park 5, Lauren A Beste 6 7, Karine Rozenberg-Ben-Dror 8, Jasmohan S Bajaj 9 10, Dawn Scott 11, Heather McCurdy 12, Emily Comstock 13, Michael Sidorovic 14, Sandra Gibson 1, Carolyn Lamorte 1, Anna Nobbe 15, Maggie Chartier 16, David Ross 16, Jason A Dominitz 17 18, Timothy R Morgan 19 20
|
|
|
|
|
|
|
|
|
|
|
|
|
557. | Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology |
|
J Natl Compr Canc Netw. 2021 May 1;19(5):541-565. doi: 10.6004/jnccn.2021.0022.
Al B Benson 1, Michael I D'Angelica 2, Daniel E Abbott 3, Daniel A Anaya 4, Robert Anders 5, Chandrakanth Are 6, Melinda Bachini 7, Mitesh Borad 8, Daniel Brown 9, Adam Burgoyne 10, Prabhleen Chahal 11, Daniel T Chang 12, Jordan Cloyd 13, Anne M Covey 2, Evan S Glazer 14, Lipika Goyal 15, William G Hawkins 16, Renuka Iyer 17, Rojymon Jacob 18, R Kate Kelley 19, Robin Kim 20, Matthew Levine 21, Manisha Palta 22, James O Park 23, Steven Raman 24, Sanjay Reddy 25, Vaibhav Sahai 26, Tracey Schefter 27, Gagandeep Singh 28, Stacey Stein 29, Jean-Nicolas Vauthey 30, Alan P Venook 19, Adam Yopp 31, Nicole R McMillian 32, Cindy Hochstetler 32, Susan D Darlow 32
|
|
|
|
|
559. | SBRT for HCC: Overview of technique and treatment response assessment |
|
Abdom Radiol (NY). 2021 May 7. doi: 10.1007/s00261-021-03107-7.Online ahead of print.
Kimberly L Shampain 1, Caitlin E Hackett 2, Sohrab Towfighi 3, Anum Aslam 2, William R Masch 2, Alison C Harris 3, Silvia D Chang 3, Kanika Khanna 4, Vivek Mendiratta 4, Ahmed M Gabr 5, Dawn Owen 6, Mishal Mendiratta-Lala 2
|
|
|
560. | The predictive value of tumor infiltrating leukocytes in Hepatocellular Carcinoma: A systematic review and meta-analysis |
|
Eur J Surg Oncol. 2021 May 4;S0748-7983(21)00473-X. doi: 10.1016/j.ejso.2021.04.042.Online ahead of print.
Markus Bo Schoenberg 1, Xiaokang Li 2, Xinyu Li 2, Yongsheng Han 2, Jingcheng Hao 3, Rainer Christoph Miksch 2, Dominik Koch 2, Nikolaus Börner 2, Nicola Theresa Beger 2, Julian Nikolaus Bucher 2, Tobias Simon Schiergens 2, Markus Otto Guba 2, Jens Werner 1, Alexandr V Bazhin 4
|
|
|
|
|
|
|
563. | African Immigrants in New York City with Hepatitis B-Related Hepatocellular Carcinoma Demonstrate High Morbidity and Mortality |
|
J Immigr Minor Health. 2021 Apr 27. doi: 10.1007/s10903-021-01205-8. Online ahead of print.
Jacquelyn Carr 1, Da Eun Cha 1, Tali Shaltiel 1, Serena Zheng 1, Cleo Siderides 1, Benjamin Golas 1, Daniel Labow 1, Deepa Magge 1, Noah Cohen 1, Andrea Branch 2, Umut Sarpel 3
|
|
|
564. | Long-term evolution of LI-RADS observations in HCV-related cirrhosis treated with direct-acting antivirals |
|
Liver Int. 2021 Apr 28. doi: 10.1111/liv.14914. Online ahead of print.
Roberto Cannella 1 2, Federica Vernuccio 1 2 3 4, Ciro Celsa 2 5, Giuseppe Cabibbo 2, Vincenza Calvaruso 2, Silvia Greco 1, Salvatore Battaglia 6, Kingshuk Roy Choudhury 7, An Tang 8, Massimo Midiri 1, Vito Di Marco 2, Calogero Cammà 2, Giuseppe Brancatelli 1
|
|
|
|
|
|
|
567. | Aspirin in hepatocellular carcinoma |
|
Cancer Res. 2021 Apr 23;canres.0758.2021. doi: 10.1158/0008-5472.CAN-21-0758.Online ahead of print.
Emanuela Ricciotti 1, Kirk J Wangensteen 2, Garret A FitzGerald 3
|
|
|
|
|
|
|
|
|
|
|
|
|
573. | How to Treat Hepatocellular Carcinoma in Elderly Patients |
|
Pharmaceuticals (Basel). 2021 Mar 8;14(3):233. doi: 10.3390/ph14030233.
Piera Federico 1, Emilio Francesco Giunta 1 2, Annalisa Pappalardo 1 2, Andrea Tufo 3, Gianpaolo Marte 3, Laura Attademo 1, Antonietta Fabbrocini 1, Angelica Petrillo 1 2, Bruno Daniele 1
|
|
|
574. | Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI) |
|
Clin Res Hepatol Gastroenterol. 2021 Mar 26;45(2):101590.doi: 10.1016/j.clinre.2020.101590. Online ahead of print.
Jean Frédéric Blanc 1, Audrey Debaillon-Vesque 2, Gaël Roth 3, Jean Claude Barbare 4, Anne Sophie Baumann 5, Valérie Boige 6, Karim Boudjema 7, Mohamed Bouattour 8, Gilles Crehange 9, Barbara Dauvois 10, Thomas Decaens 3, François Dewaele 11, Olivier Farges 8, Boris Guiu 12, Antoine Hollebecque 6, Philippe Merle 13, Janick Selves 14, Thomas Aparicio 15, Isaac Ruiz 16, Olivier Bouché 17, Thésaurus National de Cancérologie Digestive (TNCD); Société Nationale Française de Gastroentérologie (SNFGE); Fédération Francophone de Cancérologie Digestive (FFCD); Groupe Coopérateur multidisciplinaire en Oncologie (GERCOR); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Société Française de Chirurgie Digestive (SFCD); Société Française d’Endoscopie Digestive (SFED); Société Française de Radiothérapie Oncologique (SFRO); Association Française pour l’Etude du Foie (AFEF)
|
|
|
575. | Artificial intelligence in assessment of hepatocellular carcinoma treatment response |
|
Abdom Radiol (NY). 2021 Mar 31. doi: 10.1007/s00261-021-03056-1.Online ahead of print.
Bradley Spieler 1, Carl Sabottke 2, Ahmed W Moawad 3, Ahmed M Gabr 4, Mustafa R Bashir 5, Richard Kinh Gian Do 6, Vahid Yaghmai 7, Radu Rozenberg 8, Marielia Gerena 9, Joseph Yacoub 10, Khaled M Elsayes 11
|
|
|
|
|
577. | Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort |
|
J Hepatol. 2021 Mar 18;S0168-8278(21)00176-8. doi: 10.1016/j.jhep.2021.02.034.Online ahead of print.
Stephen A Harrison 1, Samer Gawrieh 2, Katharine Roberts 3, Christopher J Lisanti 4, Ryan B Schwope 4, Katherine M Cebe 5, Valerie Paradis 6, Pierre Bedossa 6, Jennifer M Aldridge Whitehead 7, Aymeric Labourdette 8, Véronique Miette 8, Stefan Neubauer 9, Céline Fournier 10, Angelo H Paredes 3, Naim Alkhouri 11
|
|
|
578. | NAFLD and MAFLD as emerging causes of HCC: A populational study |
|
JHEP Rep. 2021 Jan 19;3(2):100231. doi: 10.1016/j.jhepr.2021.100231. eCollection 2021 Apr.
Shuna Myers 1, Isabelle Neyroud-Caspar 2, Laurent Spahr 3, Konstantinos Gkouvatsos 3, Evelyne Fournier 2, Emiliano Giostra 3, Giulia Magini 3 4, Jean-Louis Frossard 3, Marie-Eve Bascaron 5, Nathalie Vernaz 6, Lucia Zampaglione 3, Francesco Negro 3 7, Nicolas Goossens 3 8
|
|
|
|
|
|
|
|
|
|
|
583. | Retrospective-Prospective Study of Safety and Efficacy of Sofosbuvir based Direct Acting Antivirals in HIV/HCV Coinfected Participants with Decompensated Liver Disease Pre or Post Liver Transplant |
|
Am J Transplant. 2020 Dec 4. doi: 10.1111/ajt.16427. Online ahead of print.
Marion G Peters 1, Shyam Kottilil 2, Norah Terrault 3, Dominic Amara 4, Jennifer Husson 2, Shirish Huprikar 5, Sander Florman 6, Mark S Sulkowski 7, Christine M Durand 7, Anne F Luetkemeyer 1, Rodney Rogers 4, Joshua Grab 1, Brandy Haydel 6, Emily Blumberg 8, Lorna Dove 9, Jean Emond 10, Kim Olthoff 11, Coleman Smith 12, Thomas Fishbein 12, Henry Masur 13, Peter G Stock 4
|
|
|
584. | Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis |
|
Cancers (Basel). 2021 Feb 15;13(4):812. doi: 10.3390/cancers13040812.
Gaël S Roth 1 2 3, Maxime Benhamou 4, Yann Teyssier 1 5, Arnaud Seigneurin 1 6, Mélodie Abousalihac 1 2, Christian Sengel 5, Olivier Seror 4 7 8, Julien Ghelfi 1 3 5, Nathalie Ganne-Carrié 7 8 9, Lorraine Blaise 9, Olivier Sutter 4, Thomas Decaens 1 2 3, Jean-Charles Nault 7 8 9
|
|
|
585. | Elevated Glycated Hemoglobin Is Associated With Liver Fibrosis, as Assessed by Elastography, in a Population-Based Study of Mexican Americans |
|
Hepatol Commun. 2020 Oct 31;4(12):1793-1801. doi: 10.1002/hep4.1603. eCollection 2020 Dec.
Gordon P Watt 1, Isela De La Cerda 2, Jen-Jung Pan 3, Michael B Fallon 4, Laura Beretta 5, Rohit Loomba 6, Miryoung Lee 2, Joseph B McCormick 2, Susan P Fisher-Hoch 2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
594. | Hepatocellular carcinoma |
|
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. doi: 10.1038/s41572-020-00240-3.
Josep M Llovet 1 2 3, Robin Kate Kelley 4, Augusto Villanueva 5, Amit G Singal 6, Eli Pikarsky 7, Sasan Roayaie 8, Riccardo Lencioni 9 10, Kazuhiko Koike 11, Jessica Zucman-Rossi 12 13, Richard S Finn 14
|
|
|
|
|
|
|
|
|
|
|
|
|
600. | Lymph node sampling in resectable hepatocellular carcinoma: national practice patterns and predictors of positive lymph nodes |
|
Surg Oncol. 2020 Dec 30;36:138-146. doi: 10.1016/j.suronc.2020.12.011. Online ahead of print.
Phillip M Kemp Bohan 1, Anne E O'Shea 1, Andrew J Lee 2, Robert C Chick 1, Timothy E Newhook 3, Hop S Tran Cao 3, Casey J Allen 3, Daniel W Nelson 4, G Travis Clifton 1, Jean-Nicolas Vauthey 3, Ching-Wei D Tzeng 3, Timothy J Vreeland 5
|
|
|
|
|
602. | Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial |
|
Cancers (Basel). 2021 Jan 7;13(2):E187. doi: 10.3390/cancers13020187.
Salomon M Stemmer 1, Nebojsa S Manojlovic 2, Mihai Vasile Marinca 3, Petar Petrov 4, Nelly Cherciu 5, Doina Ganea 6, Tudor Eliade Ciuleanu 7, Ioana Adriana Pusca 8, Muhammad Shaalan Beg 9, William T Purcell 10, Adina-Emilia Croitoru 11, Rumyana Nedyalkova Ilieva 12, Sladjana Natoševic 13, Amedeia Lavinir Nita 14, Dimitar Nikolaev Kalev 15, Zivit Harpaz 16, Motti Farbstein 16, Michael H Silverman 16, David Bristol 16, Inbal Itzhak 16, Pnina Fishman 16
|
|
|
603. | Predicting survival after liver transplantation in patients with hepatocellular carcinoma using the LiTES-HCC score |
|
J Hepatol. 2021 Jan 13;S0168-8278(21)00004-0. doi: 10.1016/j.jhep.2020.12.021.Online ahead of print.
David Goldberg 1, Alejandro Mantero 2, Craig Newcomb 3, Cindy Delgado 4, Kimberly A Forde 5, David E Kaplan 6, Binu John 7, Nadine Nuchovich 4, Barbara Dominguez 4, Ezekiel Emanuel 8, Peter P Reese 9
|
|
|
|
|
605. | Deep learning-assisted differentiation of pathologically proven atypical and typical hepatocellular carcinoma (HCC) versus non-HCC on contrast-enhanced MRI of the liver |
|
Eur Radiol. 2021 Jan 6. doi: 10.1007/s00330-020-07559-1. Online ahead of print.
Paula M Oestmann 1 2 3, Clinton J Wang 1 4, Lynn J Savic 1 2, Charlie A Hamm 1 2, Sophie Stark 1 2 5, Isabel Schobert 1 2, Bernhard Gebauer 2, Todd Schlachter 1, MingDe Lin 1, Jeffrey C Weinreb 1, Ramesh Batra 6, David Mulligan 6, Xuchen Zhang 7, James S Duncan 1 4, Julius Chapiro 8
|
|
|
|
|
|
|
608. | Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline |
|
J Clin Oncol. 2020 Dec 20;38(36):4317-4345. doi: 10.1200/JCO.20.02672. Epub 2020 Nov 16.
John D Gordan 1, Erin B Kennedy 2, Ghassan K Abou-Alfa 3, Muhammad Shaalan Beg 4, Steven T Brower 5, Terence P Gade 6, Laura Goff 7, Shilpi Gupta 8, Jennifer Guy 9, William P Harris 10, Renuka Iyer 11, Ishmael Jaiyesimi 12, Minaxi Jhawer 13, Asha Karippot 14, Ahmed O Kaseb 15, R Kate Kelley 1, Jennifer J Knox 16, Jeremy Kortmansky 17, Andrea Leaf 18, William M Remak 19, Rachna T Shroff 20, Davendra P S Sohal 21, Tamar H Taddei 22, Neeta K Venepalli 23, Andrea Wilson 24, Andrew X Zhu 25, Michal G Rose 26
|
|
|
|
|
610. | Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C |
|
Transplant Direct. 2020 Dec 8;7(1):e635. doi: 10.1097/TXD.0000000000001049.eCollection 2021 Jan.
Chung Sang Tse 1 2, Ju Dong Yang 3 4 5, Omar Y Mousa 6 7, Kevin M Nelson 6, Surakit Pungpapong 7, Andrew Keaveny 7, Bashar A Aqel 8, Hugo Vargas 8, Rolland C Dickson 8, Kymberly Watt 6, Gregory J Gores 6, Lewis R Roberts 6, Michael D Leise 6
|
|
|
|
|
612. | US-triggered Microbubble Destruction for Augmenting Hepatocellular Carcinoma Response to Transarterial Radioembolization: A Randomized Pilot Clinical Trial |
|
Radiology. 2020 Dec 15;202321. doi: 10.1148/radiol.2020202321. Online ahead of print.
John R Eisenbrey 1, Flemming Forsberg 1, Corinne E Wessner 1, Lauren J Delaney 1, Kristen Bradigan 1, Sriharsha Gummadi 1, Mohamed Tantawi 1, Andrej Lyshchik 1, Patrick O'Kane 1, Ji-Bin Liu 1, Charles Intenzo 1, Jesse Civan 1, Warren Maley 1, Scott W Keith 1, Kevin Anton 1, Allison Tan 1, Amanda Smolock 1, Susan Shamimi-Noori 1, Colette M Shaw 1
|
|
|
|
|
|
|
615. | Strategies for the delay of surgery in the management of resectable hepatobiliary malignancies during the COVID-19 pandemic |
|
Curr Oncol. 2020 Oct;27(5):e501-e511. doi: 10.3747/co.27.6785. Epub 2020 Oct 1.
S Bennett 1, K Søreide 2, S Gholami 3, P Pessaux 4, C Teh 5, E Segelov 6, H Kennecke 3, H Prenen 7, S Myrehaug 1, D Callegaro 1 8, J Hallet 1
|
|
|
|
|
|
|
618. | ACR Appropriateness Criteria® Liver Lesion-Initial Characterization |
|
Am Coll Radiol. 2020 Nov;17(11S):S429-S446.doi: 10.1016/j.jacr.2020.09.005.
Expert Panel on Gastrointestinal Imaging; Victoria Chernyak 1, Jeanne M Horowitz 2, Ihab R Kamel 3, Hina Arif-Tiwari 4, Mustafa R Bashir 5, Brooks D Cash 6, James Farrell 7, Alan Goldstein 8, Joseph R Grajo 9, Samir Gupta 10, Nicole M Hindman 11, Aya Kamaya 12, Michelle M McNamara 13, Kristin K Porter 13, Lilja Bjork Solnes 14, Pavan K Srivastava 15, Atif Zaheer 16, Laura R Carucci 17
|
|
|
|
|
|
|
|
|
622. | Getting to implementation: a protocol for a Hybrid III stepped wedge cluster randomized evaluation of using data-driven implementation strategies to improve cirrhosis care for Veterans |
|
Implement Sci. 2020 Oct 21;15(1):92. doi: 10.1186/s13012-020-01050-7.
Shari S Rogal 1 2, Vera Yakovchenko 3, Timothy Morgan 4 5, Jasmohan S Bajaj 6 7, Rachel Gonzalez 8, Angela Park 9, Lauren Beste 10 11, Edward J Miech 12, Carolyn Lamorte 13, Brittney Neely 13, Sandra Gibson 13, Patrick S Malone 14, Maggie Chartier 15, Tamar Taddei 16 17, Guadalupe Garcia-Tsao 16 17, Byron J Powell 18, Jason A Dominitz 19 20, David Ross 15, Matthew J Chinman 13 21
|
|
|
|
|
|
|
|
|
|
|
627. | Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial |
|
Thomas Yau 1, Yoon-Koo Kang 2, Tae-You Kim 3, Anthony B El-Khoueiry 4, Armando Santoro 5, Bruno Sangro 6, Ignacio Melero 7, Masatoshi Kudo 8, Ming-Mo Hou 9, Ana Matilla 10, Francesco Tovoli 11, Jennifer J Knox 12, Aiwu Ruth He 13, Bassel F El-Rayes 14, Mirelis Acosta-Rivera 15, Ho-Yeong Lim 16, Jaclyn Neely 17, Yun Shen 18, Tami Wisniewski 19, Jeffrey Anderson 19, Chiun Hsu 20
|
|
|
628. | Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation |
|
Health Technol Assess. 2020 Sep;24(48):1-264. doi: 10.3310/hta24480.
Matthew Walton 1, Ros Wade 1, Lindsay Claxton 1, Sahar Sharif-Hurst 1, Melissa Harden 1, Jai Patel 2, Ian Rowe 2, Robert Hodgson 1, Alison Eastwood 1
|
|
|
629. | Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis |
|
Hepatol Commun. 2020 Jul 6;4(9):1332-1345. doi: 10.1002/hep4.1518. eCollection 2020 Sep.
Surain B Roberts 1 2, Marwa Ismail 1, Gowthami Kanagalingam 1, Andrew L Mason 3, Mark G Swain 4, Catherine Vincent 5, Eric M Yoshida 6, Cynthia Tsien 7, Jennifer A Flemming 8, Harry L A Janssen 1, Gideon M Hirschfield 1, Bettina E Hansen 1 2, Aliya F Gulamhusein 1 2, Canadian Network for Autoimmune Liver Disease
|
|
|
630. | Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France |
|
Cardiovasc Intervent Radiol. 2020 Sep 25. doi: 10.1007/s00270-020-02643-x.Online ahead of print.
Romaric Loffroy 1, Maxime Ronot 2, Michel Greget 3, Antoine Bouvier 4, Charles Mastier 5, Christian Sengel 6, Lambros Tselikas 7, Dirk Arnold 8, Geert Maleux 9, Jean-Pierre Pelage 10, Olivier Pellerin 11, Bora Peynircioglu 12, Bruno Sangro 13, Niklaus Schaefer 14, María Urdániz 15, Nathalie Kaufmann 16, José Ignacio Bilbao 17, Thomas Helmberger 18, Valérie Vilgrain 2, CIRT-FR Principal Investigators
Collaborators
- CIRT-FR Principal Investigators:
Gilles Piana, Julien Frandon, Jean-Pierre Tasu, Hicham Kobeiter
|
|
|
631. | Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study |
|
Ann Surg Oncol. 2020 Sep 25. doi: 10.1245/s10434-020-09156-4. Online ahead of print.
Joshua P Kronenfeld 1, Emily L Ryon 1, David Goldberg 2, Rachel M Lee 3, Adam Yopp 4, Annie Wang 5, Ann Y Lee 5, Sommer Luu 6, Cary Hsu 6, Eric Silberfein 6, Maria C Russell 3, Alan S Livingstone 1, Nipun B Merchant 1, Neha Goel 7
|
|
|
|
|
|
|
634. | Hepatitis B virus preS2?38-55 variants: A newly identified risk factor for hepatocellular carcinoma |
|
JHEP Rep. 2020 Jul 11;2(5):100144. doi: 10.1016/j.jhepr.2020.100144. eCollection 2020 Oct.
Damien Cohen 1, Sumantra Ghosh 1, Yusuke Shimakawa 2, Njie Ramou 3, Pierre Simon Garcia 4 5, Anaëlle Dubois 1, Clément Guillot 1, Nora Kakwata-Nkor Deluce 1, Valentin Tilloy 6, Geoffroy Durand 3, Catherine Voegele 3, Gibril Ndow 7, Umberto d'Alessandro 7, Céline Brochier-Armanet 4, Sophie Alain 6, Florence Le Calvez-Kelm 3, Janet Hall 1, Fabien Zoulim 1 8, Maimuna Mendy 3, Mark Thursz 9, Maud Lemoine 9, Isabelle Chemin 1
|
|
|
635. | SIRT Compared with DEB-TACE for Hepatocellular Carcinoma: a Real-world Study (the SITAR Study) |
|
J Gastrointest Cancer. 2020 Sep 9. doi: 10.1007/s12029-020-00502-z. Online ahead of print.
Ryan D Hirsch 1 2, Chris Mills 3, Rohit Sawhney 4 5, Siddharth Sood 6, Virginia Bird 6, Gauri Mishra 7, Anouk Dev 7, William Kemp 8 9, John Lubel 8 9, Stuart K Roberts 8 9, Paul Gow 3, Amanda J Nicoll 4 5 6
|
|
|
|
|
637. | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial |
|
ESMO Open. 2020 Aug;5(4):e000714. doi: 10.1136/esmoopen-2020-000714.
Robin Kate Kelley 1, Baek-Yeol Ryoo 2, Philippe Merle 3, Joong-Won Park 4, Luigi Bolondi 5, Stephen L Chan 6, Ho Yeong Lim 7, Ari D Baron 8, Francis Parnis 9, Jennifer Knox 10, Stéphane Cattan 11, Thomas Yau 12, Julie C Lougheed 13, Steven Milwee 14, Anthony B El-Khoueiry 15, Ann-Lii Cheng 16, Tim Meyer 17, Ghassan K Abou-Alfa 18 19
|
|
|
638. | Individualized adaptive radiation therapy allows for safe treatment of hepatocellular carcinoma in patients with Child-Turcotte-Pugh B liver disease |
|
Int J Radiat Oncol Biol Phys. 2020 Aug 24;S0360-3016(20)34141-9.doi: 10.1016/j.ijrobp.2020.08.046. Online ahead of print.
William C Jackson 1, Ming Tang 2, Christopher Maurino 2, Mishal Mendiratta-Lala 3, Neehar D Parikh 4, Martha M Matuszak 2, Janell S Dow 2, Yue Cao 2, Charles S Mayo 2, Randall K Ten Haken 2, Matthew J Schipper 2, Kyle C Cuneo 2, Dawn Owen 2, Theodore S Lawrence 2
|
|
|
|
|
640. | Effects of Metformin Exposure on Survival in a Large National Cohort of Patients with Diabetes and Cirrhosis |
|
Clin Gastroenterol Hepatol. 2020 Aug 13;S1542-3565(20)31135-6.doi: 10.1016/j.cgh.2020.08.026. Online ahead of print.
David E Kaplan 1, Marina Serper 2, Binu V John 3, Kristen M Tessiatore 4, Renata Lerer 4, Rajni Mehta 5, Rena Fox 6, Ayse Aytaman 7, Michelle Baytarian 8, Kristel Hunt 9, Jeffrey Albrecht 10, Tamar H Taddei 5, VOCAL Study Group
|
|
|
|
|
|
|
|
|
644. | Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma |
|
J Clin Oncol. 2020 Jul 27;JCO2000808. doi: 10.1200/JCO.20.00808. Online ahead of print.
Richard S Finn 1, Masafumi Ikeda 2, Andrew X Zhu 3 4, Max W Sung 5, Ari D Baron 6, Masatoshi Kudo 7, Takuji Okusaka 8, Masahiro Kobayashi 9, Hiromitsu Kumada 9, Shuichi Kaneko 10, Marc Pracht 11, Konstantin Mamontov 12, Tim Meyer 13, Tomoki Kubota 14, Corina E Dutcus 15, Kenichi Saito 15, Abby B Siegel 16, Leonid Dubrovsky 16, Kalgi Mody 15, Josep M Llovet 17 18
|
|
|
645. | A Pilot Trial Evaluating Stereotactic Body Radiation Therapy to Induce Hyperemia in Combination with Transarterial Chemoembolization for Hepatocellular Carcinoma |
|
Int J Radiat Oncol Biol Phys. 2020 Jul 23;S0360-3016(20)31452-8.doi: 10.1016/j.ijrobp.2020.07.033. Online ahead of print.
Nikhil T Sebastian 1, Eric D Miller 1, Xiangyu Yang 2, Dayssy Alexandra Diaz 1, Yubo Tan 3, Joshua Dowell 2, James Spain 2, Ali Rikabi 2, Eric Elliott 2, Michael Knopp 2, Terence M Williams 4
|
|
|
|
|
647. | Somatic copy number profiling from hepatocellular carcinoma circulating tumor cells |
|
J Precis Oncol. 2020 Jul 2;4:16. doi: 10.1038/s41698-020-0123-0. eCollection 2020.
Colin M Court 1 2 3, Shuang Hou 1, Lian Liu 4, Paul Winograd 1 2, Benjamin J DiPardo 1 2, Sean X Liu 5, Pin-Jung Chen 5, Yazhen Zhu 5, Matthew Smalley 5, Ryan Zhang 5, Saeed Sadeghi 6, Richard S Finn 6, Fady M Kaldas 1, Ronald W Busuttil 1 7, Xianghong J Zhou 8, Hsian-Rong Tseng 5 7 9, James S Tomlinson 1 2 9, Thomas G Graeber 3 5 7 9, Vatche G Agopian 1 9
|
|
|
648. | Serum alpha-fetoprotein levels and clinical outcome in the phase 3 CELESTIAL study of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma |
|
Clin Cancer Res. 2020 Jul 7;clincanres.3884.2019. doi: 10.1158/1078-0432.CCR-19-3884.Online ahead of print.
Robin K Kelley 1, Tim Meyer 2, Lorenza Rimassa 3, Philippe Merle 4, Joong-Won Park 5, Thomas Yau 6, Stephen L Chan 7, Jean-Frederic Blanc 8, Vincent C Tam 9, Albert Tran 10, Vincenzo Dadduzio 11, David W Markby 12, Rajesh Kaldate 13, Ann-Lii Cheng 14, Anthony B El-Khoueiry 15, Ghassan K Abou-Alfa 16
|
|
|
649. | Non-invasive risk scores do not reliably identify future cirrhosis or hepatocellular carcinoma in Type 2 diabetes: The Edinburgh Type 2 Diabetes Study |
|
Liver Int. 2020 Jul 7. doi: 10.1111/liv.14590. Online ahead of print.
Sheila M Grecian 1, Stela McLachlan 1, Jonathan A Fallowfield 2, Patrick Ka Kearns 3, Peter C Hayes 2, Indra Neil Guha 4, Joanne R Morling 1, Stephen Glancy 5, Rachel M Williamson 6, Rebecca M Reynolds 7, Brian M Frier 7, Nicola N Zammitt 8, Jackie F Price 1, Mark Wj Strachan 6
|
|
|
|
|
|
|
652. | AFP Ratio Predicts HCC Recurrence After Liver Transplantation |
|
PLoS One. 2020 Jul 2;15(7):e0235576. doi: 10.1371/journal.pone.0235576. eCollection 2020.
Christine Koch 1, Theresa Bette 1, Oliver Waidmann 1, Natalie Filmann 2, Christopher Schrecker 1, Jörg Trojan 1, Nina Weiler 1, Johannes Vermehren 1, Andreas A Schnitzbauer 3, Wolf Otto Bechstein 3, Stefan Zeuzem 1, Eva Herrmann 2, Martin-Walter Welker 1
|
|
|
|
|
654. | Hepatocellular Carcinoma in Patients With No Identifiable Risk Factors |
|
(Oxford). 2020 Jun 23;S1365-182X(20)31020-0. doi: 10.1016/j.hpb.2020.05.005.Online ahead of print.
Caitlin A McIntyre 1, Joanne F Chou 2, Mithat Gonen 2, Jinru Shia 3, Maya Gambarin-Gelwan 4, Vinod P Balachandran 1, T Peter Kingham 1, Peter J Allen 1, Jeffrey A Drebin 1, William R Jarnagin 1, Michael I D'Angelica 5
|
|
|
|
|
|
|
657. | Management of Primary Hepatic Malignancies During the COVID-19 Pandemic: Recommendations for Risk Mitigation From a Multidisciplinary Perspective |
|
Lancet Gastroenterol Hepatol. 2020 Jun 5;S2468-1253(20)30182-5.doi: 10.1016/S2468-1253(20)30182-5. Online ahead of print.
Aisling Barry 1, Smith Apisarnthanarax 2, Grainne M O'Kane 3, Gonzalo Sapisochin 4, Robert Beecroft 5, Riad Salem 6, Sang Min Yoon 7, Young-Suk Lim 8, John Bridgewater 9, Brian Davidson 10, Marta Scorsetti 11, Luigi Solbiati 12, Adam Diehl 13, Pablo Munoz Schuffenegger 14, Jonathan G Sham 15, David Cavallucci 16, Zita Galvin 17, Laura A Dawson 18, Maria A Hawkins 19
|
|
|
|
|
659. | Lipid Remodelling in Hepatocyte Proliferation and Hepatocellular Carcinoma |
|
Hepatology. 2020 May 27. doi: 10.1002/hep.31391. Online ahead of print.
Zoe Hall 1 2, Davide Chiarugi 3, Evelina Charidemou 1, Jack Leslie 4, Emma Scott 4, Luca Pelligrinet 1, Michael Allison 5, Gabriele Mocciaro 1, Quentin M Anstee 4 6, Gerard I Evan 1, Matthew Hoare 5 7, Antonio Vidal-Puig 3, Fiona Oakley 4, Michele Vacca 1 3, Julian L Griffin 1 2
|
|
|
660. | Long Term Outcomes of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Without Macrovascular Invasion |
|
J Cancer. 2020 Jul;134:41-51. doi: 10.1016/j.ejca.2020.04.024. Epub 2020 May 24.
Ashwathy Susan Mathew 1, Eshetu G Atenafu 2, Dawn Owen 3, Chris Maurino 3, Anthony Brade 1, James Brierley 1, Robert Dinniwell 1, John Kim 1, Charles Cho 1, Jolie Ringash 1, Rebecca Wong 1, Kyle Cuneo 3, Mary Feng 3, Theodore S Lawrence 3, Laura A Dawson 4
|
|
|
661. | Nonsurgical Management of Advanced Hepatocellular Carcinoma: A Clinical Practice Guideline |
|
Curr Oncol. 2020 Apr;27(2):e106-e114.doi: 10.3747/co.27.5891. Epub 2020 May 1.
B M Meyers 1, J Knox 2, R Cosby 3, J R Beecroft 4, K K W Chan 5, N Coburn 5, J Feld 6, D Jonker 7, A Mahmud 8, J Ringash 2 9, Gastrointestinal Disease Site Group
|
|
|
662. | Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma |
|
J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
Richard S Finn 1, Shukui Qin 1, Masafumi Ikeda 1, Peter R Galle 1, Michel Ducreux 1, Tae-You Kim 1, Masatoshi Kudo 1, Valeriy Breder 1, Philippe Merle 1, Ahmed O Kaseb 1, Daneng Li 1, Wendy Verret 1, Derek-Zhen Xu 1, Sairy Hernandez 1, Juan Liu 1, Chen Huang 1, Sohail Mulla 1, Yulei Wang 1, Ho Yeong Lim 1, Andrew X Zhu 1, Ann-Lii Cheng 1, IMbrave150 Investigators
- IMbrave150 Investigators:
R Asghari, V Broadbridge, L Lipton, A Zekry, J Asselah, H Castel, R Goel, P Kavan, Y Bai, B Cao, M Chen, X Chen, Y Cheng, W Fang, K Gu, S Gu, Y Guo, Y He, W Li, Z Meng, H Pan, S Qin, Z Ren, B Wang, W Wang, B Xing, J Ying, X Yuan, H Zhao, B Bencsikova, B Melichar, R Anty, E Assenat, J P Bronowicki, S Cattan, F Di Fiore, M Ducreux, R Gerolami Santandrea, P Merle, M Nguimpi Tambou, Y Touchefeu, A Tran, T Berg, A Kandulski, T Müller, J Trojan, A Vogel, H Wege, M Wörns, L Chan, T Yau, G Frassineti, D Germano, G Masi, G Scagliotti, M Scartozzi, V Zagonel, T Aramaki, A Hagihara, H Hidaka, S Hige, M Ikeda, N Kato, H Koga, M Kudo, K Ogawa, N Oza, M Tanaka, K Tsuchiya, T Yamashita, J-H Baek, J-K Cheon, H-J Choi, J-E Hwang, T-Y Kim, H-Y Lim, B-Y Ryoo, A Cencelewicz, P Hudziec, E Janczewska, P Rozanowski, M Wieczorek-Rutkowska, J Wojcik-Tomaszewska, V Breder, N Volkov, J Samol, H-C Toh, A Cubillo Gracian, J Feli, T Macarulla Mercade, R Pazo Cid, J Sastre Valera, Y Chao, A L Cheng, Y-H Feng, T-S Yang, C-J Yen, J Evans, R Hubner, T Meyer, P Ross, A Baron, A Burgoyne, W Cancel, V Chiu, F Dayyani, R Finn, J Franses, P Gold, A R He, A Kaseb, R Kim, M Kundranda, D Li, D Lin, R Salgia, J Suga, N Trikalinos, J Wu, A Zhu
|
|
|
|
|
|
|
665. | Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference |
|
Hepatology. 2020 May 20. doi: 10.1002/hep.31327. Online ahead of print.
Josep M Llovet 1 2 3, Augusto Villanueva 1, Jorge A Marrero 4, Myron Schwartz 1, Tim Meyer 5, Peter R Galle 6, Riccardo Lencioni 7 8, Tim F Greten 9, Masatoshi Kudo 10, Sumithra J Mandrekar 11, Andrew X Zhu 12 13, Richard S Finn 14, Lewis R Roberts 15, AASLD Panel of experts on Trial Design in HCC
|
|
|
666. | Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States |
|
Am J Gastroenterol. 2020 May 22. doi: 10.14309/ajg.0000000000000643. Online ahead of print.
Meaghan Phipps 1, Alexandra Livanos 2, Averill Guo 3, Sydney Pomenti 3, Jonathan Yeh 4, Lara Dakhoul 5, Heather Burney 6, Carla Kettler 6, Hao Liu 6, Ethan Miller 7, Samer Gawrieh 5, Andrew deLemos 8, Andrew Scanga 9, Naga Chalasani 5, Julia Wattacheril 4
|
|
|
667. | Neutrophil-to-lymphocyte and Platelet-To-Lymphocyte Ratios as Predictors of Tumor Response in Hepatocellular Carcinoma After DEB-TACE |
|
Eur Radiol. 2020 May 19. doi: 10.1007/s00330-020-06931-5. Online ahead of print.
Isabel Theresa Schobert 1 2, Lynn Jeanette Savic 1 2, Julius Chapiro 3, Khaled Bousabarah 1 4, Evan Chen 1, Fabian Laage-Gaupp 1, Jonathan Tefera 1 2, Nariman Nezami 1, MingDe Lin 1, Jeffrey Pollak 1, Todd Schlachter 1
|
|
|
|
|
|
|
|
|
671. | GSK-3 in Liver Diseases: Friend or Foe? |
|
Biochim Biophys Acta Mol Cell Res. 2020 May 15;1867(9):118743.doi: 10.1016/j.bbamcr.2020.118743. Online ahead of print.
Maria R Emma 1, Giuseppa Augello 1, Antonella Cusimano 1, Antonina Azzolina 1, Giuseppe Montalto 2, James A McCubrey 3, Melchiorre Cervello 4
|
|
|
|
|
|
|
|
|
|
|
|
|
677. | Alternative Splicing in Hepatocellular Carcinoma |
|
Cell Mol Gastroenterol Hepatol. 2020 May 8;S2352-345X(20)30068-0.doi: 10.1016/j.jcmgh.2020.04.018. Online ahead of print.
Seung Eun Lee 1, Karel P Alcedo 2, Hong Jin Kim 3, Natasha T Snider 4
|
|
|
|
|
679. | Serum Levels of Alpha Fetoprotein Increased More Than 10 Years Before Detection of Hepatocellular Carcinoma |
|
10.1016/j.cgh.2020.04.084. Online ahead of print.
David M Hughes 1, Sarah Berhane 1, C A Emily de Groot 2, Hidenori Toyoda 3, Toshifumi Tada 3, Takashi Kumada 4, Shinji Satomura 5, Naoshi Nishida 6, Masatoshi Kudo 6, Toru Kimura 7, Yukio Osaki 8, Ruwanthi Kolamunage-Dona 1, Ruben Amoros Salvador 9, Tom Bird 10, Marta Garc?a-Fiñana 1, Philip Johnson 11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
691. | Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement |
|
Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281. Online ahead of print.
Oren K Fix 1, Bilal Hameed 2, Robert J Fontana 3, Ryan M Kwok 4, Brendan M McGuire 5, David C Mulligan 6, Daniel S Pratt 7, Mark W Russo 8, Michael L Schilsky 6, Elizabeth C Verna 9, Rohit Loomba 10, David E Cohen 11, Jorge A Bezerra 12, K Rajender Reddy 13, Raymond T Chung 7
|
|
|
|
|
|
|
|
|
|
|
|
|
697. | Minimally Invasive Versus Open Liver Resection for Hepatocellular Carcinoma in the Setting of Portal Vein Hypertension: Results of an International Multi-institutional Analysis |
|
Ruzzenente A1, Bagante F1,2, Ratti F3, Alaimo L1, Marques HP4, Silva S4, Soubrane O5, Endo I6, Sahara K6, Beal EW2, Lam V7, Poultsides GA8, Makris EA8, Popescu I9, Alexandrescu S9, Martel G10, Workneh A10, Hugh TJ11, Guglielmi A1, Aldrighetti L3, Pawlik TM12,13. Ann Surg Oncol. 2020 Apr 9. doi: 10.1245/s10434-020-08444-3. [Epub ahead of print]
|
|
|
698. | Covariate-adjusted analysis of the Phase 3 REFLECT study of lenvatinib versus sorafenib in the treatment of unresectable hepatocellular carcinoma |
|
Briggs A1, Daniele B2, Dick K3, Evans TRJ4, Galle PR5, Hubner RA6, Lopez C7, Siebert U8,9,10, Tremblay G11. Br J Cancer. 2020 Apr 8. doi: 10.1038/s41416-020-0817-7. [Epub ahead of print]
|
|
|
699. | A Sweet Connection? Fructose |
|
Dewdney B1, Roberts A1, Qiao L2, George J2, Hebbard L1,2. Biomolecules. 2020 Mar 25;10(4). pii: E496. doi: 10.3390/biom10040496.
|
|
|
700. | International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis |
|
Díaz-González Á1, Sanduzzi-Zamparelli M1, Gomes da Fonseca LL1, Di Costanzo GG2, Alves R3, Iavarone M4, Leal C5, Sacco R6, Matilla AM7, Hernández-Guerra M8, Aballay Soteras G9, Wörns MA10, Pinter M11, Varela M12, Ladekarl M13, Chagas AL14, Mínguez B15, Arenas JI16, Granito A17, Sánchez-Torrijos Y18, Rojas Á18, Rodríguez de Lope C19, Alvares-da-Silva MR20, Pascual S21, Rimassa L22, Lledó JL23, Huertas C24, Sangro B25, Giannini EG26, Delgado M27, Vergara M28, Perelló C29, Lue A30, Sala M31, Gallego A32, Coll S33, Hernáez T34, Piñero F35, Pereira G36, França A37, Marín J38, Anders M39, Mello V40, Lozano M41, Nault JC42, Menéndez J43, García Juárez I44, Bruix J1, Reig M1. Liver Int. 2020 Mar 14. doi: 10.1111/liv.14436. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
704. | Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis |
|
Wei T1,2, Zhang XF1, Bagante F3,4, Ratti F5, Marques HP6, Silva S6, Soubrane O7, Lam V8, Poultsides GA9, Popescu I10, Grigorie R10, Alexandrescu S10, Martel G11, Workneh A11, Guglielmi A4, Hugh T12, Lv Y1, Aldrighetti L5, Pawlik TM13. J Gastrointest Surg. 2020 Mar 3. doi: 10.1007/s11605-020-04553-2.
|
|
|
705. | Short- and long-term mortality after liver transplantation in patients with and without hepatocellular carcinoma in the UK |
|
Wallace D1,2, Cowling TE1, Walker K1, Suddle A2, Rowe I3,4, Callaghan C5, Gimson A6, Bernal W2, Heaton N2, van der Meulen J1. Br J Surg. 2020 Mar 3. doi: 10.1002/bjs.11451.
|
|
|
706. | "Direct-acting antivirals and hepatocellular carcinoma: no evidence of higher waitlist progression or post-transplant recurrence" |
|
Piñero F1,2, Boin I3, Chagas A4, Quiñonez E5, Marciano S6, Vilatobá M7, Santos L8, Anders M9, Hoyos Duque S10, Lima AS11, Menendez J12, Padilla M13, Poniachik J14, Zapata R15, Maraschio M16, Chong Menéndez R17, Muñoz L18, Arufe D19, Figueroa R20, Mendizabal M1, Hurtado Gomez S7, Stucchi R3, Maccali C4, Vergara Sandoval R5, Bermudez C6, McCormack L9, Varón A8, Gadano A6, Mattera J5, Rubinstein F21, Carrilho F4, Silva M1,2. Liver Transpl. 2020 Mar 4. doi: 10.1002/lt.25744.
|
|
|
707. | The association of nonalcoholic steatohepatitis and hepatocellular carcinoma |
|
Asfari MM1,2, Talal Sarmini M2, Alomari M2, Lopez R3, Dasarathy S4,5,6, McCullough AJ4,5,6. Eur J Gastroenterol Hepatol. 2020 Feb 18. doi: 10.1097/MEG.0000000000001681. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
712. | The Impact of Direct Acting Antivirals on Overall Mortality and Tumoral Recurrence in Patients with Hepatocellular Carcinoma Listed for Liver Transplantation.: An International Multicenter Study |
|
Gorgen A, Galvin Z, Huang AC, Vinaixa C, O'Rourke JM, Francoz C, Hansen BE, Durand F, Elsharkawy AM, Shah T, Berenguer M, Rubin A, Calatayud D, Mehta N, Terrault NA, Lilly LB, Selzner N, Sapisochin G. Transplantation. 2020 Jan 16. doi: 10.1097/TP.0000000000003115. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
720. | Elevated Serum a-Fetoprotein is Associated with Abbreviated Survival for Patients with Fibrolamellar Hepatocellular Carcinoma Who Undergo a Curative Resection |
|
McDonald JD1, Gupta S1, Shindorf ML1, Gamble LA1, Ruff SM1, Drake J1, Heller T2, Wan JY3, Dickson PV3, Glazer ES3, Davis JL1, Deneve JL3, Hernandez JM4. Ann Surg Oncol. 2020 Jan 10. doi: 10.1245/s10434-019-08178-x. [Epub ahead of print]
|
|
|
721. | Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival |
|
Lee MW1,2, Kang D3,4, Lim HK5,6, Cho J3,4, Sinn DH7, Kang TW1, Song KD1, Rhim H1,2, Cha DI1, Lu DSK8. Eur Radiol. 2020 Jan 3. doi: 10.1007/s00330-019-06575-0. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
726. | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial |
|
Finn RS1, Ryoo BY2, Merle P3, Kudo M4, Bouattour M5, Lim HY6, Breder V7, Edeline J8, Chao Y9, Ogasawara S10, Yau T11, Garrido M12, Chan SL13, Knox J14, Daniele B15, Ebbinghaus SW16, Chen E16, Siegel AB16, Zhu AX17, Cheng AL18; KEYNOTE-240 investigators. J Clin Oncol. 2019 Dec 2:JCO1901307. doi: 10.1200/JCO.19.01307. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
733. | HCV Cure Rates are Reduced in Patients with Active but not Inactive Hepatocellular Carcinoma- A Practice Implication |
|
Ogawa E1, Toyoda H2, Iio E3, Jun DW4, Huang CF5, Enomoto M6, Hsu YC7, Haga H8, Iwane S9, Wong G10,11, Lee DH12, Tada T2, Liu CH13,14, Chuang WL5, Hayashi J15, Cheung R16,17, Yasuda S2, Tseng CH7, Takahashi H9,18, Tran S16, Yeo YH16, Henry L16, Barnett SD16, Nomura H19, Nakamuta M20, Dai CY5, Huang JF5, Yang HI21, Lee MH22, Jung Jun M12, Kao JH13,14, Eguchi Y9, Ueno Y8, Tamori A6, Furusyo N1, Yu ML5, Tanaka Y3, Nguyen MH16; REAL-C Investigators, Ahn SB23, Azuma K24, Dohmen K25, Yoon Jeong J26, Jung JH27, Kajiwara E28, Kato M29, Kawano A30, Koyanagi T31, Ooho A32, Park SH33, Satoh T34, Shimoda S35, Song DS36, Takahashi K37, Yeh ML5, Yoon EL38. Clin Infect Dis. 2019 Nov 28. pii: ciz1160. doi: 10.1093/cid/ciz1160. [Epub ahead of print]
|
|
|
|
|
735. | Tumor grade may be used to select patients with multifocal hepatocellular carcinoma for resection |
|
Ruff SM1, Rothermel LD2, Diggs LP1, Wach MM1, Ayabe RI1, Martin SP1, Boulware D2, Anaya D2, Davis JL1, Mullinax JE3, Hernandez JM4. HPB (Oxford). 2019 Nov 13. pii: S1365-182X(19)32273-7. doi: 10.1016/j.hpb.2019.10.1531. [Epub ahead of print]
|
|
|
|
|
|
|
738. | Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis |
|
McDonald SA1, Pollock KG2, Barclay ST3, Goldberg DJ1, Bathgate A4, Bramley P5, Dillon JF6, Fraser A7, Innes HA1, Kennedy N8, Morris J7, Went A9, Hayes PC4, Hutchinson SJ1. J Viral Hepat. 2019 Nov 6. doi: 10.1111/jvh.13232. [Epub ahead of print]
|
|
|
739. | Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach |
|
Han G1, Berhane S2, Toyoda H3, Bettinger D4, Elshaarawy O5, Chan AWH6, Kirstein M7, Mosconi C8, Hucke F9, Palmer D10, Pinato DJ11, Sharma R11, Ottaviani D12, Jang JW13, Labeur TA14, van Delden OM15, Pirisi M16, Stern N17, Sangro B18, Meyer T19, Fateen W20,21, García-Fiñana M2, Gomaa A5, Waked I5, Rewisha E5, Aithal GP20,21, Travis S22, Kudo M23, Cucchetti A24, Peck-Radosavljevic M9, Takkenberg RB14, Chan SL25, Vogel A7, Johnson PJ10. Hepatology. 2019 Nov 7. doi: 10.1002/hep.31022. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
745. | Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis |
|
Bettinger D1,2, Pinato DJ3, Schultheiss M1, Sharma R3, Rimassa L4, Pressiani T4, Burlone ME5, Pirisi M5, Kudo M6, Park JW7, Buettner N1, Neumann-Haefelin C1, Boettler T1, Abbasi-Senger N8, Alheit H9, Baus W10, Blanck O11, Gerum S12, Guckenberger M13, Habermehl D14,15, Ostheimer C16, Riesterer O13, Tamihardja J17, Grosu AL18,19,20, Thimme R1, Brunner TB19,20,21, Gkika E18. Erratum. [Liver Cancer. 2019] Liver Cancer. 2019 Jul;8(4):281-294. doi: 10.1159/000490260. Epub 2018 Jul 12.
|
|
|
|
|
|
|
|
|
749. | International trends in hepatocellular carcinoma incidence, 1978-2012 |
|
Petrick JL1,2, Florio AA1, Znaor A3, Ruggieri D4, Laversanne M3, Alvarez CS1, Ferlay J3, Valery PC5, Bray F3, McGlynn KA1. Int J Cancer. 2019 Oct 9. doi: 10.1002/ijc.32723. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
761. | Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy |
|
Wallace MC1,2,3, Sek K4, Francis RJ5,4, Samuelson S6, Ferguson J6, Tibballs J6, Asad A7, Preen DB8, MacQuillan G9,5, Garas G9,5, Adams LA9,5, Jeffrey GP9,5. Dig Dis Sci. 2019 Aug 22. doi: 10.1007/s10620-019-05781-6. [Epub ahead of print]
|
|
|
762. | Liver Transplant for Hepatocellular Carcinoma in the United States: Evolving Trends over the Last Three Decades |
|
Puigvehí M1, Hashim D2, Haber PK1, Dinani A3, Schiano TD4, Asgharpour A3, Kushner T3, Kakked G3, Tabrizian P4, Schwartz M4, Gurakar A5, Dieterich D3, Boffetta P2, Friedman SL3, Llovet JM1,6,7, Saberi B3. Am J Transplant. 2019 Aug 22. doi: 10.1111/ajt.15576. [Epub ahead of print]
|
|
|
|
|
764. | Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE) |
|
Moehler M1, Heo J2, Lee HC3, Tak WY4, Chao Y5, Paik SW6, Yim HJ7, Byun KS8, Baron A9, Ungerechts G10, Jonker D11, Ruo L12, Cho M13, Kaubisch A14, Wege H15, Merle P16, Ebert O17, Habersetzer F18, Blanc JF19, Rosmorduc O20, Lencioni R21, Patt R22, Leen AM23, Foerster F1, Homerin M24, Stojkowitz N25, Lusky M26, Limacher JM27, Hennequi M28, Gaspar N29, McFadden B30, De Silva N31, Shen D31, Pelusio A31, Kirn DH32, Breitbach CJ31, Burke JM31. Oncoimmunology. 2019 Jun 3;8(8):1615817. doi: 10.1080/2162402X.2019.1615817. eCollection 2019.
|
|
|
765. | Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma |
|
Ricke J1, Klumpen HJ2, Amthauer H3, Bargellini I4, Bartenstein P5, de Toni E6, Gasbarrini A7, Pech M8, Peck-Radosavljevic M9, Popovic P10, Rosmorduc O11, Schott E12, Seidensticker M13, Verslype C14, Sangro B15, Malfertheiner P16. J Hepatol. 2019 Aug 14. pii: S0168-8278(19)30472-6. doi: 10.1016/j.jhep.2019.08.006. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
769. | Sorafenib activity and disposition in liver cancer does not depend on organic cation transporter 1 (OCT1) |
|
Chen M1, Neul C2,3, Schaeffeler E2,3,4, Frisch F2,3, Winter S2,3, Schwab M2,4,5, Koepsell H6, Hu S1, Laufer S4,7, Baker SD1, Sparreboom A1, Nies AT2,3,4. Clin Pharmacol Ther. 2019 Jul 27. doi: 10.1002/cpt.1588. [Epub ahead of print]
|
|
|
|
|
|
|
772. | Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA |
|
Kaseb AO1, Sánchez NS2, Sen S3, Kelley RK4, Tan BR5, Bocobo AG6, Lim KH7, Abdel-Wahab R8, Uemura MI3, Carmagnani Pestana R9, Qiao W10, Xiao L10, Morris J10, Amin HM11, Hassam MM8, Rashid A12, Banks KC13, Lanman RB14, Talasaz A15, Mills Shaw KR16, George B17, Haque A18, Raghav K19, Wolf RA20, Yao JC21, Meric-Bernstam F22, Ikeda S23, Kurzrock R24. Clin Cancer Res. 2019 Jul 30. pii: clincanres.3341.2018. doi: 10.1158/1078-0432.CCR-18-3341. [Epub ahead of print]
|
|
|
773. | Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation |
|
Iavarone M1, Invernizzi F1, Czauderna C2, Sanduzzi-Zamparelli M3, Bhoori S4, Amaddeo G5, Manini MA6, Fraile López M7, Anders M8, Pinter M9, Blanco Rodríguez MJ10, Romero Cristóbal M11, Aballay Soteras G12, Piñero F13, Villadsen GE14, Weinmann A2, Crespo G15, Mazzaferro V16, Regnault H5, De Giorgio M6, González-Diéguez ML7, Donato MF1, Varela M7, Wörns MA2, Bruix J3, Lampertico P1, Reig M3. Am J Transplant. 2019 Jul 31. doi: 10.1111/ajt.15551. [Epub ahead of print]
|
|
|
|
|
|
|
776. | Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients with Hepatocellular Carcinoma |
|
Rich NE1, Yang JD2, Perumalswami PV3, Alkhouri N4, Jackson W5, Parikh ND6, Mehta N7, Salgia R8, Duarte-Rojo A9, Kulik L10, Rakoski M11, Said A12, Oloruntoba O13, Ioannou GN14, Hoteit MA15, Moon AM16, Rangnekar AS17, Eswaran SL18, Zheng E19, Jou JH20, Hanje J21, Pillai A22, Hernaez R23, Wong R24, Scaglione S25, Samant H26, Kapuria D27, Chandna S28, Rosenblatt R29, Ajmera V30, Frenette C31, Satapathy SK32, Mantry P33, Jalal P34, John BV35, Fix OK36, Leise M37, Lindenmeyer CC38, Flores A39, Patel N40, Jiang ZG41, Latt N42, Dhanasekaran R43, Odewole M1, Kagan S1, Marrero JA1, Singal AG1. Clin Gastroenterol Hepatol. 2019 Jul 26. pii: S1542-3565(19)30786-4. doi: 10.1016/j.cgh.2019.07.042. [Epub ahead of print]
|
|
|
777. | Direct-Acting Antiviral Therapy for HCV Infection is Associated with Increased Survival in Patients With a History of Hepatocellular Carcinoma |
|
Singal AG1, Rich NE2, Mehta N3, Branch A4, Pillai A5, Hoteit M6, Volk M7, Odewole M2, Scaglione S8, Guy J9, Said A10, Feld JJ11, John BV12, Frenette C13, Mantry P14, Rangnekar AS15, Oloruntoba O16, Leise M17, Jou JH18, Bhamidimarri KR19, Kulik L20, Ioannou GN21, Huang A3, Tran T22, Samant H23, Dhanasekaran R24, Duarte-Rojo A25, Salgia R26, Eswaran S27, Jalal P28, Flores A29, Satapathy SK30, Kagan S2, Gopal P31, Wong R32, Parikh ND33, Murphy CC2. Gastroenterology. 2019 Jul 30. pii: S0016-5085(19)41137-2. doi: 10.1053/j.gastro.2019.07.040. [Epub ahead of print]
|
|
|
|
|
779. | Meat intake and risk of hepatocellular carcinoma in two large US prospective cohorts of women and men |
|
Ma Y1,2, Yang W2,3, Li T2, Liu Y2,4, Simon TG5,6,7, Sui J2,8, Wu K9, Giovannucci EL2,9,10, Chan AT2,6,7, Zhang X2,9. Int J Epidemiol. 2019 Jul 13. pii: dyz146. doi: 10.1093/ije/dyz146. [Epub ahead of print]
|
|
|
|
|
781. | A Phase 2 Study of Galunisertib (TGF-ß1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
|
Kelley RK1, Gane E2, Assenat E3, Siebler J4, Galle PR5, Merle P6, Hourmand IO7, Cleverly A8, Zhao Y9, Gueorguieva I8, Lahn M9, Faivre S10, Benhadji KA9, Giannelli G11. Clin Transl Gastroenterol. 2019 Jul 1. doi: 10.14309/ctg.0000000000000056. [Epub ahead of print]
|
|
|
782. | Effect of fragmentation of cancer care on treatment use and survival in hepatocellular carcinoma |
|
Hester CA1, Karbhari N1, Rich NE2, Augustine M1, Mansour JC1, Polanco PM1, Porembka MR1, Wang SC1, Zeh HJ 3rd1, Singal AG2, Yopp AC1. Cancer. 2019 Jul 12. doi: 10.1002/cncr.32336. [Epub ahead of print]
|
|
|
783. | Validation of an algorithm using inpatient electronic health records to determine the presence and severity of cirrhosis in patients with hepatocellular carcinoma in England: an observational study |
|
Driver RJ1,2,3, Balachandrakumar V4, Burton A5, Shearer J2, Downing A1,3, Cross T4, Morris E1,3, Rowe IA1,2,3. BMJ Open. 2019 Jul 9;9(7):e028571. doi: 10.1136/bmjopen-2018-028571.
|
|
|
|
|
|
|
786. | Real-world observational experience with direct-acting antivirals for hepatitis C: baseline resistance, efficacy, and need for long-term surveillance |
|
Loo N1, Hanysak B1, Mann J1, Ramirez R1, Kim J1, Mitchell R1, Van Frank T1, Guerrero R1, Hinojosa K1, Christensen K1, Pedicone LD2, Alkhouri N1, Wells J1, Landaverde C1, Rodas F1, Lawitz E1, Poordad F1. Medicine (Baltimore). 2019 Jun;98(26):e16254. doi: 10.1097/MD.0000000000016254.
|
|
|
|
|
|
|
|
|
790. | A proposal for a useful algorithm to diagnose small hepatocellular carcinoma on MRI |
|
Coty JB1, Paisant A2, Esvan M3,4, Lonjon J5, Seror O6, Rode A7, Ronot M8,9, Lebigot J2, Vilgrain V6,8, Aubé C2,10. Eur J Gastroenterol Hepatol. 2019 Jun 17. doi: 10.1097/MEG.0000000000001476. [Epub ahead of print]
|
|
|
791. | Outcomes of Liver transplantation for hepatocellular carcinoma (HCC) beyond the University of California San Francisco (UCSF) criteria: a single center experience |
|
Victor DW 3rd, Monsour HP Jr, Boktour M, Lunsford K, Balogh J, Graviss EA, Nguyen DT, McFadden R, Divatia MK, Heyne K, Ankoma-Sey V, Egwim C, Galati J, Duchini A, Saharia A, Mobley C, Gaber AO, Ghobrial RM. Transplantation. 2019 Jun 18. doi: 10.1097/TP.0000000000002835. [Epub ahead of print]
|
|
|
792. | Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents |
|
Kanwal F1,2,3, Kramer JR1,3, Asch SM4,5, Cao Y1,3, Li L6, El-Serag HB1,2. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30823. [Epub ahead of print]
|
|
|
|
|
|
|
795. | Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis |
|
Bitterman DS1,2, Sanford NN3, Niemierko A4, Mahal BA1,2, Qadan M5, Ganguli S6, Blaszkowsky LS7,8, Zhu AX8, Hong TS9, Devlin PM10, Goyal L8, Wo JY9. Am J Clin Oncol. 2019 Jun 3. doi: 10.1097/COC.0000000000000560. [Epub ahead of print]
|
|
|
796. | Nivolumab in Advanced Hepatocellular Carcinoma: Sorafenib-Experienced Asian Cohort Analysis |
|
Yau T1, Hsu C2, Kim TY3, Choo SP4, Kang YK5, Hou MM6, Numata K7, Yeo W8, Chopra A9, Ikeda M10, Kuromatsu R11, Moriguchi M12, Chao Y13, Zhao H14, Anderson J14, Dela Cruz C14, Kudo M15. J Hepatol. 2019 Jun 6. pii: S0168-8278(19)30300-9. doi: 10.1016/j.jhep.2019.05.014. [Epub ahead of print]
|
|
|
797. | Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. |
|
Casadei Gardini A1, Puzzoni M2, Montagnani F3, Marisi G4, Tamburini E5, Cucchetti A6,7, Solaini L6,7, Foschi FG8, Conti F8, Ercolani G6,7, Cascinu S1, Scartozzi M2.
Onco Targets Ther. 2019 Apr 24;12:2981-2988. doi: 10.2147/OTT.S192572. eCollection 2019
|
|
|
|
|
799. | Quality measures, all-cause mortality, and healthcare utilization in a national cohort of Veterans with cirrhosis |
|
Serper M1,2,3, Kaplan DE1,2, Shults J4, Reese PP3,4,5, Beste LA6,7,8, Taddei TH9,10, Werner RM1,3,11. Hepatology. 2019 May 20. doi: 10.1002/hep.30779. [Epub ahead of print]
|
|
|
|
|
801. | Bridging Hepatocellular Carcinoma to Transplant: Transarterial Chemoembolization Response, Tumor Biology, and Recurrence after Transplantation in a 12-Year Transplant Cohort |
|
Sandow T1, Pavlus J2, Field D2, Lacayo E2, Cohen E2, Lynskey G2, Caridi T2, Buckley D2, Cardella J2, Kallakury B3, Spies J2, Kim AY4. J Vasc Interv Radiol. 2019 May 17. pii: S1051-0443(19)30027-2. doi: 10.1016/j.jvir.2018.12.736. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
805. | The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers |
|
Tapper EB1,2, Hao S3, Lin M3, Mafi JN4,5, McCurdy H2, Parikh ND1,2, Lok AS1,2. Hepatology. 2019 May 7. doi: 10.1002/hep.30695. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
820. | Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial |
|
Merle P1, Blanc JF2, Phelip JM3, Pelletier G4, Bronowicki JP5, Touchefeu Y6, Pageaux G7, Gerolami R8, Habersetzer F9, Nguyen-Khac E10, Casadei-Gardini A11, Borbath I12, Tran A13, Wege H14, Saad AS15, Colombo M16, Abergel A17, Richou C18, Waked I19, Yee NS20, Molé A21, Attali P21, Le Boulicaut J22, Vasseur B21; RELIVE Investigators.
Collaborators (69) Lancet Gastroenterol Hepatol. 2019 Apr 3. pii: S2468-1253(19)30040-8. doi: 10.1016/S2468-1253(19)30040-8. [Epub ahead of print]
|
|
|
|
|
822. | Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial |
|
Assenat E1,2, Pageaux GP3, Thézenas S4, Peron JM5, Bécouarn Y6, Seitz JF7, Merle P8, Blanc JF9, Bouché O10, Ramdani M11, Poujol S4, de Forges H4, Ychou M4, Boige V12. Br J Cancer. 2019 Apr 4. doi: 10.1038/s41416-019-0443-4. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
832. | HCC Immune Surveillance and Antiviral Therapy of Hepatitis C Virus Infection |
|
Owusu Sekyere S1, Schlevogt B1,2, Mettke F1, Kabbani M1, Deterding K1, Wirth TC1, Vogel A1, Manns MP1,3,4, Falk CS1,5, Cornberg M1,3, Wedemeyer H1,3,4,6. Liver Cancer. 2019 Feb;8(1):41-65. doi: 10.1159/000490360. Epub 2018 Jul 18.
|
|
|
|
|
|
|
835. | Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis |
|
Wiltberger G1, Wu Y2, Lange U3, Hau HM3, Tapper E2, Krenzien F4, Atanasov G4, Benzing C4, Feldbrügge L4, Csizmadia E2, Broschewitz J2, Bartels M5, Seehofer D2, Jonas S6, Berg T7, Hessel P8, Ascherl R9, Neumann UP1, Pratschke J4, Robson SC2, Schmelzle M4. Aliment Pharmacol Ther. 2019 Mar;49(6):779-788. doi: 10.1111/apt.15089.
|
|
|
836. | OPTN/SRTR 2017 Annual Data Report: Liver |
|
Kim WR1,2, Lake JR1,3, Smith JM1,4, Schladt DP1, Skeans MA1, Noreen SM5,6, Robinson AM5,6, Miller E5,6, Snyder JJ1,7, Israni AK1,7,8, Kasiske BL1,8. Am J Transplant. 2019 Feb;19 Suppl 2:184-283. doi: 10.1111/ajt.15276.
|
|
|
|
|
838. | Patterns and Predictors of Mortality after Waitlist Dropout of Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
|
Gorgen A1,2, Rosales R1, Sadler E2, Beecroft R3, Knox J4, Dawson LA5, Ghanekar A1,2, Grant D1,2, Greig PD1,2, Sapisochin G1,2. Transplantation. 2019 Feb 18. doi: 10.1097/TP.0000000000002616. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
842. | Association of Intake of Whole Grains and Dietary Fiber With Risk of Hepatocellular Carcinoma in US Adults |
|
Yang W1,2, Ma Y2,3, Liu Y2,4, Smith-Warner SA5,6, Simon TG7,8,9, Chong DQ10, Qi Q11, Meyerhardt JA12, Giovannucci EL2,5,6, Chan AT2,8,9, Zhang X2. JAMA Oncol. 2019 Feb 21. doi: 10.1001/jamaoncol.2018.7159. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
851. | Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study |
|
Carrat F1, Fontaine H2, Dorival C3, Simony M4, Diallo A5, Hezode C6, De Ledinghen V7, Larrey D8, Haour G3, Bronowicki JP9, Zoulim F10, Asselah T11, Marcellin P11, Thabut D12, Leroy V13, Tran A14, Habersetzer F15, Samuel D16, Guyader D17, Chazouilleres O18, Mathurin P19, Metivier S20, Alric L21, Riachi G22, Gournay J23, Abergel A24, Cales P25, Ganne N26, Loustaud-Ratti V27, D'Alteroche L28, Causse X29, Geist C30, Minello A31, Rosa I32, Gelu-Simeon M33, Portal I34, Raffi F35, Bourliere M36, Pol S37; French ANRS CO22 Hepather cohort. Lancet. 2019 Feb 11. pii: S0140-6736(18)32111-1. doi: 10.1016/S0140-6736(18)32111-1. [Epub ahead of print]
|
|
|
|
|
|
|
|
|
855. | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased ?-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial |
|
-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial~Zhu AX1, Kang YK2, Yen CJ3, Finn RS4, Galle PR5, Llovet JM6, Assenat E7, Bran |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
862. | Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis |
|
Kaplan DE1, Serper M2, Mehta R3, Fox R4, John B5, Aytaman A6, Baytarian M7, Hunt K8, Albrecht J9, Njei B3, Taddei TH3; VOCAL Study Group. Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30053-8. doi: 10.1053/j.gastro.2019.01.026. [Epub ahead of print] |
|
|
|
|
|
|
865. | Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma |
|
Schulte L1, Scheiner B2, Voigtländer T1, Koch S3, Schweitzer N1, Marhenke S1, Ivanyi P4, Manns MP1, Rodt T5, Hinrichs JB5, Weinmann A3, Pinter M2, Vogel A1, Kirstein MM1. Liver Int. 2019 Jan 21. doi: 10.1111/liv.14048. [Epub ahead of print] |
|
|
866. | Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study |
|
Singal AG, Rich NE, Mehta N, Branch A, Pillai A, Hoteit M, Volk M, Odewole M, Scaglione S, Guy J, Said A, Feld JJ, John BV, Frenette C, Mantry P, Rangnekar AS, Oloruntoba O, Leise M, Jou JH, Bhamidimarri KR, Kulik L, Tran T, Samant H, Dhanasekaran R, Duarte-Rojo A, Salgia R, Eswaran S, Jalal P, Flores A, Satapathy SK, Wong R, Huang A, Misra S, Schwartz M, Mitrani R, Nakka S, Noureddine W, Ho C, Konjeti VR, Dao A, Nelson K, Delarosa K, Rahim U, Mavuram M, Xie JJ, Murphy CC, Parikh ND. Gastroenterology. 2019 Jan 17. pii: S0016-5085(19)30057-5. doi: 10.1053/j.gastro.2019.01.027. [Epub ahead of print] |
|
|
867. | Waist Circumference Might Be a Predictor of Primary Liver Cancer: A Population-Based Cohort Study |
|
Wei L1, Li N1, Wang G2, Feng X1, Lyu Z1, Li X1, Wen Y1, Chen Y1, Chen H1, Chen S3, Wu S3, Dai M1, He J1,4. Front Oncol. 2018 Dec 12;8:607. doi: 10.3389/fonc.2018.00607. eCollection 2018. |
|
|
|
|
|
|
|
|
|
|
|
|
873. | Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression |
|
Apostolidis L1,2, Pfeiffenberger J3,2, Gotthardt D3,2, Radeleff B4,2, Mehrabi A5,2, Schemmer P5,6,2, Jäger D1,2, Schirmacher P7,2, Stremmel W3,2, Schulze-Bergkamen H1,8,2, Springfeld C1,2, Weiss KH3,2. Gastrointest Tumors. 2018 Sep;5(1-2):38-46. doi: 10.1159/000487635. Epub 2018 Apr 11. |
|
|
874. | Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden |
|
Dakhoul L1, Gawrieh S1, Jones KR1, Ghabril M1, McShane C2, Orman E1, Vilar-Gomez E1, Chalasani N1, Nephew L1. Hepatol Commun. 2018 Dec 3;3(1):52-62. doi: 10.1002/hep4.1277. eCollection 2019 Jan. |
|
|
|
|
876. | Live Donor Liver Transplantation for Patients with Hepatocellular Carcinoma Offers Increased Survival vs. Deceased Donation |
|
Goldaracena N1, Gorgen A1, Doyle A2, Hansen BE3, Tomiyama K1, Zhang W1, Ghanekar A1, Lilly L2, Cattral M1, Galvin Z2, Selzner M1, Bhat M2, Selzner N2, McGilvray I1, Greig PD1, Grant DR1, Sapisochin G4. J Hepatol. 2019 Jan 7. pii: S0168-8278(19)30003-0. doi: 10.1016/j.jhep.2018.12.029. [Epub ahead of print] |
|
|
|
|
878. | Association of Physical Activity and Risk of Hepatobiliary Cancers: A Multinational Cohort Study |
|
Baumeister SE1, Schlesinger S2, Aleksandrova K3, Jochem C4, Jenab M5, Gunter MJ5, Overvad K6, Tjønneland A7, Boutron-Ruault MC8, Carbonnel F9, Fournier A8, Kühn T10, Kaaks R10, Pischon T11, Boeing H3, Trichopoulou A12, Bamia C12, La Vecchia C13, Masala G14, Panico S15, Fasanelli F16, Tumino R17, Grioni S18, de Mesquita BB19, Vermeulen R20, May AM21, Borch KB22, Oyeyemi SO22, Ardanaz E23, Rodríguez-Barranco M24, López MDC25, Felez-Nobrega M26, Sonestedt E27, Ohlsson B28, Hemmingsson O29, Werner M30, Perez-Cornago A31, Ferrari P5, Stepien M5, Freisling H5, Tsilidis KK31, Ward H32, Riboli E32, Weiderpass E33, Leitzmann MF4. J Hepatol. 2018 Dec 21. pii: S0168-8278(18)32633-3. doi: 10.1016/j.jhep.2018.12.014. [Epub ahead of print] |
|
|
|
|
880. | Hepatocellular carcinoma: resection with adjuvant hepatic artery infusion therapy vs resection alone. A systematic review and meta-analysis |
|
Moran A1, Ramos LF1, Picado O1, Pendola F2, Sleeman D3,4, Dudeja V1,4, Merchant N1,4, Yakoub D1,4. J Surg Oncol. 2018 Dec 21. doi: 10.1002/jso.25338. [Epub ahead of print] |
|
|
881. | The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis |
|
Huang P1,2, Liu M1, Zang F1, Yao Y1, Yue M3, Wang J4, Fan H1, Zhuo L1, Wu J1, Xia X5, Feng Y5, Yu R1,2. Carcinogenesis. 2018 Dec 31;39(12):1497-1505. doi: 10.1093/carcin/bgy099. |
|
|
882. | Long-Term Zinc Supplementation Improves Liver Function and Decreases the Risk of Developing Hepatocellular Carcinoma |
|
Hosui A1, Kimura E2, Abe S3, Tanimoto T4, Onishi K5, Kusumoto Y6, Sueyoshi Y7, Matsumoto K8, Hirao M9, Yamada T10, Hiramatsu N11. Nutrients. 2018 Dec 10;10(12). pii: E1955. doi: 10.3390/nu10121955. |
|
|
883. | Changing Landscape of Liver Cancer in California: A Glimpse Into the Future of Liver Cancer in the United States |
|
Han SS1,2,3, Kelly SP4, Li Y1,5, Yang B1, Nguyen M1,2, So S1,6, Rosenberg PS4, Hsing AW1,3,7. J Natl Cancer Inst. 2018 Dec 13. doi: 10.1093/jnci/djy180. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
890. | Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness? |
|
Piñero F1,2,3, Rubinstein F4, Marciano S5, Fernández N6, Silva J7, Zambelo Y8, Anders M9, Zerega A10, Ridruejo E11,12, Miguez C13, Ameigeiras B14, D'Amico C15, Gaite L16, Bermúdez C5, Rosales C7, Romero G13, McCormack L9, Reggiardo V8, Colombato L6, Gadano A5, Silva M11. Dig Dis Sci. 2018 Dec 3. doi: 10.1007/s10620-018-5390-z. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
900. | Efficacy of Sorafenib for the Treatment of Post-Transplant Hepatocellular Carcinoma Recurrence |
|
Kang SH1,2, Cho H1, Cho EJ1, Lee JH1, Yu SJ1, Kim YJ1, Yi NJ3, Lee KW3, Suh KS3, Yoon JH1. J Korean Med Sci. 2018 Oct 12;33(45):e283. doi: 10.3346/jkms.2018.33.e283. eCollection 2018 Nov 5. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
907. | Future Trends in Demand for Liver Transplant: Birth-Cohort Effects among Patients with NASH and HCC |
|
Shingina A1,2, DeWitt PE3, Dodge JL2,4, Biggins SW1,2, Gralla J5, Sprague D6, Bambha K1,2. Transplantation. 2018 Nov 16. doi: 10.1097/TP.0000000000002497. [Epub ahead of print] |
|
|
908. | Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis |
|
McNamara MG1, Slagter AE2, Nuttall C3, Frizziero M3, Pihlak R4, Lamarca A3, Tariq N4, Valle JW4, Hubner RA3, Knox JJ5, Amir E5. Eur J Cancer. 2018 Oct 29;105:1-9. doi: 10.1016/j.ejca.2018.09.031. [Epub ahead of print] |
|
|
|
|
|
|
911. | Functional MRI and delay discounting in patients infected with hepatitis C |
|
McCready H1,2,3, Kohno M1,2,3, Kolessar M1,4, Dennis L1,2,3, Kriz D1, Luber H1, Anderson R1, Chang M1,5, Sasaki A1,5, Flora K6, Vandenbark A1,7,8, Mitchell SH2,3,9, Loftis JM1,3,5, Hoffman WF1,2,3,10, Huckans M11,12,13,14. J Neurovirol. 2018 Oct 8. doi: 10.1007/s13365-018-0670-0. [Epub ahead of print] |
|
|
|
|
913. | Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies |
|
Harding JJ1, Nandakumar S2, Armenia J3, Khalil DN4, Albano M5, Ly M5, Shia J6, Hechtman JF6, Kundra R7, El Dika I8, Do RK9, Sun Y10, Kingham TP11, D'Angelica MI12, Berger MF7, Hyman DM13, Jarnagin WR12, Klimstra DS14, Janjigian YY15, Solit DB10, Schultz N16, Abou-Alfa GK8. Clin Cancer Res. 2018 Oct 29. pii: clincanres.2293.2018. doi: 10.1158/1078-0432.CCR-18-2293. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
919. | Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? |
|
Marisi G1, Cucchetti A2, Ulivi P1, Canale M1, Cabibbo G3, Solaini L2, Foschi FG4, De Matteis S1, Ercolani G2, Valgiusti M5, Frassineti GL5, Scartozzi M6, Casadei Gardini A5. World J Gastroenterol. 2018 Sep 28;24(36):4152-4163. doi: 10.3748/wjg.v24.i36.4152. |
|
|
|
|
921. | Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma |
|
Mak LY1, Cruz-Ramón V1, Chinchilla-López P1, Torres HA1, LoConte NK1, Rice JP1, Foxhall LE1, Sturgis EM1, Merrill JK1, Bailey HH1, Méndez-Sánchez N1, Yuen MF1, Hwang JP1. Am Soc Clin Oncol Educ Book. 2018 May 23;(38):262-279. doi: 10.1200/EDBK_200939. |
|
|
|
|
|
|
|
|
|
|
926. | Burden of Liver Diseases in the World |
|
Asrani SK1, Devarbhavi H2, Eaton J3, Kamath PS4. J Hepatol. 2018 Sep 25. pii: S0168-8278(18)32388-2. doi: 10.1016/j.jhep.2018.09.014. [Epub ahead of print] |
|
|
927. | Association Between Aspirin Use and Risk of Hepatocellular Carcinoma |
|
Simon TG1,2,3, Ma Y4,5, Ludvigsson JF6,7,8, Chong DQ9, Giovannucci EL5,10,11, Fuchs CS12, Meyerhardt JA13, Corey KE1,2,4, Chung RT1,2, Zhang X5, Chan AT2,3,5,14,15. JAMA Oncol. 2018 Oct 4. doi: 10.1001/jamaoncol.2018.4154. [Epub ahead of print] |
|
|
|
|
929. | Clinical outcomes with long-term sorafenib treatment of patients with hepatocellular carcinoma: a multicenter real-life study |
|
Sacco R1, Granito A2, Bargellini I3, Zolfino T4, Saitta C5, Marzi L6, Tapete G1, Bresci G1, Marinelli S2, Tovoli F2, Attardo S7, Rossi M7, Urbani L8, Marchi S9, Buccianti P8, Cabibbo G7. Future Oncol. 2018 Aug 9. doi: 10.2217/fon-2018-0281. [Epub ahead of print] |
|
|
|
|
931. | Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial |
|
Finn RS1, Merle P2, Granito A3, Huang YH4, Bodoky G5, Pracht M6, Yokosuka O7, Rosmorduc O8, Gerolami R9, Caparello C10, Cabrera R11, Chang C12, Sun W13, LeBerre MA14, Baumhauer A15, Meinhardt G16, Bruix J17. J Hepatol. 2018 Aug;69(2):353-358. doi: 10.1016/j.jhep.2018.04.010. Epub 2018 Apr 26. |
|
|
|
|
|
|
934. | Risk of Hepatocellular Cancer in Patients with Non-alcoholic Fatty Liver Disease |
|
Kanwal F1, Kramer JR2, Mapakshi S2, Natarajan Y3, Chayanupatkul M3, Richardson PA2, Li L4, Desiderio R2, Thrift AP5, Asch SM6, Chu J7, El-Serag HB8. Gastroenterology. 2018 Aug 22. pii: S0016-5085(18)34889-3. doi: 10.1053/j.gastro.2018.08.024. [Epub ahead of print] |
|
|
935. | Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study |
|
Chau I1, Park JO2, Ryoo BY3, Yen CJ4, Poon R5, Pastorelli D6, Blanc JF7, Kudo M8, Pfiffer T9, Hatano E10, Chung HC11, Kopeckova K12, Phelip JM13, Brandi G14, Ohkawa S15, Li CP16,17, Okusaka T18, Hsu Y19, Abada PB20, Zhu AX21. Br J Cancer. 2018 Jul;119(1):19-26. doi: 10.1038/s41416-018-0103-0. Epub 2018 May 29. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
943. | Precision oncology in liver cancer |
|
Sullivan KM1, Kenerson HL1, Pillarisetty VG1, Riehle KJ1, Yeung RS1. Ann Transl Med. 2018 Jul;6(14):285. doi: 10.21037/atm.2018.06.14. |
|
|
944. | Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis |
|
Lewis RH1, Glazer ES1,2, Bittenbinder DM1, O'Brien T3, Deneve JL1,2, Shibata D1,2, Behrman SW1, Vanatta JM4, Satapathy SK5, Dickson PV6,7. J Gastrointest Cancer. 2018 Aug 16. doi: 10.1007/s12029-018-0152-x. [Epub ahead of print] |
|
|
|
|
946. | Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with hcv-related cirrhosis |
|
Masetti C1, Lionetti R2, Lupo M3, Siciliano M4, Giannelli V5, Ponziani FR6, Teti E7, Dell'Unto C8, Francioso S1, Brega A1, Montalbano M2, Visco-Comandini U2, Taibi C2, Galati G8, Vespasiani Gentilucci U8, Picardi A8, Andreoni M7, Pompili M6, Pellicelli AM5, D'Offizi G2, Gasbarrini A4, De Santis A3, Angelico M1. J Viral Hepat. 2018 Aug 16. doi: 10.1111/jvh.12982. [Epub ahead of print] |
|
|
947. | Impact of the Treating Hospital on Care Outcomes for Hepatocellular Carcinoma |
|
Cotton RT1, Tran Cao HS2, Rana AA1, Sada YH3,4, Axelrod DA5, Goss JA1, Wilson MA6, Curley SA2, Massarweh NN2,4. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30128. [Epub ahead of print] |
|
|
|
|
949. | Cancer Site-Specific Disparities in New York, Including the 1945-1965 Birth Cohort's Impact on Liver Cancer Patterns |
|
Pinheiro PS1,2, Callahan KE3, Boscoe FP4,5, Balise RR6,2, Cobb TR3, Lee DJ6,7, Kobetz E2.Cancer Epidemiol Biomarkers Prev. 2018 Aug;27(8):917-927. doi: 10.1158/1055-9965.EPI-18-0194. Epub 2018 Jul 19. |
|
|
950. | Cardiac Events Within the 30-Day Postoperative Period Is Associated With Increased 1-Year Mortality Among Deceased-Donor Liver Transplant Recipients |
|
James TW1, Shay JES, Furfaro D, Ozseker B, Russell SD, Pustavoitau A, Rizkalla N, Saberi B, Philosophe B, Cameron AM, Gurakar A. Exp Clin Transplant. 2018 Aug 6. doi: 10.6002/ect.2017.0276. [Epub ahead of print] |
|
|
951. | Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma |
|
Abou-Alfa GK1,2, Qin S3, Ryoo BY4, Lu SN5,6, Yen CJ7, Feng YH8, Lim HY9, Izzo F10, Colombo M11, Sarker D12, Bolondi L13, Vaccaro G14, Harris WP15, Chen Z16, Hubner RA17, Meyer T18, Sun W19, Harding JJ1,2, Hollywood EM1, Ma J1, Wan PJ1, Ly M1, Bomalaski J20, Johnston A20, Lin CC21, Chao Y22, Chen LT6,23,24. Ann Oncol. 2018 Jun 1;29(6):1402-1408. doi: 10.1093/annonc/mdy101. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
961. | Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma |
|
DeLeon TT1, Ahn DH1, Bogenberger JM1, Anastasiadis PZ2, Arora M1, Ramanathan RK1, Aqel BA3, Vasmatzis G4, Truty MJ5, Oklu R6, Bekaii-Saab TS1, Borad MJ1. Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20. |
|
|
962. | Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma |
|
Harding JJ1,1, Abu-Zeinah G1, Chou JF1, Owen DH1, Ly M1, Lowery MA1,1, Capanu M1, Do R1,1, Kemeny NE1,1, O'Reilly EM1,1, Saltz LB1,1, Abou-Alfa GK1,1. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024. |
|
|
963. | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma |
|
Abou-Alfa GK1, Meyer T1, Cheng AL1, El-Khoueiry AB1, Rimassa L1, Ryoo BY1, Cicin I1, Merle P1, Chen Y1, Park JW1, Blanc JF1, Bolondi L1, Klümpen HJ1, Chan SL1, Zagonel V1, Pressiani T1, Ryu MH1, Venook AP1, Hessel C1, Borgman-Hagey AE1, Schwab G1, Kelley RK1. N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002. |
|
|
|
|
|
|
|
|
967. | Radioembolization Super Survivors: Extended Survival in Non-operative Hepatocellular Carcinoma |
|
Gordon AC1, Gabr A1, Riaz A1, Uddin OM1, Abouchaleh N1, Ali R1, Kallini J1, Salem R1,2,3, Lewandowski RJ4,5,6. Cardiovasc Intervent Radiol. 2018 Jun 12. doi: 10.1007/s00270-018-2008-y. [Epub ahead of print] |
|
|
|
|
|
|
970. | Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates |
|
Younossi Z1, Stepanova M2, Ong JP3, Jacobson IM4, Bugianesi E5, Duseja A6, Eguchi Y7, Wong VW8, Negro F9, Yilmaz Y10, Romero-Gomez M11, George J12, Ahmed A13, Wong R14, Younossi I2, Ziayee M2, Afendy A2; Global NASH Council.. Clin Gastroenterol Hepatol. 2018 Jun 13. pii: S1542-3565(18)30611-6. doi: 10.1016/j.cgh.2018.05.057. [Epub ahead of print] |
|
|
|
|
|
|
|
|
974. | The Prognostic Ability of Major Hepatocellular Carcinoma Staging Systems Is Improved by Including a Treatment Variable |
|
Wallace MC1,2,3, Knuiman M4, Huang Y5, Garas G6,5, Adams LA6,5, MacQuillan G6,5, Preen DB4, Jeffrey GP6,5. Dig Dis Sci. 2018 May 28. doi: 10.1007/s10620-018-5132-2. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
979. | Liver Stiffness measurement in the primary care setting detects high rates of advanced fibrosis and predicts liver related events in hepatitis C |
|
Bloom S1, Kemp W2, Nicoll A3, Roberts SK2, Gow P4, Dev A5, Bell S6, Sood S7, Kronborg I8, Knight V5, Lewis D9, Lubel J9. J Hepatol. 2018 Apr 27. pii: S0168-8278(18)32023-3. doi: 10.1016/j.jhep.2018.04.013. [Epub ahead of print] |
|
|
980. | Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial |
|
Finn RS1, Merle P2, Granito A3, Huang YH4, Bodoky G5, Pracht M6, Yokosuka O7, Rosmorduc O8, Gerolami R9, Caparello C10, Cabrera R11, Chang C12, Sun W13, LeBerre MA14, Baumhauer A15, Meinhardt G16, Bruix J17; RESORCE Investigators. J Hepatol. 2018 Apr 25. pii: S0168-8278(18)32018-X. doi: 10.1016/j.jhep.2018.04.010. [Epub ahead of print] |
|
|
|
|
982. | A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma |
|
Thomas MB1,2, Garrett-Mayer E1, Anis M1, Anderton K1, Bentz T1, Edwards A1, Brisendine A1, Weiss G3, Siegel AB4, Bendell J5, Baron A6, Duddalwar V7, El-Khoueiry A7. Oncology. 2018 May 2;94(6):329-339. doi: 10.1159/000485384. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
987. | Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system |
|
Hsu CY1,2,3, Liu PH1,2,4, Ho SY1,2, Huang YH1,5, Lee YH1,2, Lee RC2,6, Nagaria TS7, Hou MC1,2, Huo TI1,2,8. Liver Int. 2018 Apr 2. doi: 10.1111/liv.13748. [Epub ahead of print] |
|
|
|
|
989. | Sorafenib versus Transarterial chemoembolization for advanced-stage hepatocellular carcinoma: a cost-effectiveness analysis |
|
Chen S1, Peng Z2,3, Wei M4, Liu W5, Dai Z4, Wang H3, Mei J3, Cheong M6, Zhang H6, Kuang M7,8. BMC Cancer. 2018 Apr 5;18(1):392. doi: 10.1186/s12885-018-4308-7. |
|
|
|
|
|
|
992. | Stereotactic Body Radiation Therapy (SBRT) for Hepatocellular Carcinoma: High Rates of Local Control With Low Toxicity |
|
Baumann BC1,2,3, Wei J4, Plastaras JP1, Lukens JN1, Damjanov N5, Hoteit M6, Hsu C6, Levine M7, Mondschein J8, Nadolski G8, Olthoff K7, Reiss KA5, Rosen M9, Siegelman E9, Metz JM1, Ben-Josef E1. Am J Clin Oncol. 2018 Mar 16. doi: 10.1097/COC.0000000000000435. [Epub ahead of print] |
|
|
|
|
|
|
995. | Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study |
|
Romano A1, Angeli P1, Piovesan S2, Noventa F2, Anastassopoulos G2, Chemello L1, Cavalletto L1, Gambato M3, Russo FP3, Burra P3, Vincenzi V4, Scotton PG5, Panese S6, Tempesta D7, Bertin T8, Carrara M9, Carlotto A10, Capra F11, Carolo G12, Scroccaro G13, Alberti A14. J Hepatol. 2018 Mar 15. pii: S0168-8278(18)30172-7. doi: 10.1016/j.jhep.2018.03.009. [Epub ahead of print] |
|
|
|
|
|
|
|
|
999. | Bridging therapies to liver transplantation for hepatocellular carcinoma: A bridge to nowhere? |
|
Tan CHN1,2, Yu Y3, Tan YRN3, Lim BLK4,2, Iyer SG1,2, Madhavan K1,2, Kow AWC1,2. Ann Hepatobiliary Pancreat Surg. 2018 Feb;22(1):27-35. doi: 10.14701/ahbps.2018.22.1.27. Epub 2018 Feb 26. |
|
|
|
|
1001. | SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma |
|
Chow PKH1, Gandhi M1, Tan SB1, Khin MW1, Khasbazar A1, Ong J1, Choo SP1, Cheow PC1, Chotipanich C1, Lim K1, Lesmana LA1, Manuaba TW1, Yoong BK1, Raj A1, Law CS1, Cua IHY1, Lobo RR1, Teh CSC1, Kim YH1, Jong YW1, Han HS1, Bae SH1, Yoon HK1, Lee RC1, Hung CF1, Peng CY1, Liang PC1, Bartlett A1, Kok KYY1, Thng CH1, Low AS1, Goh ASW1, Tay KH1, Lo RHG1, Goh BKP1, Ng DCE1, Lekurwale G1, Liew WM1, Gebski V1, Mak KSW1, Soo KC1; Asia-Pacific Hepatocellular CarcinomaTrials Group. J Clin Oncol. 2018 Mar 2:JCO2017760892. doi: 10.1200/JCO.2017.76.0892. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1005. | Novel targeted therapy strategies for biliary tract cancers and hepatocellular carcinoma |
|
DeLeon TT1, Ahn DH1, Bogenberger JM1, Anastasiadis PZ2, Arora M1, Ramanathan RK1, Aqel BA3, Vasmatzis G4, Truty MJ5, Oklu R6, Bekaii-Saab TS1, Borad MJ1. Future Oncol. 2018 Mar;14(6):553-566. doi: 10.2217/fon-2017-0451. Epub 2018 Feb 20. |
|
|
|
|
|
|
1008. | The impact of treatment of hepatitis C with DAAs on the occurrence of HCC |
|
Roche B1,2,3,4, Coilly A1,2,3,4, Duclos-Vallee JC1,2,3,4, Samuel D1,2,3,4. Liver Int. 2018 Feb;38 Suppl 1:139-145. doi: 10.1111/liv.13659. |
|
|
|
|
|
|
1011. | Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System |
|
Tayob N1, Richardson P2,3, White DL2,3, Yu X4, Davila JA2,3, Kanwal F2,3, Feng Z5, El-Serag HB2,3. BMC Med Res Methodol. 2018 Jan 4;18(1):1. doi: 10.1186/s12874-017-0458-6. |
|
|
1012. | Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome |
|
Harms MH1, Lammers WJ1, Thorburn D2,3, Corpechot C4, Invernizzi P5, Janssen HLA6, Battezzati PM7, Nevens F8, Lindor KD9,10, Floreani A11, Ponsioen CY12, Mayo MJ13, Dalekos GN14, Bruns T15, Parés A16, Mason AL17, Verhelst X18, Kowdley KV19, Goet JC1, Hirschfield GM20, Hansen BE1,6, van Buuren HR1. Am J Gastroenterol. 2017 Dec 12. doi: 10.1038/ajg.2017.440. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1019. | Utility of Tumor Burden Score to Stratify Prognosis of Patients with Hepatocellular Cancer: Results of 4759 Cases from ITA.LI.CA Study Group |
|
Vitale A1, Lai Q2, Farinati F1, Bucci L3, Giannini EG4, Napoli L5, Ciccarese F6, Rapaccini GL7, Di Marco M8, Caturelli E9, Zoli M5, Borzio F10, Sacco R11, Cabibbo G12, Virdone R13, Marra F14, Felder M15, Morisco F16, Benvegnù L17, Gasbarrini A18, Svegliati-Baroni G19, Foschi FG20, Missale G21, Masotto A22, Nardone G23, Colecchia A24, Bernardi M3, Trevisani F3, Pawlik TM25; Italian Liver Cancer (ITA.LI.CA) group. J Gastrointest Surg. 2018 Jan 19. doi: 10.1007/s11605-018-3688-y. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1025. | Patterns of Discordance Between Pretransplant Imaging Stage of Hepatocellular Carcinoma and Posttransplant Pathologic Stage: A Contemporary Appraisal of the Milan Criteria |
|
Ecker BL1, Hoteit MA2, Forde KA2,3, Hsu CC2, Reddy KR2, Furth EE4, Siegelman ES5, Habibollahi P5, Ben-Josef E6, Porrett PM1, Abt PL1, Shaked A1, Olthoff KM1, Levine MH1. Transplantation. 2018 Jan 10. doi: 10.1097/TP.0000000000002056. [Epub ahead of print] |
|
|
1026. | Hepatocellular carcinoma |
|
Forner A1, Reig M2, Bruix J2. Lancet. 2018 Jan 4. pii: S0140-6736(18)30010-2. doi: 10.1016/S0140-6736(18)30010-2. [Epub ahead of print] |
|
|
|
|
1028. | Frequency, Morbidity, and Mortality of Bone Metastases in Advanced Hepatocellular Carcinoma |
|
Harding JJ1,1, Abu-Zeinah G1, Chou JF1, Owen DH1, Ly M1, Lowery MA1,1, Capanu M1, Do R1,1, Kemeny NE1,1, O'Reilly EM1,1, Saltz LB1,1, Abou-Alfa GK1,1. J Natl Compr Canc Netw. 2018 Jan;16(1):50-58. doi: 10.6004/jnccn.2017.7024. |
|
|
|
|
1030. | Trans-arterial radio-embolization: a new chance for patients with hepatocellularcancer to access liver transplantation, a world review |
|
Levi Sandri GB1, Ettorre GM1, Giannelli V2, Colasanti M1, Sciuto R3, Pizzi G4, Cianni R5, D'Offizi G6, Antonini M7, Vennarecci G1, Lucatelli P8. Transl Gastroenterol Hepatol. 2017 Nov 27;2:98. doi: 10.21037/tgh.2017.11.11. eCollection 2017. |
|
|
|
|
|
|
1033. | Benefits of laparoscopic liver resection in patients with hepatocellular carcinomaand portal hypertension: a case-matched study |
|
Molina V1, Sampson-Dávila J1, Ferrer J1, Fondevila C1, Díaz Del Gobbo R1, Calatayud D1, Bruix J2,3, García-Valdecasas JC1, Fuster J4,5,6. Surg Endosc. 2017 Dec 7. doi: 10.1007/s00464-017-5930-1. [Epub ahead of print] |
|
|
|
|
1035. | An Ecological Study of the Association between Air Pollution and Hepatocellular Carcinoma Incidence in Texas |
|
Cicalese L1, Raun L2, Shirafkan A1, Campos L2, Zorzi D1, Montalbano M1, Rhoads C1, Gazis V1, Ensor K2, Rastellini C1,3. Liver Cancer. 2017 Nov;6(4):287-296. doi: 10.1159/000475776. Epub 2017 Aug 29. |
|
|
|
|
1037. | Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature |
|
Tapper EB1, Kanwal F2,3,4, Asrani SK5, Ho C6, Ovchinsky N7, Poterucha J8, Flores A9, Smith JE10, Ankoma-Sey V11, Luxon B12, Volk M13. Hepatology. 2017 Dec 22. doi: 10.1002/hep.29756. [Epub ahead of print] |
|
|
|
|
|
|
1040. | Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular CarcinomaRecurrence in a 5-year Transplant Cohort |
|
Sandow TA1, Arndt SE1, Albar AA1, DeVun DA1, Kirsch DS1, Gimenez JM1, Bohorquez HE1, Gilbert PJ1, Thevenot PT1, Nunez KG1, Galliano GA1, Cohen AJ1, Kay D1, Gulotta PM1. Radiology. 2017 Dec 4:170731. doi: 10.1148/radiol.2017170731. [Epub ahead of print] |
|
|
1041. | The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib |
|
Conroy G1, Salleron J2, Belle A1, Bensenane M1, Nani A1, Ayav A3, Peiffert D4, Lopez A1, Baumann C5, Barraud H1, Bronowicki JP1. Oncotarget. 2017 Sep 30;8(56):95853-95864. doi: 10.18632/oncotarget.21401. eCollection 2017 Nov 10. |
|
|
|
|
1043. | Survival of children after liver transplantation for hepatocellular carcinoma |
|
Baumann U1, Adam R2, Duvoux C3, Mikolajczyk R4,5, Karam V2, D'Antiga L6, Chardot C7, Coker A8, Colledan M9, Erizon BG10, Line PD11, Hadzic N12, Isoniemi H13, Klempnauer JL14, Reding R15, McKiernan PJ16, McLin V17, Paul A18, Salizzoni M19, Furtado ESB20, Schneeberger S21, Karch A4,5. Liver Transpl. 2017 Dec 9. doi: 10.1002/lt.24994. [Epub ahead of print] |
|
|
|
|
|
|
1046. | Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies |
|
Simon TG1,2,3,4, King LY5, Chong DQ6, Nguyen L1,2,3,4, Ma Y3,7,8, VoPham T3,9,8, Giovannucci EL3,9,10,8, Fuchs CS11, Meyerhardt JA3,12, Corey KE1,2,3,4, Khalili H2,3,4, Chung RT1,2,3, Zhang X3,8, Chan AT2,3,4,8. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29660. [Epub ahead of print] |
|
|
|
|
1048. | Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma |
|
Gerbes A1, Zoulim F2,3, Tilg H4, Dufour JF5,6, Bruix J7, Paradis V8, Salem R9, Peck-Radosavljevic M10, Galle PR11, Greten TF12,13, Nault JC14,15,16, Avila MA17. Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068. [Epub ahead of print] |
|
|
1049. | The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen |
|
Innes H1, Barclay ST2, Hayes PC3, Fraser A4, Dillon JF5, Stanley A2, Bathgate A3, McDonald SA1, Goldberg D6, Valerio H1, Fox R7, Kennedy N8, Bramley P9, Hutchinson SJ1. J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429-7. doi: 10.1016/j.jhep.2017.10.033. [Epub ahead of print] |
|
|
|
|
1051. | Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma |
|
Gerbes A1, Zoulim F2,3, Tilg H4, Dufour JF5,6, Bruix J7, Paradis V8, Salem R9, Peck-Radosavljevic M10, Galle PR11, Greten TF12,13, Nault JC14,15,16, Avila MA17. Gut. 2017 Nov 17. pii: gutjnl-2017-315068. doi: 10.1136/gutjnl-2017-315068. [Epub ahead of print] |
|
|
1052. | Diabetes, Metabolic Comorbidities and Risk of Hepatocellular Carcinoma: Results from Two Prospective Cohort Studies |
|
Simon TG1,2,3,4, King LY5, Chong DQ6, Nguyen L1,2,3,4, Ma Y3,7,8, VoPham T3,9,8, Giovannucci EL3,9,10,8, Fuchs CS11, Meyerhardt JA3,12, Corey KE1,2,3,4, Khalili H2,3,4, Chung RT1,2,3, Zhang X3,8, Chan AT2,3,4,8. Hepatology. 2017 Nov 20. doi: 10.1002/hep.29660. [Epub ahead of print] |
|
|
1053. | The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen |
|
Innes H1, Barclay ST2, Hayes PC3, Fraser A4, Dillon JF5, Stanley A2, Bathgate A3, McDonald SA1, Goldberg D6, Valerio H1, Fox R7, Kennedy N8, Bramley P9, Hutchinson SJ1. J Hepatol. 2017 Nov 15. pii: S0168-8278(17)32429-7. doi: 10.1016/j.jhep.2017.10.033. [Epub ahead of print] |
|
|
1054. | Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma? |
|
Margetts J1,2, Ogle LF2, Chan SL3,4, Chan AWH5, Chan KCA6, Jamieson D2, Willoughby CE2, Mann DA7, Wilson CL7, Manas DM8, Yeo W3, Reeves HL1,9. Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.386. [Epub ahead of print] |
|
|
|
|
|
|
1057. | Pilot study of living donor liver transplantation for patients with HCC exceeding Milan criteria (BCLC extended criteria) |
|
Llovet JM1,2,3, Pavel M4, Rimola J1, Diaz MA5, Colmenero J4,6, Saavedra D4, Fondevila C4, Ayuso C1, Fuster J1,4, Ginès P4,6, Bruix J1,6, Garcia Valdecasas JC4. Liver Transpl. 2017 Nov 15. doi: 10.1002/lt.24977. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1062. | Angiosomal radiopathologic analysis of transarterial radioembolization for the treatment of hepatocellular carcinoma |
|
Ahmed AF1, Samreen N2,3, Grajo JR2, Zendejas I4, Sistrom CL2, Collinsworth A5, Esnakula A5, Shah JL2, Cabrera R6, Geller BS2, Toskich BB2,7. Abdom Radiol (NY). 2017 Oct 20. doi: 10.1007/s00261-017-1354-6. [Epub ahead of print] |
|
|
1063. | The Liver in Oncology |
|
Dhanasekaran R1, Kwo PY2. Clin Liver Dis. 2017 Nov;21(4):697-707. doi: 10.1016/j.cld.2017.06.003. Epub 2017 Jul 26. |
|
|
1064. | Nonstandardized Terminology to Describe Focal Liver Lesions in Patients at Risk for Hepatocellular Carcinoma: Implications Regarding Clinical Communication |
|
Corwin MT1,2,3, Lee AY1,2,3, Fananapazir G1,2,3, Loehfelm TW1,2,3, Sarkar S1,2,3, Sirlin CB1,2,3. AJR Am J Roentgenol. 2017 Oct 12:1-6. doi: 10.2214/AJR.17.18416. [Epub ahead of print] |
|
|
|
|
1066. | Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients With Unresectable Hepatocellular Carcinoma Lesions |
|
Tak WY1, Lin SM2, Wang Y3, Zheng J4, Vecchione A5, Park SY6, Chen MH7, Wong S8, Xu R9, Peng CY10, Chiou YY11, Huang GT12, Cai J13, Abdullah BJ14, Lee JS15, Lee JY16, Choi JY17, Gopez-Cervantes J18, Sherman M19, Finn RS20, Omata M21, O'Neal M22, Makris L23, Borys N24, Poon R25, Lencioni R26. Clin Cancer Res. 2017 Oct 10. pii: clincanres.2433.2016. doi: 10.1158/1078-0432.CCR-16-2433. [Epub ahead of print] |
|
|
|
|
1068. | Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting |
|
Thein HH1,2, Qiao Y1, Zaheen A3, Jembere N1, Sapisochin G4, Chan KKW3,5,6, Yoshida EM7, Earle CC2,6,8,9. PLoS One. 2017 Oct 10;12(10):e0185198. doi: 10.1371/journal.pone.0185198. eCollection 2017. |
|
|
|
|
|
|
|
|
1072. | Differential Serum Cytokine Profiles in Patients with Chronic Hepatitis B, C, and Hepatocellular Carcinoma |
|
Estevez J1,2, Chen VL3,4, Podlaha O5, Li B5, Le A1, Vutien P1,6, Chang ET7, Rosenberg-Hasson Y8, Jiang Z5, Pflanz S5, Ge D5, Gaggar A5, Nguyen MH9. Sci Rep. 2017 Sep 19;7(1):11867. doi: 10.1038/s41598-017-11975-7. |
|
|
1073. | Feasibility and outcomes of percutaneous thermal ablation of hepatocellular carcinoma in a transplanted allograft |
|
Welch BT1,2,3,4, Schmitz JJ5, Kurup AN5, Atwell TD5, Callstrom MR5, Frey G6, Paz-Fumagalli R6, Allen A7, Watt K7, Heimbach J8, Schmit GD5. Abdom Radiol (NY). 2017 Sep 21. doi: 10.1007/s00261-017-1323-0. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1079. | Long-Term Follow-Up of Clinical Trial Patients Treated for Chronic HCV Infection with Daclatasvir-Based Regimens |
|
Reddy KR1, Pol S2, Thuluvath PJ3, Kumada H4, Toyota J5, Chayama K6, Levin J7, Lawitz EJ8, Gadano A9, Ghesquiere W10, Gerken G11, Brunetto MR12, Peng CY13, Silva M14, Strasser SI15, Heo J16, McPhee F17, Liu Z18, Yang R17, Linaberry M19, Noviello S19. Liver Int. 2017 Sep 21. doi: 10.1111/liv.13596. [Epub ahead of print] |
|
|
|
|
|
|
1082. | Can More Aggressive Treatment Improve Prognosis in Patients with Hepatocellular Carcinoma? A Direct Comparison of the Hong Kong Liver Cancer and Barcelona Clinic Liver Cancer Algorithms |
|
Lee YS1, Seo YS1, Kim JH1, Lee J2, Kim HR1, Yoo YJ1, Kim TS3, Kang SH1, Suh SJ1, Joo MK1, Jung YK1, Lee BJ1, Yim HJ1, Yeon JE1, Kim JS1, Park JJ1, Um SH1, Bak YT1, Byun KS1. Gut Liver. 2017 Sep 7. doi: 10.5009/gnl17040. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1086. | Hepatitis C virus-related complications are increasing in women veterans: A national cohort study |
|
Kramer JR1,2, El-Serag HB1,3, Taylor TJ4, White DL1,3,2, Asch SM4, Frayne SM4, Cao Y1, Smith DL1, Kanwal F1,3. J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1096. | Nomogram for individualized prediction of hepatocellular carcinoma occurrence in HCV-cirrhosis (ANRS CO12 CirVir) |
|
Ganne-Carrié N1,2,3, Layese R4, Bourcier V1, Cagnot C5, Marcellin P6, Guyader D7, Pol S8, Larrey D9, de Lédinghen V10, Ouzan D11, Zoulim F12, Roulot D2,13, Tran A14, Bronowicki JP15, Zarski JP16, Riachi G17, Calès P18, Péron JM19, Alric L20, Bourlière M21, Mathurin P22, Blanc JF23, Abergel A24, Serfaty L25, Mallat A26, Grangé JD27, Attali P28, Bacq Y29, Wartelle C30, Dao T31, Benhamou Y32, Pilette C33, Silvain C34, Christidis C35, Capron D36, Bernard-Chabert B37, Zucman D38, Di Martino V39, Trinchet JC1,2,3, Nahon P1,2,3, Roudot-Thoraval F4; ANRS CO12 CirVir study group. Hepatology. 2016 Jun 27. doi: 10.1002/hep.28702. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1102. | Randomized, Open-Label Phase 2 Study Comparing Frontline Dovitinib vs Sorafenib in Patients With Advanced Hepatocellular Carcinoma |
|
Cheng AL1, Thongprasert S2, Lim HY3, Sukeepaisarnjaroen W4, Yang TS5, Wu CC6, Chao Y7, Chan SL8, Kudo M9, Ikeda M10, Kang YK11, Pan H12, Numata K13, Han G14, Balsara B15, Zhang Y15, Rodriguez AM16, Zhang Y15, Wang Y15, Poon RT17. Hepatology. 2016 Apr 15. doi: 10.1002/hep.28600. [Epub ahead of print] |
|
|
|
|
|
|
1105. | Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer |
|
Ryerson AB1, Eheman CR1, Altekruse SF2, Ward JW3, Jemal A4, Sherman RL5, Henley SJ1, Holtzman D3, Lake A6, Noone AM2, Anderson RN7, Ma J4, Ly KN3, Cronin KA2, Penberthy L2, Kohler BA5. Cancer. 2016 Mar 9. doi: 10.1002/cncr.29936. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1116. | Molecular subclasses of hepatocellular carcinoma predict sensitivity to fibroblast growth factor receptor inhibition |
|
Schmidt B1, Wei L1, DePeralta DK1, Hoshida Y2, Tan P2,3, Sun X2, Sventek JP1, Lanuti M4, Tanabe KK1, Fuchs BC1. Int J Cancer. 2015 Oct 20. doi: 10.1002/ijc.29893. [Epub ahead of print] |
|
|
|
|
|
|
1119. | The impact of viral hepatitis-related hepatocellular carcinoma to post-transplant outcomes |
|
Younossi ZM1,2, Stepanova M1,2, Saab S3, Ahmed A4, Lam B1, Srishord M1,2, Venkatesan C1, Wai H1, Henry L1,2. J Viral Hepat. 2015 Aug 20. doi: 10.1111/jvh.12449. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1124. | Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B |
|
Kim WR1, Loomba R2, Berg T3, Aguilar Schall RE4, Yee LJ4, Dinh PV4, Flaherty JF4, Martins EB4, Therneau TM5, Jacobson I6, Fung S7, Gurel S8, Buti M9, Marcellin P10. Cancer. 2015 Jul 15. doi: 10.1002/cncr.29537. [Epub ahead of print] |
|
|
1125. | Development and performance of an algorithm to estimate the Child-Turcotte-Pugh Score from a national electronic healthcare database |
|
Kaplan DE1, Dai F2, Aytaman A3, Baytarian M4, Fox R5, Hunt K6, Knott A7, Pedrosa M4, Pocha C7, Mehta R2, Duggal M2, Skanderson M8, Valderrama A9, Taddei T2; VOCAL Study Group. Clin Gastroenterol Hepatol. 2015 Jul 15. pii: S1542-3565(15)00966-0. doi: 10.1016/j.cgh.2015.07.010. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1132. | Dietary Fat, Fat Subtypes and Hepatocellular Carcinoma in a Large European Cohort |
|
Laursen AS7, Hansen L8, Overvad K7, Tjønneland A8, Boutron-Ruault MC9,10, Fagherazzi G9,10, His M9,10, Boeing H3, Katzke V11, Kühn T11, Trichopoulou A6,12, Valanou E4,12, Kritikou M12, Masala G13, Panico S14, Sieri S15, Ricceri F16,17, Tumino R18, Bueno-de-Mesquita HB19,20,21,22, Peeters PH21,23, Hjartåker A24, Skeie G25, Weiderpass E25,26,27,28, Ardanaz E29,30, Bonet C31, Chirlaque MD30,32, Dorronsoro M33, Quirós JR34, Johansson I35, Ohlsson B36, Sjöberg K36,37, Wennberg M38, Khaw KT39, Travis RC40, Wareham N41, Ferrari P1, Freisling H1, Romieu I1, Cross AJ42, Gunter M42, Lu Y42, Jenab M1. Int J Cancer. 2015 Jun 16. doi: 10.1002/ijc.29643. [Epub ahead |
|
|
|
|
|
|
1135. | Current systemic treatment of hepatocellular carcinoma: A review of the literature |
|
Chen KW1, Ou TM1, Hsu CW1, Horng CT1, Lee CC1, Tsai YY1, Tsai CC1, Liou YS1, Yang CC1, Hsueh CW1, Kuo WH1. World J Hepatol. 2015 Jun 8;7(10):1412-20. doi: 10.4254/wjh.v7.i10.1412. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1145. | Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial |
|
Hoffmann K1, Ganten T2, Gotthardtp D3, Radeleff B4, Settmacher U5, Kollmar O6, Nadalin S7, Karapanagiotou-Schenkel I8, von Kalle C9, Jäger D10, Büchler MW11, Schemmer P12,13. BMC Cancer. 2015 May 11;15(1):392. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1152. | Impact of clinically evident portal hypertension on the course of hepatocellular carcinoma in patients listed for liver transplantation |
|
Faitot F1, Allard MA, Pittau G, Ciacio O, Adam R, Castaing D, Sa Cunha A, Pelletier G, Cherqui D, Samuel D, Vibert E. Hepatology. 2015 Apr 24. doi: 10.1002/hep.27864. [Epub ahead of print] |
|
|
|
|
1154. | Early and resectable HCC: Definition and validation of a subgroup of patients who could avoid liver transplantation |
|
Scatton O1, Goumard C, Cauchy F, Fartoux L, Perdigao F, Conti F, Calmus Y, Boelle PY, Belghiti J, Rosmorduc O, Soubrane O. J Surg Oncol. 2015 Apr 28. doi: 10.1002/jso.23916. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1160. | Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis |
|
Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Hepatol Res. 2015 Apr;45(4):363-77. doi: 10.1111/hepr.12511. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1170. | Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study |
|
Park JW1, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, Kudo M, Johnson P, Wagner S, Orsini LS, Sherman M. Liver Int. 2015 Mar 5. doi: 10.1111/liv.12818. [Epub ahead of print] |
|
|
|
|
1172. | Reproductive factors, exogenous hormone use and risk of hepatocellular carcinoma among US women: results from the Liver Cancer Pooling Project |
|
McGlynn KA1, Sahasrabuddhe VV1, Campbell PT2, Graubard BI1, Chen J1, Schwartz LM1, Petrick JL1, Alavanja MC1, Andreotti G1, Boggs DA3, Buring JE4, Chan AT5, Freedman ND1, Gapstur SM2, Hollenbeck AR6, Hou L7, King LY5, Koshiol J1, Linet M1, Palmer JR3, Poynter JN8, Purdue M1, Robien K9, Schairer C1, Sesso HD4, Sigurdson A1, Wactawski-Wende J10, Zeleniuch-Jacquotte A11. Br J Cancer. 2015 Mar 5. doi: 10.1038/bjc.2015.58. [Epub ahead of print] |
|
|
1173. | Fruit and vegetable consumption in relation to hepatocellular carcinoma in a multi-centre, European cohort study |
|
Bamia C1, Lagiou P2, Jenab M3, Aleksandrova K4, Fedirko V5, Trichopoulos D6, Overvad K7, Tjønneland A8, Olsen A8, Clavel-Chapelon F9, Boutron-Ruault MC9, Kvaskoff M9, Katzke VA10, Kühn T10, Boeing H4, Nöthlings U11, Palli D12, Sieri S13, Panico S14, Tumino R15, Naccarati A16, Bueno-de-Mesquita HA17, Peeters PH18, Weiderpass E19, Skeie G20, Quirós JR21, Agudo A22, Chirlaque MD23, Sanchez MJ24, Ardanaz E25, Dorronsoro M26, Ericson U27, Nilsson LM28, Wennberg M29, Khaw KT30, Wareham N31, Key TJ32, Travis RC32, Ferrari P3, Stepien M3, Duarte-Salles T3, Norat T33, Murphy N33, Riboli E33, Trichopoulou A34. Br J Cancer. 2015 Mar 5. doi: 10.1038/bjc.2014.654. [Epub ahead of print] |
|
|
1174. | Surgical Treatment of Hepatocellular Carcinoma in North America: Can Hepatic Resection Still Be Justified? |
|
Chapman WC1, Klintmalm G2, Hemming A3, Vachharajani N4, Majella Doyle MB4, DeMatteo R5, Zaydfudim V6, Chung H4, Cavaness K2, Goldstein R2, Zendajas I7, Melstrom LG8, Nagorney D9, Jarnagin W5. J Am Coll Surg. 2015 Jan 6. pii: S1072-7515(14)01927-9. doi: 10.1016/j.jamcollsurg.2014.12.030. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1178. | Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma |
|
Ren Z1, Zhu K1, Kang H1, Lu M1, Qu Z1, Lu L1, Song T1, Zhou W1, Wang H1, Yang W1, Wang X1, Yang Y1, Shi L1, Bai Y1, Guo X1, Ye SL2. J Clin Oncol. 2015 Feb 9. pii: JCO.2013.52.9651. [Epub ahead of print] |
|
|
|
|
1180. | Risk factors for the Long-Term Efficacy, Recurrence, and Metastasis in Small Hepatocellular Carcinomas |
|
Chen Y1, Gao SG, Chen JM, Wang GP, Wang ZF, Zhou B, Jin CH, Yang YT, Feng XS. Cell Biochem Biophys. 2015 Feb 8. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1188. | Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma |
|
Kim BK1, Kim SU2, Kim KA3, Chung YE4, Kim MJ4, Park MS4, Park JY1, Kim DY1, Ahn SH5, Kim MD4, Park SI4, Won JY4, Lee DY4, Han KH5. J Hepatol. 2015 Jan 28. pii: S0168-8278(15)00053-7. doi: 10.1016/j.jhep.2015.01.022. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1193. | USP7 accelerates p14ARF degradation by deubiquitinating TRIP12 and promotes HCC progression |
|
Cai JB1, Shi GM, Dong ZR, Ke AW, Ma HH, Gao Q, Shen ZZ, Huang XY, Chen H, Yu DD, Liu LX, Zhang PF, Zhang C, Hu MY, Yang LX, Shi YH, Wang XY, Ding ZB, Qiu SJ, Sun HC, Zhou J, Shi YG, Fan J. Hepatology. 2014 Dec 29. doi: 10.1002/hep.27682. [Epub ahead of print] |
|
|
1194. | Comparison of improved prognosis between hepatitis B- and hepatitis C- related hepatocellular carcinoma |
|
Minami T1, Tateishi R, Shiina S, Nakagomi R, Kondo M, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Yoshida H, Koike K. Hepatol Res. 2015 Jan 6. doi: 10.1111/hepr.12468. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1200. | Optimal Methods for Measuring Eligibility for Liver Transplant in Hepatocellular Carcinoma Patients Undergoing Transarterial Chemoembolization |
|
Kim H1, Shim JH2, Kim G3, Shin YM4, Yu E5, Lee S6, Lee D3, Kim KM3, Lim Y3, Lee HC3, Chung Y3, Lee YS3. J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00934-9. doi: 10.1016/j.jhep.2014.12.013. [Epub ahead of print] |
|
|
|
|
1202. | Non-hypervascular Hepatobiliary phase Hypointense Nodules on Gadoxetic Acid-enhanced MRI: Risk of HCC Recurrence after Radiofrequency Ablation |
|
Lee DH1, Lee JM2, Lee JY3, Kim SH3, Kim JH3, Yoon JH4, Kim YJ4, Lee J4, Yu SJ4, Han JK3, Choi BI3. J Hepatol. 2014 Dec 18. pii: S0168-8278(14)00936-2. doi: 10.1016/j.jhep.2014.12.015. [Epub ahead of print] |
|
|
|
|
1204. | Genomic predictors for recurrence patterns of hepatocellular carcinoma: model derivation and validation |
|
Kim JH1, Sohn BH2, Lee HS2, Kim SB2, Yoo JE3, Park YY4, Jeong W5, Lee SS6, Park ES7, Kaseb A8, Kim BH9, Kim WB10, Yeon JE11, Byun KS11, Chu IS12, Kim SS13, Wang XW14, Thorgeirsson SS15, Luk JM16, Kang KJ17, Heo J18, Park YN3, Lee JS19. PLoS Med. 2014 Dec 23;11(12):e1001770. doi: 10.1371/journal.pmed.1001770. eCollection 2014. |
|
|
|
|
|
|
1207. | Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants |
|
Pais R1, Lebray P1, Rousseau G2, Charlotte F3, Esselma G1, Savier E2, Thabut D1, Rudler M1, Eyraud D4, Vezinet C4, Siksik JM2, Vaillant JC2, Hannoun L2, Poynard T1, Ratziu V5. |
|
|
|
|
|
|
|
|
|
|
1212. | Treatment of hepatocellular carcinoma with child-pugh C cirrhosis |
|
Nouso K1, Kokudo N, Tanaka M, Kuromatsu R, Nishikawa H, Toyoda H, Oishi N, Kuwaki K, Kusanaga M, Sakaguchi T, Morise Z, Kitai S, Kudo M. Oncology. 2014;87 Suppl 1:99-103. doi: 10.1159/000368152. Epub 2014 Nov 22. |
|
|
|
|
1214. | Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib |
|
Arizumi T1, Ueshima K, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Sakurai T, Nishida N, Kudo M. Dig Dis. 2014;32(6):705-10. doi: 10.1159/000368006. Epub 2014 Oct 29. |
|
|
1215. | Impact of alpha-fetoprotein on hepatocellular carcinoma development during entecavir treatment of chronic hepatitis B virus infection |
|
Yamada R1, Hiramatsu N, Oze T, Morishita N, Harada N, Yakushijin T, Iio S, Doi Y, Yamada A, Kaneko A, Hagiwara H, Mita E, Oshita M, Itoh T, Fukui H, Hijioka T, Katayama K, Tamura S, Yoshihara H, Imai Y, Kato M, Miyagi T, Yoshida Y, Tatsumi T, Kasahara A, Hamasaki T, Hayashi N, Takehara T; the Osaka Liver Forum. J Gastroenterol. 2014 Nov 11. [Epub ahead of print] |
|
|
|
|
1217. | Combination Therapy With Sorafenib and Radiofrequency Ablation for BCLC Stage 0-B1 Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study |
|
Feng X1, Xu R2, Du X3, Dou K4, Qin X5, Xu J6, Jia W7, Wang Z8, Zhao H9, Yang S10, Guo C11, Liu T12, Ma K1. Am J Gastroenterol. 2014 Nov 18. doi: 10.1038/ajg.2014.343. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1224. | Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study |
|
Curry MP1, Forns X2, Chung RT3, Terrault NA4, Brown R Jr5, Fenkel JM6, Gordon F7, O'Leary J8, Kuo A9, Schiano T10, Everson G11, Schiff E12, Befeler A13, Gane E14, Saab S15, McHutchison JG16, Subramanian GM16, Symonds WT16, Denning J16, McNair L16, Arterburn S16, Svarovskaia E16, Moonka D17, Afdhal N18. Gastroenterology. 2014 Sep 24. pii: S0016-5085(14)01145-7. doi: 10.1053/j.gastro.2014.09.023. [Epub ahead of print] |
|
|
|
|
1226. | Hepatic resection is safe and effective for patients with hepatocellular carcinoma and portal hypertension |
|
Zhong JH1, Li H2, Xiao N3, Ye XP4, Ke Y1, Wang YY1, Ma L1, Chen J1, You XM1, Zhang ZY1, Lu SD1, Li LQ1. PLoS One. 2014 Sep 30;9(9):e108755. doi: 10.1371/journal.pone.0108755. eCollection 2014. |
|
|
|
|
|
|
1229. | Prognosis prediction and staging |
|
Forner A1, Díaz-González A2, Liccioni A2, Vilana R3. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):855-865. doi: 10.1016/j.bpg.2014.08.002. Epub 2014 Aug 23. |
|
|
|
|
|
|
1232. | Comparison of standard-dose and half?dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis |
|
Nishikawa H1, Osaki Y1, Endo M1, Takeda H1, Tsuchiya K2, Joko K3, Ogawa C4, Taniguchi H5, Orito E6, Uchida Y7, Izumi N2. Int J Oncol. 2014 Sep 16. doi: 10.3892/ijo.2014.2654. [Epub ahead of print] |
|
|
|
|
|
|
1235. | Radiofrequency Ablation versus Laser Ablation for the Treatment of Small Hepatocellular Carcinoma in Cirrhosis: a Randomized Trial |
|
Di Costanzo GG1, Tortora R, D Adamo G, De Luca M, Lampasi F, Addario L, Galeota Lanza A, Picciotto FP, Tartaglione MT, Cordone G, Imparato M, Mattera S, Pacella CM. J Gastroenterol Hepatol. 2014 Sep 24. doi: 10.1111/jgh.12791. [Epub ahead of print] |
|
|
1236. | Hepatocellular carcinoma epidemiology |
|
Bosetti C1, Turati F2, La Vecchia C3. Best Pract Res Clin Gastroenterol. 2014 Oct;28(5):753-770. doi: 10.1016/j.bpg.2014.08.007. Epub 2014 Aug 23. |
|
|
|
|
1238. | Randomized Trial of [131I] Metuximab in Treatment of Hepatocellular Carcinoma After Percutaneous Radiofrequency Ablation |
|
Bian H1, Zheng JS1, Nan G1, Li R1, Chen C1, Hu CX1, Zhang Y1, Sun B1, Wang XL1, Cui SC1, Wu J1, Xu J1, Wei D1, Zhang X1, Liu H1, Yang W1, Ding Y1, Li J1, Chen ZN2. J Natl Cancer Inst. 2014 Sep 10;106(9). pii: dju239. doi: 10.1093/jnci/dju239. Print 2014 Aug. |
|
|
|
|
|
|
|
|
1242. | Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population: Multi-centre, prospective cohort study |
|
Bamia C1, Lagiou P, Jenab M, Trichopoulou A, Fedirko V, Aleksandrova K, Pischon T, Overvad K, Olsen A, Tjønneland A, Boutron-Ruault MC, Fagherazzi G, Racine A, Kuhn T, Boeing H, Floegel A, Benetou V, Palli D, Grioni S, Panico S, Tumino R, Vineis P, Bueno-De-Mesquita HB, Dik VK, Bhoo-Pathy N, Uiterwaal CS, Weiderpass E, Lund E, Quirós JR, Zamora-Ros R, Molina-Montes E, Chirlaque MD, Ardanaz E, Dorronsoro M, Lindkvist B, Wallström P, Nilsson LM, Sund M, Khaw KT, Wareham N, Bradbury KE, Travis RC, Ferrari P, Duarte-Salles T, Stepien M, Gunter M, Murphy N, Riboli E, Trichopoulos D. Int J Cancer. 2014 Sep 15. doi: 10.1002/ijc.29214. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1248. | The C-Reactive Protein/Albumin Ratio, a Novel Inflammation-Based Prognostic Score, Predicts Outcomes in Patients with Hepatocellular Carcinoma |
|
Kinoshita A1, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M. Ann Surg Oncol. 2014 Sep 5. [Epub ahead of print] |
|
|
1249. | The Effect of a Regional Hepatopancreaticobiliary Surgical Program on Clinical Volume, Quality of Cancer Care, and Outcomes in the Veterans Affairs System |
|
Lau K1, Salami A1, Barden G2, Khawja S1, Castillo DL1, Poppelaars V3, Artinyan A4, Awad SS5, Berger DH5, Albo D6, Anaya DA5. JAMA Surg. 2014 Sep 10. doi: 10.1001/jamasurg.2014.1711. [Epub ahead of print] |
|
|
|
|
1251. | Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey |
|
Santini D1, Pantano F1, Riccardi F2, Di Costanzo GG3, Addeo R4, Guida FM1, Ceruso MS1, Barni S5, Bertocchi P6, Marinelli S7, Marchetti P8, Russo A9, Scartozzi M10, Faloppi L10, Santoni M10, Cascinu S10, Maiello E11, Silvestris F12, Tucci M12, Ibrahim T13, Masi G14, Gnoni A15, Comandone A16, Fazio N17, Conti A18, Imarisio I19, Pisconti S20, Giommoni E21, Cinieri S22, Catalano V23, Palmieri VO24, Infante G25, Aieta M26, Trogu A27, Gadaleta CD28, Brunetti AE29, Lorusso V29, Silvestris N29. PLoS One. 2014 Aug 29;9(8):e105268. doi: 10.1371/journal.pone.0105268. eCollection 2014. |
|
|
|
|
1253. | Serum autoantibody measurement for the detection of hepatocellular carcinoma |
|
Middleton CH1, Irving W2, Robertson JF1, Murray A3, Parsy-Kowalska CB3, Macdonald IK3, McElveen J3, Allen J3, Healey GF3, Thomson BJ2, Ryder SJ2, Holdenrieder S4, Chapman CJ1. PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1265. | Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma |
|
Tsuchiya K, Asahina Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Kurosaki M, Enomoto N, Izumi N. Liver Transpl. 2014 Mar;20(3):291-7. |
|
|
|
|
|
|
1268. | Adjuvant Intraarterial Lipiodol or 131I-Lipiodol After Curative Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial |
|
Dumortier J1, Decullier E, Hilleret MN, Bin-Dorel S, Valette PJ, Boillot O, Partensky C, Letoublon C, Ducerf C, Leroy V, Vuillez JP, Borson-Chazot F. J Nucl Med. 2014 Apr 10. [Epub ahead of print] |
|
|
|
|
1270. | Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use |
|
Giannini EG1, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Gasbarrini A, Sacco R, Foschi FG, Missale G, Morisco F, Svegliati Baroni G, Virdone R, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) Group. Cancer. 2014 Apr 10. doi: 10.1002/cncr.28706. [Epub ahead of print] |
|
|
1271. | Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study |
|
Okita K1, Izumi N, Matsui O, Tanaka K, Kaneko S, Moriwaki H, Ikeda K, Osaki Y, Numata K, Nakachi K, Kokudo N, Imanaka K, Nishiguchi S, Okusaka T, Nishigaki Y, Shiomi S, Kudo M, Ido K, Karino Y, Hayashi N, Ohashi Y, Makuuchi M, Kumada H; Peretinoin Study Group. J Gastroenterol. 2014 Apr 13. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1278. | Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib |
|
Ronot M1, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S. Oncologist. 2014 Mar 20. [Epub ahead of print] |
|
|
|
|
1280. | Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients |
|
D'Amico G1, Pasta L, Morabito A, D'Amico M, Caltagirone M, Malizia G, Tinè F, Giannuoli G, Traina M, Vizzini G, Politi F, Luca A, Virdone R, Licata A, Pagliaro L. Aliment Pharmacol Ther. 2014 Mar 24. doi: 10.1111/apt.12721. [Epub ahead of print] |
|
|
|
|
1282. | Impact of pretreatment serum cholinesterase level in unresectable advanced hepatocellular carcinoma patients treated with sorafenib |
|
Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Hatamaru K, Henmi S, Saito S, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y. Mol Clin Oncol. 2013 Mar;1(2):241-248. Epub 2012 Dec 3. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1289. | Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson Experience |
|
Tsimberidou AM, Vaklavas C, Fu S, Wen S, Lim JA, Hong D, Wheler J, Naing A, Uehara C, Wallace M, Kurzrock R. Hepatogastroenterology. 2013 Oct;60(127):1611-23. |
|
|
|
|
|
|
1292. | Prognosis of Unresectable Hepatocellular Carcinoma: Comparison of Seven Staging Systems (TNM, Okuda, BCLC, CLIP, CUPI, JIS, CIS) in a Chinese Cohort |
|
Zhang JF1, Shu ZJ2, Xie CY3, Li Q4, Jin XH5, Gu W6, Jiang FJ1, Ling CQ6. PLoS One. 2014 Mar 7;9(3):e88182. doi: 10.1371/journal.pone.0088182. eCollection 2014. |
|
|
|
|
1294. | Dairy products and risk of hepatocellular carcinoma: The European Prospective Investigation into Cancer and Nutrition (EPIC) |
|
Duarte-Salles T1, Fedirko V, Stepien M, Trichopoulou A, Bamia C, Lagiou P, Lukanova A, Trepo E, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Racine A, Cadeau C, Kühn T, Aleksandrova K, Trichopoulos D, Tsiotas K, Boffetta P, Palli D, Pala V, Tumino R, Sacerdote C, Panico S, Bueno-de-Mesquita HB, Dik VK, Peeters PH, Weiderpass E, Gram IT, Hjartåker A, Quirós JR, Fonseca-Nunes A, Molina-Montes E, Dorronsoro M, Navarro Sanchez C, Barricarte A, Lindkvist B, Sonestedt E, Johansson I, Wennberg M, Khaw KT, Wareham N, Travis RC, Romieu I, Riboli E, Jenab M. Int J Cancer. 2014 Feb 26. doi: 10.1002/ijc.28812. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1301. | Repeatability of Diagnostic Features and Scoring Systems for Hepatocellular Carcinoma by Using MR Imaging |
|
Davenport MS1, Khalatbari S, Liu PS, Maturen KE, Kaza RK, Wasnik AP, Al-Hawary MM, Glazer DI, Stein EB, Patel J, Somashekar DK, Viglianti BL, Hussain HK. Radiology. 2014 Feb 18:131963. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1307. | Multimodality Therapy and Liver Transplantation for Hepatocellular Carcinoma: A 14-Year Prospective Analysis of Outcomes |
|
Ramanathan R, Sharma A, Lee DD, Behnke M, Bornstein K, Stravitz RT, Sydnor M, Fulcher A, Cotterell A, Posner MP, Fisher RA. Transplantation. 2014 Feb 5. [Epub ahead of print] |
|
|
1308. | Bland- versus Chemo-Embolization of Hepatocellular Carcinoma Prior to Transplantation |
|
Kluger K, Halazun K, Barroso R, Fox A, Olsen S, Madoff D, Siegel A, Weintraub J, Susman J, Brown R, Cherqui D, Emond J. Liver Transpl. 2014 Feb 3. doi: 10.1002/lt.23846. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1312. | Inflammatory and metabolic biomarkers and risk of liver and bilary tract cancer |
|
Aleksandrova K, Boeing H, Nöthlings U, Jenab M, Fedirko V, Kaaks R, Lukanova A, Trichopoulou A, Trichopoulos D, Boffetta P, Trepo E, Westhpal S, Duarte-Salles T, Stepien M, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Dossus L, Racine A, Lagiou P, Bamia C, Benetou V, Agnoli C, Palli D, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita B, Peeters PH, Gram IT, Lund E, Weiderpass E, Quirós JR, Agudo A, Sánchez MJ, Gavrila D, Barricarte A, Dorronsoro M, Ohlsson B, Lindkvist B, Johansson A, Sund M, Khaw KT, Wareham N, Travis RC, Riboli E, Pischon T. Hepatology. 2014 Jan 17. doi: 10.1002/hep.27016. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1318. | Triple positive tumor markers predict recurrence and survival in early stage hepatocellular carcinoma |
|
Nakagawa S, Beppu T, Okabe H, Sakamoto K, Kuroki H, Mima K, Nitta H, Imai K, Hayashi H, Sakamoto Y, Hashimoto D, Chikamoto A, Ishiko T, Watanabe M, Baba H. Hepatol Res. 2013 Nov 19. doi: 10.1111/hepr.12277. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1327. | Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors |
|
Inoue T, Hyodo T, Murakami T, Takayama Y, Nishie A, Higaki A, Korenaga K, Sakamoto A, Osaki Y, Aikata H, Chayama K, Suda T, Takano T, Miyoshi K, Koda M, Numata K, Tanaka H, Iijima H, Ochi H, Hirooka M, Imai Y, Kudo M. Dig Dis. 2013;31(5-6):472-9. doi: 10.1159/000355248. Epub 2013 Nov 21. |
|
|
|
|
1329. | Long-term outcome of elderly patients (75 years or older) with hepatocellular carcinoma |
|
Hori M, Tanaka M, Ando E, Sakata M, Simose S, Ohno M, Yutani S, Kuraoka K, Kuromatsu R, Sumie S, Sata M. Hepatol Res. 2013 Nov 21. doi: 10.1111/hepr.12279. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1335. | Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib |
|
Nagai H, Kanekawa T, Kobayashi K, Mukozu T, Matsui D, Matsui T, Kanayama M, Wakui N, Momiyama K, Shinohara M, Ishii K, Igarashi Y, Sumino Y. Cancer Chemother Pharmacol. 2013 Nov 13. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1342. | Mediterranean diet and hepatocellular carcinoma |
|
Turati F, Trichopoulos D, Polesel J, Bravi F, Rossi M, Talamini R, Franceschi S, Montella M, Trichopoulou A, La Vecchia C, Lagiou P. J Hepatol. 2013 Nov 14. pii: S0168-8278(13)00797-6. doi: 10.1016/j.jhep.2013.10.034. [Epub ahead of print] |
|
|
1343. | Long term results of liver transplantation for Wilson's disease: Experience in France |
|
Guillaud O1, Dumortier J2, Sobesky R3, Debray D4, Wolf P5, Vanlemmens C6, Durand F7, Calmus Y8, Duvoux C9, Dharancy S10, Kamar N11, Boudjema K12, Bernard PH13, Pageaux GP14, Salamé E15, Gugenheim J16, Lachaux A17, Habes D18, Radenne S19, Hardwigsen J20, Chazouillères O21, Trocello JM22, Woimant F22, Ichai P3, Branchereau S18, Soubrane O23, Castaing D3, Jacquemin E18, Samuel D3, Duclos-Vallée JC3. J Hepatol. 2013 Nov 6. pii: S0168-8278(13)00751-4. doi: 10.1016/j.jhep.2013.10.025. [Epub ahead of print] |
|
|
|
|
|
|
1346. | The Detection of Hepatocellular Carcinoma Using a Prospectively Developed and Validated Model Based on Serological Biomarkers |
|
Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, Morse J, Hull D, Patman G, Kagebayashi C, Hussain S, Graham J, Reeves H, Satomura S. Cancer Epidemiol Biomarkers Prev. 2013 Dec 26. [Epub ahead of print] |
|
|
|
|
1348. | Unresectable Hepatocellular Carcinoma: Randomized Controlled Trial of Transarterial Ethanol Ablation versus Transcatheter Arterial Chemoembolization |
|
Yu SC, Hui JW, Hui EP, Chan SL, Lee KF, Mo F, Wong J, Ma B, Lai P, Mok T, Yeo W. Radiology. 2013 Oct 14. [Epub ahead of print] |
|
|
|
|
|
|
1351. | Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B |
|
Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. J Hepatol. 2013 Oct 12. pii: S0168-8278(13)00695-8. doi: 10.1016/j.jhep.2013.09.029. [Epub ahead of print] |
|
|
1352. | Prediction of liver stiffness hepatocellular carcinoma in chronic hepatitis C patients on interferon-based anti-viral therapy |
|
Narita Y, Genda T, Tsuzura H, Sato S, Kanemitsu Y, Ishikawa S, Kikuchi T, Hirano K, Iijima K, Wada R, Ichida T. J Gastroenterol Hepatol. 2014 Jan;29(1):137-43. doi: 10.1111/jgh.12401. |
|
|
1353. | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials |
|
Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Int J Cancer. 2013 Oct 11. doi: 10.1002/ijc.28544. [Epub ahead of print] |
|
|
|
|
|
|
1356. | Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data |
|
Trépo E, Nahon P, Bontempi G, Valenti L, Falleti E, Nischalke HD, Hamza S, Corradini SG, Burza MA, Guyot E, Donati B, Spengler U, Hillon P, Toniutto P, Henrion J, Franchimont D, Devière J, Mathurin P, Moreno C, Romeo S, Deltenre P. Hepatology. 2013 Oct 1. doi: 10.1002/hep.26767. [Epub ahead of print] |
|
|
|
|
1358. | A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding |
|
Reverter E1, Tandon P2, Augustin S3, Turon F4, Casu S4, Bastiampillai R2, Keough A2, Llop E4, González A3, Seijo S4, Berzigotti A4, Ma M2, Genescà J5, Bosch J1, García-Pagán JC1, Abraldes JG6. Gastroenterology. 2013 Oct 19. pii: S0016-5085(13)01492-3. doi: 10.1053/j.gastro.2013.10.018. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1364. | Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis |
|
Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K, Kumada H. J Med Virol. 2014 Jan;86(1):131-8. doi: 10.1002/jmv.23790. Epub 2013 Oct 12. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1378. | Long-term survival outcomes for living donor liver transplant recipients with pathologically nonviable hepatocellular carcinoma |
|
Park HW, Hwang S, Ahn CS, Kim KH, Moon DB, Ha TY, Song GW, Jung DH, Park GC, Namgoong JM, Park CS, Park YH, Kang SH, Jung BH, Lee SG. Transplant Proc. 2013 Oct;45(8):3032-4. doi: 10.1016/j.transproceed.2013.08.027. |
|
|
1379. | Risk-based long-term screening for hepatocellular carcinoma recurrence after living donor liver transplantation |
|
Hwang S, Moon DB, Ahn CS, Kim KH, Ha TY, Song GW, Jung DH, Park GC, Lee HC, Lee YS, Chung YH, Abdulkarim BA, Lee SG. Transplant Proc. 2013 Oct;45(8):3076-84. doi: 10.1016/j.transproceed.2013.08.068. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1392. | Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B |
|
Wong GL, Chan HL, Wong CK, Leung C, Chan CY, Ho PP, Chung VC, Chan ZC, Tse YK, Chim AM, Lau TK, Wong VW. J Hepatol. 2013 Oct 12. pii: S0168-8278(13)00695-8. doi: 10.1016/j.jhep.2013.09.029. [Epub ahead of print] |
|
|
1393. | Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma |
|
Tsuchiya K, Asahina Y, Matsuda S, Muraoka M, Nakata T, Suzuki Y, Tamaki N, Yasui Y, Suzuki S, Hosokawa T, Nishimura T, Ueda K, Kuzuya T, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Izumi N. Cancer. 2013 Oct 7. doi: 10.1002/cncr.28384. [Epub ahead of print] |
|
|
1394. | A systematic review of sorafenib in Child-Pugh a patients with unresectable hepatocellular carcinoma |
|
Shen A, Tang C, Wang Y, Chen Y, Yan X, Zhang C, Liu R, Wei X, Zhu Y, Zhang H, Wu Z. J Clin Gastroenterol. 2013 Nov-Dec;47(10):871-80. doi: 10.1097/MCG.0b013e3182a87cfd. |
|
|
1395. | Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: A systematic review and meta-analysis of clinical trials |
|
Santoni M, Conti A, De Giorgi U, Iacovelli R, Pantano F, Burattini L, Muzzonigro G, Berardi R, Santini D, Cascinu S. Int J Cancer. 2013 Oct 11. doi: 10.1002/ijc.28544. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1399. | The Impact of PNPLA3 Polymorphisms on the Development of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Virus Infection |
|
Sato M, Kato N, Tateishi R, Muroyama R, Kowatari N, Li W, Goto K, Otsuka M, Shiina S, Yoshida H, Omata M, Koike K. Hepatol Res. 2013 Oct 11. doi: 10.1111/hepr.12258. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1405. | Long-term outcome of splenectomy in advanced cirrhotic patients with hepatocellular carcinoma and thrombocytopenia |
|
Ogata T, Okuda K, Sato T, Hirakawa Y, Yasunaga M, Horiuchi H, Nomura Y, Kage M, Ide T, Kuromatsu R, Kinoshita H, Tanaka H. Kurume Med J. 2013 Sep 20. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1419. | Absence of Viable HCC in the Native Liver Is an Independent Protective Factor of Tumor Recurrence After Liver Transplantation |
|
Montalti R, Mimmo A, Rompianesi G, Di Gregorio C, Serra V, Cautero N, Ballarin R, Spaggiari M, Tarantino G, D'Amico G, De Santis M, De Pietri L, Troisi RI, Gerunda GE, Di Benedetto F. Transplantation. 2013 Sep 19. [Epub ahead of print] |
|
|
|
|
1421. | Living-Donor Liver Transplantation Associated with Higher Incidence of Hepatocellular Carcinoma Recurrence Than Deceased-Donor Liver Transplantation |
|
Park MS, Lee KW, Suh SW, You T, Choi Y, Kim H, Hong G, Yi NJ, Kwon CH, Joh JW, Lee SK, Suh KS. Transplantation. 2013 Sep 19. [Epub ahead of print] |
|
|
1422. | Decreased expression of interleukin-36? correlates with poor prognosis in hepatocellular carcinoma |
|
Pan QZ, Pan K, Zhao JJ, Chen JG, Li JJ, Lv L, Wang DD, Zheng HX, Jiang SS, Zhang XF, Xia JC. Cancer Immunol Immunother. 2013 Nov;62(11):1675-85. doi: 10.1007/s00262-013-1471-1. Epub 2013 Sep 6. |
|
|
|
|
1424. | Downstaging Disease in Patients with Hepatocellular Carcinoma Outside of Milan Criteria: Strategies Using Drug-eluting Bead Chemoembolization |
|
Green TJ, Rochon PJ, Chang S, Ray CE Jr, Winston H, Ruef R, Kreidler SM, Glueck DH, Shulman BC, Brown AC, Durham J. J Vasc Interv Radiol. 2013 Nov;24(11):1613-22. doi: 10.1016/j.jvir.2013.07.024. Epub 2013 Sep 20. |
|
|
|
|
|
|
|
|
|
|
|
|
1430. | Systemic Cytotoxic Chemotherapy of Patients With Advanced Hepatocellular Carcinoma in the Era of Sorafenib Nonavailability |
|
Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS. J Clin Gastroenterol. 2013 Sep 16. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1434. | Characterization of Hepatocellular Carcinoma Related Genes and Metabolites in Human Nonalcoholic Fatty Liver Disease |
|
Clarke JD, Novak P, Lake AD, Shipkova P, Aranibar N, Robertson D, Severson PL, Reily MD, Futscher BW, Lehman-McKeeman LD, Cherrington NJ. Dig Dis Sci. 2013 Sep 19. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1439. | Trends in Epidemiology, Treatment, and Survival of Hepatocellular Carcinoma Patients Between 1998 and 2009: An Analysis of 1066 Cases of a German HCC Registry |
|
Weinmann A, Koch S, Niederle IM, Schulze-Bergkamen H, König J, Hoppe-Lotichius M, Hansen T, Pitton MB, Düber C, Otto G, Schuchmann M, Galle PR, Wörns MA. J Clin Gastroenterol. 2013 Sep 25. [Epub ahead of print] |
|
|
|
|
1441. | Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma |
|
Miyahara K, Nouso K, Morimoto Y, Takeuchi Y, Hagihara H, Kuwaki K, Onishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Honda M, Kaneko S, Sato T, Sato S, Obi S, Iwadou S, Kobayashi Y, Takaguchi K, Kariyama K, Takuma Y, Takabatake H, Yamamoto K; Okayama Liver Cancer Group. Br J Cancer. 2013 Oct 15;109(8):2072-8. doi: 10.1038/bjc.2013.554. Epub 2013 Sep 17. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1450. | Branched-chain Amino Acids Prevent Hepatocarcinogenesis and Prolong Survival of Patients With Cirrhosis |
|
Kawaguchi T, Shiraishi K, Ito T, Suzuki K, Koreeda C, Ohtake T, Iwasa M, Tokumoto Y, Endo R, Kawamura NH, Shiraki M, Habu D, Tsuruta S, Miwa Y, Kawaguchi A, Kakuma T, Sakai H, Kawada N, Hanai T, Takahashi SI, Kato A, Onji M, Takei Y, Kohgo Y, Seki T, Tamano M, Katayama K, Mine T, Sata M, Moriwaki H, Suzuki K. Clin Gastroenterol Hepatol. 2013 Sep 10. pii: S1542-3565(13)01312-8. doi: 10.1016/j.cgh.2013.08.050. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1461. | Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study |
|
Yin J, Li N, Han Y, Xue J, Deng Y, Shi J, Guo W, Zhang H, Wang H, Cheng S, Cao G. J Clin Oncol. 2013 Oct 10;31(29):3647-55. doi: 10.1200/JCO.2012.48.5896. Epub 2013 Sep 3. |
|
|
|
|
1463. | Targeted Therapies in Hepatocellular Carcinoma |
|
Bronte F, Bronte G, Cusenza S, Fiorentino E, Rolfo C, Cicero G, Bronte E, Di Marco V, Angarano G, Fontana T, Russo A. Curr Med Chem. 2013 Aug 23. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1482. | Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study |
|
Llovet JM, Decaens T, Raoul JL, Boucher E, Kudo M, Chang C, Kang YK, Assenat E, Lim HY, Boige V, Mathurin P, Fartoux L, Lin DY, Bruix J, Poon RT, Sherman M, Blanc JF, Finn RS, Tak WY, Chao Y, Ezzeddine R, Liu D, Walters I, Park JW. J Clin Oncol. 2013 Oct 1;31(28):3509-16. doi: 10.1200/JCO.2012.47.3009. Epub 2013 Aug 26. |
|
|
1483. | Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study |
|
Johnson PJ, Qin S, Park JW, Poon RT, Raoul JL, Philip PA, Hsu CH, Hu TH, Heo J, Xu J, Lu L, Chao Y, Boucher E, Han KH, Paik SW, Robles-Aviña J, Kudo M, Yan L, Sobhonslidsuk A, Komov D, Decaens T, Tak WY, Jeng LB, Liu D, Ezzeddine R, Walters I, Cheng AL. J Clin Oncol. 2013 Oct 1;31(28):3517-24. doi: 10.1200/JCO.2012.48.4410. Epub 2013 Aug 26. |
|
|
1484. | HCC-ART score, a simple, highly sensitive and specific test for early diagnosis of hepatocellular carcinoma: a large-scale, multicentre study |
|
Attallah AM, Omran MM, Attallah AA, Abdallah SO, Farid K, Darwish H, El-Dosoky I, Shaker YM. Br J Cancer. 2013 Sep 17;109(6):1657-65. doi: 10.1038/bjc.2013.481. Epub 2013 Aug 27. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1492. | Obesity promotes liver carcinogenesis via Mcl-1 stabilization independent of IL-6R? signaling |
|
Gruber S, Straub BK, Ackermann PJ, Wunderlich CM, Mauer J, Seeger JM, Büning H, Heukamp L, Kashkar H, Schirmacher P, Brüning JC, Wunderlich FT. Cell Rep. 2013 Aug 29;4(4):669-80. doi: 10.1016/j.celrep.2013.07.023. Epub 2013 Aug 15. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1501. | Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study |
|
Ripoll C, Genescà J, Araujo IK, Graupera I, Augustin S, Tejedor M, Cirera I, Aracil C, Sala M, Hernandez-Guerra M, Llop E, Escorsell A, Vega Catalina M, Cañete N, Albillos A, Villanueva C, Abraldes JG, Bañares R, Bosch J. Hepatology. 2013 Jul 31. doi: 10.1002/hep.26629. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1515. | The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients |
|
Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, Wang QJ, Huang LX, He J, Chen SP, Ke ML, Wu PH, Chen MS, Li SP, Xia JC, Zeng YX. Ann Surg Oncol. 2013 Jul 27. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1524. | A re-emerging marker for prognosis in hepatocellular carcinoma: the add-value of fishing c-myc gene for early relapse |
|
Pedica F, Ruzzenente A, Bagante F, Capelli P, Cataldo I, Pedron S, Iacono C, Chilosi M, Scarpa A, Brunelli M, Tomezzoli A, Martignoni G, Guglielmi A. PLoS One. 2013 Jul 10;8(7):e68203. doi: 10.1371/journal.pone.0068203. Print 2013. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1532. | Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C |
|
Asahina Y, Tsuchiya K, Nishimura T, Muraoka M, Suzuki Y, Tamaki N, Yasui Y, Hosokawa T, Ueda K, Nakanishi H, Itakura J, Takahashi Y, Kurosaki M, Enomoto N, Nakagawa M, Kakinuma S, Watanabe M, Izumi N. J Gastroenterol. 2013 Jul 17. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1537. | Spontaneous clearance of serum hepatitis C virus RNA during the clinical course of hepatocellular carcinoma in patients with chronic hepatitis C |
|
Minami T, Tateishi R, Shiina S, Fujiwara N, Mikami S, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Yoshida H, Koike K. Hepatol Res. 2013 Jul 11. doi: 10.1111/hepr.12203. [Epub ahead of print] |
|
|
|
|
|
|
1540. | Active treatments are a rational approach for hepatocellular carcinoma in elderly patients |
|
Suda T, Nagashima A, Takahashi S, Kanefuji T, Kamimura K, Tamura Y, Takamura M, Igarashi M, Kawai H, Yamagiwa S, Nomoto M, Aoyagi Y. World J Gastroenterol. 2013 Jun 28;19(24):3831-40. doi: 10.3748/wjg.v19.i24.3831. |
|
|
1541. | Bevacizumab with Erlotinib as First-line Therapy in Asian Patients with Advanced Hepatocellular Carcinoma: A Multicenter Phase II Study |
|
Hsu CH, Kang YK, Yang TS, Shun CT, Shao YY, Su WC, Sandoval-Tan J, Chiou TJ, Jin K, Hsu C, Cheng AL. Oncology. 2013;85(1):44-52. doi: 10.1159/000350841. Epub 2013 Jul 4. |
|
|
|
|
|
|
|
|
1545. | Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells |
|
Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N, Toriguchi K, Hatano E, Endo K, Hirooka Y, Shiota G. J Hepatol. 2013 Jul 2. pii: S0168-8278(13)00441-8. doi: 10.1016/j.jhep.2013.06.024. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1551. | Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma |
|
Lee SS, Jeong SH, Byoun YS, Chung SM, Seong MH, Sohn HR, Min BY, Jang ES, Kim JW, Park GJ, Lee YJ, Lee KH, Ahn S. BMC Cancer. 2013 Jul 8;13:335. doi: 10.1186/1471-2407-13-335. |
|
|
|
|
|
|
1554. | Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: The role of dynamic contrast enhanced ultrasound |
|
Zocco MA, Garcovich M, Lupascu A, Di Stasio E, Roccarina D, Annicchiarico BE, Riccardi L, Ainora ME, Ponziani F, Caracciolo G, Rapaccini GL, Landolfi R, Siciliano M, Pompili M, Gasbarrini A. J Hepatol. 2013 Jun 25. pii: S0168-8278(13)00427-3. doi: 10.1016/j.jhep.2013.06.011. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1563. | Prediagnostic plasma testosterone, sex hormone-binding globulin, IGF-I and hepatocellular carcinoma: Etiological factors or risk markers? |
|
Lukanova A, Becker S, Hüsing A, Schock H, Fedirko V, Trepo E, Trichopoulou A, Bamia C, Lagiou P, Benetou V, Trichopoulos D, Nöthlings U, Tjønneland A, Overvad K, Dossus L, Teucher B, Boeing H, Aleksandrova K, Palli D, Pala V, Panico S, Tumino R, Ricceri F, Bueno-de-Mesquita HB, Siersema PD, Peeters PH, Quiros JR, Duell EJ, Molina-Montes E, Chirlaque MD, Gurrea AB, Dorronsoro M, Lindkvist B, Johansen D, Werner M, Sund M, Khaw KT, Wareham N, Key TJ, Travis RC, Rinaldi S, Romieu I, Gunter MJ, Riboli E, Jenab M, Kaaks R. Int J Cancer. 2013 Jun 25. doi: 10.1002/ijc.28342. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1571. | Prediction of Disease-free Survival in Hepatocellular Carcinoma by Gene Expression Profiling |
|
Lim HY, Sohn I, Deng S, Lee J, Jung SH, Mao M, Xu J, Wang K, Shi S, Joh JW, Choi YL, Park CK. Ann Surg Oncol. 2013 Jun 26. [Epub ahead of print] |
|
|
|
|
1573. | Occupational Exposure to Hepatitis C Virus: Early T-Cell Responses in the Absence of Seroconversion in a Longitudinal Cohort Study |
|
Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Herrine SK, Stevens M, Schmitt J, Rehermann B. |
|
|
|
|
1575. | Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization |
|
Ikeda M, Mitsunaga S, Shimizu S, Ohno I, Takahashi H, Okuyama H, Kuwahara A, Kondo S, Morizane C, Ueno H, Satake M, Arai Y, Okusaka T. J Gastroenterol. 2013 Jun 23. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1581. | Genetic Polymorphisms in DNA Repair Genes XRCC4 and XRCC5 and Aflatoxin B1-related Hepatocellular Carcinoma |
|
Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, Wei ZH, Liu M, Zeng LX, Mo XQ, Zhang JJ, Xue F, Zhai B, Xia Q. Epidemiology. 2013 Sep;24(5):671-81. doi: 10.1097/EDE.0b013e31829d2744. |
|
|
1582. | Genetic Polymorphisms in DNA Repair Genes XRCC4 and XRCC5 and Aflatoxin B1-related Hepatocellular Carcinoma |
|
Long XD, Zhao D, Wang C, Huang XY, Yao JG, Ma Y, Wei ZH, Liu M, Zeng LX, Mo XQ, Zhang JJ, Xue F, Zhai B, Xia Q. Epidemiology. 2013 Sep;24(5):671-81. doi: 10.1097/EDE.0b013e31829d2744. |
|
|
|
|
|
|
1585. | Consensus report of the Fifth International Forum for Liver MRI |
|
Zech CJ, Bartolozzi C, Bioulac-Sage P, Chow PK, Forner A, Grazioli L, Huppertz A, Laumonier H, Min Lee J, Murakami T, Ricke J, Sirlin CB. AJR Am J Roentgenol. 2013 Jul;201(1):97-107. doi: 10.2214/AJR.12.9491. |
|
|
|
|
1587. | Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis |
|
Nault JC, Guyot E, Laguillier C, Chevret S, Ganne-Carrie N, N'kontchou G, Beaugrand M, Seror O, Trinchet JC, Coelho J, Lasalle P, Charnaux N, Delehedde M, Sutton A, Nahon P. Cancer Epidemiol Biomarkers Prev. 2013 Aug;22(8):1343-1352. Epub 2013 Jun 18. |
|
|
|
|
1589. | Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma |
|
Lu L, Sun HC, Zhang W, Chai ZT, Zhu XD, Kong LQ, Wang WQ, Zhang KZ, Zhang YY, Zhang QB, Ao JY, Li JQ, Wang L, Wu WZ, Tang ZY. PLoS One. 2013 May 31;8(5):e65023. doi: 10.1371/journal.pone.0065023. Print 2013. |
|
|
|
|
|
|
1592. | Recurrence after Liver Transplantation for Hepatocellular Carcinoma According to Up-to-Seven Criteria |
|
Gugenheim J, Bredt LC, Iannelli A, Decaens T, Roudot-Thoraval F, Meyer C, Durand F, Bernard PH, Boillot O, Sulpice L, Calmus Y, Hardwigsen J, Ducerf C, Pageaux GP, Dharancy S, Chazouilleres O, Cherqui D, Duvoux C, Hadni-Bresson S. Hepatogastroenterology. 2013 Jun 6;60(126):799-806. doi: 10.5754/hge12997. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1608. | Methylation of the HACE1 Gene is Frequently Detected in Hepatocellular Carcinoma |
|
Sakata M, Yokomizo K, Kitamura Y, Sakuraba K, Shirahata A, Goto T, Mizukami H, Saito M, Ishibashi K, Kigawa G, Nemoto H, Hibi K. Hepatogastroenterology. 2013 Jun 3;60(124):781-3. doi: 10.5754/hge10439. |
|
|
|
|
1610. | High-intensity focused ultrasound ablation assisted using color Doppler imaging for the treatment of hepatocellular carcinomas |
|
Fukuda H, Numata K, Nozaki A, Kondo M, Morimoto M, Maeda S, Tanaka K, Ohto M, Ito R, Ishibashi Y, Oshima N, Ito A, Zhu H, Wang ZB. Abdom Imaging. 2013 Jun 2. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1618. | Diabetes mellitus, insulin treatment, diabetes duration, and risk of biliary tract cancer and hepatocellular carcinoma in a European cohort |
|
Schlesinger S, Aleksandrova K, Pischon T, Jenab M, Fedirko V, Trepo E, Overvad K, Roswall N, Tjønneland A, Boutron-Ruault MC, Fagherazzi G, Racine A, Kaaks R, Grote VA, Boeing H, Trichopoulou A, Pantzalis M, Kritikou M, Mattiello A, Sieri S, Sacerdote C, Palli D, Tumino R, Peeters PH, Bueno-de-Mesquita HB, Weiderpass E, Quirós JR, Zamora-Ros R, Sánchez MJ, Arriola L, Ardanaz E, Tormo MJ, Nilsson P, Lindkvist B, Sund M, Rolandsson O, Khaw KT, Wareham N, Travis RC, Riboli E, Nöthlings U. Ann Oncol. 2013 May 29. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1629. | Assessment of treatment response in hepatocellular carcinoma: a review of the literature |
|
Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Future Oncol. 2013 Jun;9(6):845-54. doi: 10.2217/fon.13.33. |
|
|
|
|
|
|
1632. | Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma |
|
Zhu WW, Guo JJ, Guo L, Jia HL, Zhu M, Zhang JB, Loffredo CA, Forgues M, Huang H, Xing XJ, Ren N, Dong QZ, Zhou HJ, Ren ZG, Zhao NQ, Wang XW, Tang ZY, Qin LX, Ye QH. Clin Cancer Res. 2013 Jun 26. [Epub ahead of print] |
|
|
|
|
|
|
1635. | New malignant grading system for hepatocellular carcinoma using the Sonazoid contrast agent for ultrasonography |
|
Tanaka H, Iijima H, Higashiura A, Yoh K, Ishii A, Takashima T, Sakai Y, Aizawa N, Iwata K, Ikeda N, Iwata Y, Enomoto H, Saito M, Imanishi H, Hirota S, Fujimoto J, Nishiguchi S. J Gastroenterol. 2013 May 30. [Epub ahead of print] |
|
|
|
|
1637. | Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients |
|
Huang ZM, Li W, Li S, Gao F, Zhou QM, Wu FM, He N, Pan CC, Xia JC, Wu PH, Zhao M. J Immunother. 2013 Jun;36(5):287-93. doi: 10.1097/CJI.0b013e3182948452. |
|
|
|
|
|
|
1640. | IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction |
|
Bibert S, Roger T, Calandra T, Bochud M, Cerny A, Semmo N, Duong FH, Gerlach T, Malinverni R, Moradpour D, Negro F, Müllhaupt B, Bochud PY; Swiss Hepatitis C Cohort Study. J Exp Med. 2013 Jun 3;210(6):1109-16. doi: 10.1084/jem.20130012. Epub 2013 May 27. |
|
|
|
|
1642. | Comparison of the survival and tolerability of radioembolization in elderly versus younger patients with unresectable hepatocellular carcinoma |
|
Golfieri R, Bilbao JI, Carpanese L, Cianni R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Cappelli A, Rodriguez M, Ettorre GM, Saltarelli A, Geatti O, Ahmadzadehfar H, Haug AR, Izzo F, Giampalma E, Sangro B, Pizzi G, Notarianni E, Vit A, Wilhelm K, Jakobs TF, Lastoria S; on behalf of the European Network on Radioembolization with Yttrium-90 Microspheres (ENRY) study collaborators. J Hepatol. 2013 May 23. pii: S0168-8278(13)00356-5. doi: 10.1016/j.jhep.2013.05.025. [Epub ahead of print |
|
|
|
|
|
|
1645. | Branched-chain amino acids suppress the cumulative recurrence of hepatocellular carcinoma under conditions of insulin-resistance |
|
Yoshiji H, Noguchi R, Namisaki T, Moriya K, Kitade M, Aihara Y, Douhara A, Yamao J, Fujimoto M, Toyohara M, Mitoro A, Sawai M, Yoshida M, Morioka C, Uejima M, Uemura M, Fukui H. Oncol Rep. 2013 Aug;30(2):545-52. doi: 10.3892/or.2013.2497. Epub 2013 May 27. |
|
|
|
|
1647. | Randomized multicenter trial comparing tacrolimus plus mycophenolate mofetil with tacrolimus plus steroids among HCV-positive recipients of living donor liver transplantation |
|
Takada Y, Kaido T, Asonuma K, Sakurai H, Kubo S, Kiuchi T, Inomata Y, Isaji S, Tsumura H, Teramukai S, Matsubara Y, Sakabayashi S, Uemoto S. Liver Transpl. 2013 May 21. doi: 10.1002/lt.23679. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1651. | Pathological Diagnosis of Hepatocellular Cellular Adenoma according to the Clinical Context |
|
Bioulac-Sage P, Sempoux C, Possenti L, Frulio N, Laumonier H, Laurent C, Chiche L, Frédéric Blanc J, Saric J, Trillaud H, Le Bail B, Balabaud C. Int J Hepatol. 2013;2013:253261. doi: 10.1155/2013/253261. Epub 2013 Apr 18. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1663. | Consumption of fish and meats and risk of hepatocellular carcinoma: the European Prospective Investigation into Cancer and Nutrition (EPIC) |
|
Fedirko V, Trichopolou A, Bamia C, Duarte-Salles T, Trepo E, Aleksandrova K, Nöthlings U, Lukanova A, Lagiou P, Boffetta P, Trichopoulos D, Katzke VA, Overvad K, Tjønneland A, Hansen L, Boutron-Ruault MC, Fagherazzi G, Bastide N, Panico S, Grioni S, Vineis P, Palli D, Tumino R, Bueno-de-Mesquita HB, Peeters PH, Skeie G, Engeset D, Parr CL, Jakszyn P, Sánchez MJ, Barricarte A, Amiano P, Chirlaque M, Quirós JR, Sund M, Werner M, Sonestedt E, Ericson U, Key TJ, Khaw KT, Ferrari P, Romieu I, Riboli E, Jenab M. Ann Oncol. 2013 May 12. [Epub ahead of print] |
|
|
|
|
1665. | Expression of apoptosis- and vitamin d pathway-related genes in hepatocellular carcinoma |
|
Fingas CD, Altinbas A, Schlattjan M, Beilfuss A, Sowa JP, Sydor S, Bechmann LP, Ertle J, Akkiz H, Herzer K, Paul A, Gerken G, Baba HA, Canbay A. Digestion. 2013;87(3):176-81. doi: 10.1159/000348441. Epub 2013 Apr 27. |
|
|
|
|
|
|
1668. | Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma - benchmark for a prospective multi-institutional study |
|
Eriguchi T, Takeda A, Oku Y, Ishikura S, Kimura T, Ozawa S, Nakashima T, Matsuo Y, Nakamura M, Matsumoto Y, Yamazaki S, Sanuki N, Ito Y. Radiat Oncol. 2013 May 4;8:113. doi: 10.1186/1748-717X-8-113. |
|
|
|
|
1670. | Promoter polymorphisms of pri-miR-34b/c are associated with hepatocellular carcinoma |
|
Son MS, Jang MJ, Jeon YJ, Kim WH, Kwon CI, Ko KH, Park PW, Hong SP, Rim KS, Kwon SW, Hwang SG, Kim NK. Gene. 2013 Jul 25;524(2):156-60. doi: 10.1016/j.gene.2013.04.042. Epub 2013 Apr 28. |
|
|
|
|
1672. | Genetic Polymorphism of the Kinesin-Like Protein KIF1B Gene and the Risk of Hepatocellular Carcinoma |
|
Wang ZC, Gao Q, Shi JY, Yang LX, Zhou J, Wang XY, Shi YH, Ke AW, Shi GM, Ding ZB, Dai Z, Qiu SJ, Fan J. PLoS One. 2013 Apr 25;8(4):e62571. doi: 10.1371/journal.pone.0062571. Print 2013. |
|
|
|
|
|
|
1675. | CT With Hepatic Arterioportography as a Pretreatment Examination for Hepatocellular Carcinoma Patients: A Randomized Controlled Trial |
|
Ohki T, Tateishi R, Akahane M, Mikami S, Sato M, Uchino K, Arano T, Enooku K, Kondo Y, Yamashiki N, Goto T, Shiina S, Yoshida H, Matsuyama Y, Omata M, Ohtomo K, Koike K. Am J Gastroenterol. 2013 Apr 30. doi: 10.1038/ajg.2013.109. [Epub ahead of print] |
|
|
1676. | Clinical significance of cell cycle inhibitors in hepatocellular carcinoma |
|
Matsuda Y, Wakai T, Kubota M, Takamura M, Yamagiwa S, Aoyagi Y, Osawa M, Fujimaki S, Sanpei A, Genda T, Ichida T. Med Mol Morphol. 2013 May 3. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1680. | Diagnosis of hepatocellular carcinoma in cirrhotic patients: a proof-of-concept study using serum micro-Raman spectroscopy |
|
Taleb I, Thiéfin G, Gobinet C, Untereiner V, Bernard-Chabert B, Heurgué A, Truntzer C, Hillon P, Manfait M, Ducoroy P, Sockalingum GD. Analyst. 2013 Apr 22. [Epub ahead of print] |
|
|
|
|
|
|
1683. | Post-therapeutic needle biopsy in patients with hepatocellular carcinoma is a useful tool to evaluate response to proton irradiation |
|
Saito Y, Matsuzaki Y, Honda A, Iwamoto J, Ikegami T, Chiba T, Sugahara S, Okumura T, Tsujii H, Doy M, Tokuuye K. Hepatol Res. 2013 Apr 15. doi: 10.1111/hepr.12133. [Epub ahead of print] |
|
|
1684. | Treatment of hepatocellular carcinoma: present and future |
|
Genco C, Cabibbo G, Maida M, Brancatelli G, Galia M, Alessi N, Butera G, Genova C, Romano P, Raineri M, Giarratano A, Midiri M, Cammà C. Expert Rev Anticancer Ther. 2013 Apr;13(4):469-79. doi: 10.1586/era.13.21. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1691. | Inflammation in background cirrhosis evokes malignant progression in HCC development from HCV-associated liver cirrhosis |
|
Tarao K, Ohkawa S, Miyagi Y, Morinaga S, Ohshige K, Yamamoto N, Ueno M, Kobayashi S, Kameda R, Tamai S, Nakamura Y, Miyakawa K, Kameda Y, Okudaira M. Scand J Gastroenterol. 2013 Apr 5. [Epub ahead of print] |
|
|
1692. | Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma |
|
Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL, Chen J. Hepatobiliary Pancreat Dis Int. 2013 Apr;12(2):171-9. |
|
|
|
|
1694. | Long-Term Outcomes Comparing Surgery to Embolization-Ablation for Treatment of Solitary HCC <7 cm |
|
Elnekave E, Erinjeri JP, Brown KT, Thornton RH, Petre EN, Maybody M, Maluccio MA, Hsu M, Sofocleous CT, Getrajdman GI, Brody LA, Solomon SB, Alago W, Fong Y, Jarnagin WR, Covey AM. Ann Surg Oncol. 2013 Apr 7. [Epub ahead of print] |
|
|
1695. | Expression and prognostic value of VEGFR-2, PDGFR-?, and c-Met in advanced hepatocellular carcinoma |
|
Chu JS, Ge FJ, Zhang B, Wang Y, Silvestris N, Liu LJ, Zhao CH, Lin L, Brunetti AE, Fu YL, Wang J, Paradiso A, Xu JM. J Exp Clin Cancer Res. 2013 Apr 3;32:16. doi: 10.1186/1756-9966-32-16. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1703. | The Clinical Significance of the CD163+ and CD68+ Macrophages in Patients with Hepatocellular Carcinoma |
|
Kong LQ, Zhu XD, Xu HX, Zhang JB, Lu L, Wang WQ, Zhang QB, Wu WZ, Wang L, Fan J, Tang ZY, Sun HC. PLoS One. 2013;8(3):e59771. doi: 10.1371/journal.pone.0059771. Epub 2013 Mar 29. |
|
|
|
|
|
|
|
|
1707. | Endogenous retrotransposition activates oncogenic pathways in hepatocellular carcinoma |
|
Shukla R, Upton KR, Muñoz-Lopez M, Gerhardt DJ, Fisher ME, Nguyen T, Brennan PM, Baillie JK, Collino A, Ghisletti S, Sinha S, Iannelli F, Radaelli E, Dos Santos A, Rapoud D, Guettier C, Samuel D, Natoli G, Carninci P, Ciccarelli FD, Garcia-Perez JL, Faivre J, Faulkner GJ. Cell. 2013 Mar 28;153(1):101-11. doi: 10.1016/j.cell.2013.02.032. |
|
|
|
|
|
|
1710. | Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients |
|
Li SL, Su M, Peng T, Xiao KY, Shang LM, Xu BH, Su ZX, Ye XP, Peng N, Qin QL, Chen DF, Chen J, Li LQ. Asian Pac J Cancer Prev. 2013;14(1):217-23. |
|
|
|
|
|
|
1713. | Mitochondrial metabolism in the noncancerous liver determine the occurrence of hepatocellular carcinoma: a prospective study |
|
Kudo A, Mogushi K, Takayama T, Matsumura S, Ban D, Irie T, Ochiai T, Nakamura N, Tanaka H, Anzai N, Sakamoto M, Tanaka S, Arii S. J Gastroenterol. 2013 Mar 30. [Epub ahead of print] |
|
|
1714. | Influence of percutaneous local therapy for hepatocellular carcinoma on gastric function |
|
Kobayashi M, Kinekawa F, Matsuda K, Fujihara S, Nishiyama N, Nomura T, Tani J, Miyoshi H, Kobara H, Deguchi A, Yoneyama H, Mori H, Masaki T. World J Gastroenterol. 2013 Mar 14;19(10):1618-24. doi: 10.3748/wjg.v19.i10.1618. |
|
|
|
|
|
|
|
|
1718. | A novel panel of biomarkers in distinction of small well-differentiated HCC from dysplastic nodules and outcome values |
|
Jin GZ, Dong H, Yu WL, Li Y, Lu XY, Yu H, Xian ZH, Dong W, Liu YK, Cong WM, Wu MC. BMC Cancer. 2013 Mar 27;13:161. doi: 10.1186/1471-2407-13-161. |
|
|
|
|
|
|
|
|
1722. | Transarterial embolization as neo-adjuvant therapy pretransplantation in patients with hepatocellular carcinoma |
|
Tsochatzis E, Garcovich M, Marelli L, Papastergiou V, Fatourou E, Rodriguez-Peralvarez ML, Germani G, Davies N, Yu D, Luong TV, Dhillon AP, Thorburn D, Patch D, O'Beirne J, Meyer T, Burroughs AK. Liver Int. 2013 Feb 20. doi: 10.1111/liv.12144. [Epub ahead of print] |
|
|
|
|
|
|
1725. | Inflammation induced hepatocellular carcinoma is dependent on CCR5 |
|
Barashi N, Weiss ID, Wald O, Wald H, Beider K, Abraham M, Klein S, Goldenberg D, Axelrod J, Pikarsky E, Abramovitch R, Zeira E, Galun E, Peled A. Hepatology. 2013 Mar 21. doi: 10.1002/hep.26403. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1731. | Prospective Study of Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: An Asian Cooperative Study between Japan and Korea |
|
Ikeda M, Arai Y, Park SJ, Takeuchi Y, Anai H, Kim JK, Inaba Y, Aramaki T, Kwon SH, Yamamoto S, Okusaka T; Japan Interventional Radiology in Oncology Study Group (JIVROSG), and Korea Interventional Radiology in Oncology Study Group (KIVROSG). J Vasc Interv Radiol. 2013 Apr;24(4):490-500. doi: 10.1016/j.jvir.2013.01.003. Epub 2013 Mar 7. |
|
|
|
|
1733. | Adjuvant Hepatic Intra-arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma: A Prospective Randomized Trial |
|
Chung AY, Ooi LL, Machin D, Tan SB, Goh BK, Wong JS, Chen YM, Li PC, Gandhi M, Thng CH, Yu SW, Tan BS, Lo RH, Htoo AM, Tay KH, Sundram FX, Goh AS, Chew SP, Liau KH, Chow PK, Tay KH, Tan YM, Cheow PC, Ho CK, Soo KC. World J Surg. 2013 Mar 6. [Epub ahead of print] |
|
|
|
|
|
|
1736. | A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C |
|
Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, Lasarte JJ, Pérez-Gracia JL, Melero I, Prieto J Hepatol. 2013 Mar 4. pii: S0168-8278(13)00144-X. doi: 10.1016/j.jhep.2013.02.022. [Epub ahead of print] |
|
|
|
|
|
|
1739. | Evaluation of the Clinical Features of HCC following Hepatectomy for Different Stages of HCC |
|
Ma C, Chi M, Su H, Cheng X, Chen L, Kan Y, Wei W, Huang X, Li Y, Li L, Lin K, Huang Y, Wu Y, Huang X, Huang A, Liu J. Hepatogastroenterology. 2012 Oct;59(119):2104-11. doi: 10.5754/hge12109. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1746. | Role of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic Acid-enhanced magnetic resonance imaging in the management of hepatocellular carcinoma: consensus at the symposium of the 48th annual meeting of the liver cancer study group of Japan |
|
Kudo M, Matsui O, Sakamoto M, Kitao A, Kim T, Ariizumi S, Ichikawa T, Kobayashi S, Imai Y, Izumi N, Fujinaga Y, Arii S. Oncology. 2013;84 Suppl 1:21-7. doi: 10.1159/000345885. Epub 2013 Feb 20. |
|
|
1747. | Prognotic impact of serum follistatin in patients with hepatocellular carcinoma |
|
Tomoda T, Nouso K, Miyahara K, Kobayashi S, Kinugasa H, Toyosawa J, Hagihara H, Kuwaki K, Onishi H, Nakamura S, Ikeda F, Miyake Y, Shiraha H, Takaki A, Yamamoto K. J Gastroenterol Hepatol. 2013 Feb 22. doi: 10.1111/jgh.12167. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1753. | Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells |
|
Sprinzl MF, Reisinger F, Puschnik A, Ringelhan M, Ackermann K, Hartmann D, Schiemann M, Weinmann A, Galle PR, Schuchmann M, Friess H, Otto G, Heikenwalder M, Protzer U. Hepatology. 2013 Feb 19. doi: 10.1002/hep.26328. [Epub ahead of print] |
|
|
|
|
1755. | A Snapshot of the Effective Indications and Results of Surgery for Hepatocellular Carcinoma in Tertiary Referral Centers: Is It Adherent to the EASL & AASLD Recommendations?: An Observational Study of the HCC East-West Study Group |
|
Torzilli G, Belghiti J, Kokudo N, Takayama T, Capussotti L, Nuzzo G, Vauthey JN, Choti MA, De Santibanes E, Donadon M, Morenghi E, Makuuchi M. Ann Surg. 2013 Feb 19. [Epub ahead of print] |
|
|
|
|
1757. | Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis |
|
Wong GL, Chan HL, Mak CH, Lee SK, Ip ZM, Lam AT, Iu HW, Leung JM, Lai JW, Lo AO, Chan HY, Wong VW. Hepatology. 2013 Feb 6. doi: 10.1002/hep.26301. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1763. | Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies. |
|
El-Gazzaz G, Sourianarayanane A, Menon KN, Sanabria J, Hashimoto K, Quintini C, Kelly D, Eghtesad B, Miller C, Fung J, Aucejo F. Hepatobiliary Pancreat Dis Int. 2013 Feb;12(1):34-41. |
|
|
|
|
|
|
|
|
|
|
1768. | Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study |
|
Borzio M, Fornari F, De Sio I, Andriulli A, Terracciano F, Parisi G, Francica G, Salvagnini M, Marignani M, Salmi A, Farinati F, Carella A, Pedicino C, Dionigi E, Fanigliulo L, Cazzaniga M, Ginanni B, Sacco R. Future Oncol. 2013 Feb;9(2):283-94. doi: 10.2217/fon.12.183. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1783. | Integrated Metabolite and Gene Expression Profiles Identify Lipid Biomarkers Associated with Progression of Hepatocellular Carcinoma and Patient Outcomes |
|
Budhu A, Roessler S, Zhao X, Yu Z, Forgues M, Ji J, Karoly E, Qin LX, Ye QH, Jia HL, Fan J, Sun HC, Tang ZY, Wang XW. Gastroenterology. 2013 Jan 31. pii: S0016-5085(13)00150-9. doi: 10.1053/j.gastro.2013.01.054. [Epub ahead of print] |
|
|
1784. | The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma |
|
Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, Fushiya N, Koike K, Nishino H, Matsushima M, Saeki C, Tajiri H. BMC Cancer. 2013 Feb 2;13:52. doi: 10.1186/1471-2407-13-52. |
|
|
|
|
1786. | Liver resection and transplantation offer similar 5-year survival for Child-Pugh-Turcotte A HCC-patients with a single nodule up to 5 cm: A multicenter, exploratory analysis |
|
Silva MF, Sapisochin G, Strasser SI, Hewa-Geeganage S, Chen J, Wigg AJ, Jones R, Saraiva R, Kikuchi L, Carrilho F, Fontes PR, Charco R. Eur J Surg Oncol. 2013 Jan 30. pii: S0748-7983(12)01350-9. doi: 10.1016/j.ejso.2012.12.011. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1795. | Evaluation of the effect of sorafenib using serum NX-des-?-carboxyprothrombin in patients with hepatocellular carcinoma |
|
Miyahara K, Nouso K, Morimoto Y, Tomoda T, Kobayashi S, Takeuchi Y, Hagihara H, Kuwaki K, Ohnishi H, Ikeda F, Miyake Y, Nakamura S, Shiraha H, Takaki A, Yamamoto K; Okayama Liver Cancer Group. Hepatol Res. 2012 Dec 26. doi: 10.1111/hepr.12055. [Epub ahead of print] |
|
|
|
|
|
|
|
|
1799. | Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC) |
|
Park JW, Amarapurkar D, Chao Y, Chen PJ, Geschwind JF, Goh KL, Han KH, Kudo M, Lee HC, Lee RC, Lesmana LA, Lim HY, Paik S, Poon RT, Tan CK, Tanwandee T, Teng G, Cheng AL. Liver Int. 2012 Nov 24. doi: 10.1111/liv.12083. [Epub ahead of print] |
|
|
|
|
|
|
1802. | Clinicopathological Features of Recurrence in Patients After 10-year Disease-free Survival Following Curative Hepatic Resection of Hepatocellular Carcinoma |
|
Kaibori M, Kubo S, Nagano H, Hayashi M, Haji S, Nakai T, Ishizaki M, Matsui K, Uenishi T, Takemura S, Wada H, Marubashi S, Komeda K, Hirokawa F, Nakata Y, Uchiyama K, Kwon AH. World J Surg. 2013 Jan 24. [Epub ahead of print] |
|
|
|
|
|
|
1805. | Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan |
|
Wu WC, Chen YT, Hwang CY, Su1 CW, Li SY, Chen TJ, Liu CJ, Kao WY, Chao Y, Lin HC, Wu JC. Liver Int. 2012 Dec 21. doi: 10.1111/liv.12103. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1816. | Hepatocellular Carcinoma Surveillance at 4- vs. 12-Month Intervals for Patients With Chronic Viral Hepatitis: A Randomized Study in Community |
|
Wang JH, Chang KC, Kee KM, Chen PF, Yen YH, Tseng PL, Kuo YH, Tsai MC, Hung CH, Chen CH, Tai WC, Tsai LS, Chen SC, Lin SC, Lu SN. Am J Gastroenterol. 2013 Jan 15. doi: 10.1038/ajg.2012.445. [Epub ahead of print] |
|
|
|
|
1818. | Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma |
|
Di Costanzo GG, Tortora R, De Luca M, Galeota Lanza A, Lampasi F, Tartaglione MT, Picciotto FP, Imparato M, Mattera S, Cordone G, Ascione A. Med Oncol. 2013 Mar;30(1):446. doi: 10.1007/s12032-012-0446-y. Epub 2013 Jan 10. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1825. | Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma |
|
Ishibashi M, Kogo R, Shibata K, Sawada G, Takahashi Y, Kurashige J, Akiyoshi S, Sasaki S, Iwaya T, Sudo T, Sugimachi K, Mimori K, Wakabayashi G, Mori M. Oncol Rep. 2012 Dec 28. doi: 10.3892/or.2012.2219. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
1830. | Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma |
|
Chen L, Li Y, Lin CH, Chan TH, Chow RK, Song Y, Liu M, Yuan YF, Fu L, Kong KL, Qi L, Li Y, Zhang N, Tong AH, Kwong DL, Man K, Lo CM, Lok S, Tenen DG, Guan XY. Nat Med. 2013 Jan 6. doi: 10.1038/nm.3043. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1845. | Overexpression of MMSET is Correlation with Poor Prognosis in Hepatocellular Carcinoma |
|
Zhou P, Wu LL, Wu KM, Jiang W, Li JD, Zhou LD, Li XY, Chang S, Huang Y, Tan H, Zhang GW, He F, Wang ZM. Pathol Oncol Res. 2012 Dec 8. [Epub ahead of print] |
|
|
|
|
|
|
1848. | Milan Criteria, Multi-nodularity, and Microvascular Invasion Predict the Recurrence Patterns of Hepatocellular Carcinoma After Resection |
|
Hung HH, Lei HJ, Chau GY, Su CW, Hsia CY, Kao WY, Lui WY, Wu WC, Lin HC, Wu JC. J Gastrointest Surg. 2012 Dec 6. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1858. | Long-term effectiveness of Radiofrequency Ablation for solitary small Hepatocellular Carcinoma: A retrospective analysis of 363 patients |
|
Francica G, Saviano A, De Sio I, De Matthaeis N, Brunello F, Cantamessa A, Giorgio A, Scognamiglio U, Fornari F, Giangregorio F, Piscaglia F, Gualandi S, Caturelli E, Roselli P, Rapaccini GL, Pompili M. Dig Liver Dis. 2012 Dec 12. pii: S1590-8658(12)00425-2. doi: 10.1016/j.dld.2012.10.022. [Epub ahead of print] |
|
|
|
|
1860. | Analysis of Notch and TGF-? Signaling Expression in Different Stages of Disease Progression During Hepatitis B Virus Infection |
|
Trehanpati N, Shrivastav S, Shivakumar B, Khosla R, Bhardwaj S, Chaturvedi J, Sukriti, Kumar B, Bose S, Mani Tripathi D, Das T, Sakhuja P, Rastogi A, Bhihari C, Singh S, Gupta S, Kottilil S, Sarin SK. Clin Transl Gastroenterol. 2012 Oct 4;3:e23. doi: 10.1038/ctg.2012.17. |
|
|
|
|
|
|
|
|
1864. | Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma |
|
Honda Y, Kimura T, Aikata H, Kobayashi T, Fukuhara T, Masaki K, Nakahara T, Naeshiro N, Ono A, Miyaki D, Nagaoki Y, Kawaoka T, Takaki S, Hiramatsu A, Ishikawa M, Kakizawa H, Kenjo M, Takahashi S, Awai K, Nagata Y, Chayama K. J Gastroenterol Hepatol. 2012 Dec 7. doi: 10.1111/jgh.12087. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
1870. | Evidence of associations of APOBEC3B gene deletion with susceptibility to persistent HBV infection and hepatocellular carcinoma |
|
Zhang T, Cai J, Chang J, Yu D, Wu C, Yan T, Zhai K, Bi X, Zhao H, Xu J, Tan W, Qu C, Lin D. Hum Mol Genet. 2012 Dec 18. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1877. | Multimodality Treatment for Early-Stage Hepatocellular Carcinoma: A Bridging Therapy for Liver Transplantation |
|
Ashoori N, Bamberg F, Paprottka P, Rentsch M, Kolligs FT, Siegert S, Peporte A, Al-Tubaikh JA, D'Anastasi M, Hoffmann RT, Reiser MF, Jakobs TF. Digestion. 2012 Nov 28;86(4):338-348. [Epub ahead of print] |
|
|
|
|
|
|
|
|
|